European S2k Guideline on Chronic Pruritus

In cooperation with the European Dermatology Forum (EDF)

Authors

  • Elke Weisshaar Section of Occupational Dermatology, Department of Dermatology, Ruprecht-Karls-University Heidelberg, Germany
  • Simon Müller Department of Dermatology, Universitätsspital Basel, Switzerland
  • Jacek C. Szepietowski Department of Dermato-Venereology, Faculty of Medicine, 4th Military Hospital, Wroclaw University of Science and Technology, Wroclaw, Poland, and Wroclaw Medical University, Poland
  • Florence Dalgard Department of Psychiatry, Vestfold Hospital Trust, Tønsberg, Norway and Department of Dermatology and Venerology, Skane University Hospital, Lund University, Malmö, Sweden
  • Simone Garcovich Institute of Dermatology, F. Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
  • Jörg Kupfer Institute of Medical Psychology, Justus-Liebig University of Giessen, Germany
  • Ana Gimenez-Arnau Department of Dermatology, Hospital del Mar-Institut Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
  • Julien Lambert Department of Dermatology, University Hospital of Antwerp, University of Antwerp, Belgium
  • Thomas Mettang Department of Nephrology, DKD Helios Wiesbaden, Germany
  • Laurent Misery Department of Dermatology, University Hospital Brest, France
  • Ekin Savk Department of Dermatology, Aydin Adnan Menderes University, Aydin, Turkey
  • Erwin Tschachler Department of Dermatology and Venereology, Lund University, Lund, Sweden
  • Joanna Wallengren Department of Dermatology and Venereology, Lund University, Lund, Sweden
  • Sonja Ständer Section for Pruritus Medicine, Department of Dermatology and Center for Chronic Pruritus, University Hospital Muenster, Germany

DOI:

https://doi.org/10.2340/actadv.v105.44220

Keywords:

itch, Guideline, chronic pruritus, European Dermatology Forum

Abstract

Pruritus is a frequent symptom in medicine. Population-based studies show that one in five persons in the general population has suffered from chronic pruritus (CP) at least once in their lifetime, with a 12-month incidence of 7%. CP, which can affect all age groups, is associated with numerous, often interdisciplinary medical conditions. It needs a precise diagnostic work-up to identify causes and relevant comorbidities. Management of CP comprises treatment of the underlying disease as well as topical and systemic therapies. Treating CP needs to be targeted, multimodal and performed in a step-wise procedure requiring an interdisciplinary approach. In recent years, novel on-label therapies have been approved for CP, including therapies for chronic prurigo and cholestatic pruritus. We present the updated European guideline on chronic pruritus by a team of European pruritus experts from different disciplines.

Downloads

Download data is not yet available.

References

Abella, B. S., W. E. Berger, M. S. Blaiss, I. G. Stiell, J. P. Herres, J. J. Moellman, S. Suner, A. Kessler, H. A. Klausner, J. M. Caterino and J. Du (2020). “Intravenous Cetirizine Versus Intravenous Diphenhydramine for the Treatment of Acute Urticaria: A Phase III Randomized Controlled Noninferiority Trial.” Ann Emerg Med 76(4): 489–500.

https://doi.org/10.1016/j.annemergmed.2020.05.025 DOI: https://doi.org/10.1016/j.annemergmed.2020.05.025

Aboeldahab, S., F. Khalil and R. Ezz Eldawla (2021). “Clinical and Laboratory Characteristics of Elderly Patients with Pruritus.” Clin Cosmet Investig Dermatol 14: 1009–1015.

https://doi.org/10.2147/CCID.S322527

Aboeldahab, S. S., F. J. Khalil and R. E. Eldawla (2021). “Clinical and Laboratory Characteristics of Elderly Patients with Pruritus.” Clin Cosmet Investig Dermatol 14: 1009–1015.

https://doi.org/10.2147/CCID.S322527 DOI: https://doi.org/10.2147/CCID.S322527

Acevedo Ribo, M., J. M. Moreno Planas, C. Sanz Moreno, E. E. Rubio Gonzalez, E. Rubio Gonzalez, E. Boullosa Grana, V. Sanchez-Turrion, D. Sanz Guajardo and V. Cuervas-Mons (2005). “Therapy of intractable pruritus with MARS.” Transplant Proc 37(3): 1480–1481.

https://doi.org/10.1016/j.transproceed.2005.02.002 DOI: https://doi.org/10.1016/j.transproceed.2005.02.002

Ada, S., D. Seckin, I. Budakoglu and F. N. Ozdemir (2005). “Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study.” J Am Acad Dermatol 53(1): 149–151.

https://doi.org/10.1016/j.jaad.2004.12.052 DOI: https://doi.org/10.1016/j.jaad.2004.12.052

Adams, S. (1989). “Iron deficiency, serum ferritin, generalized pruritus and systemic disease: a case control study.” Br J Dermatol 121(s34): 15.

Adreev, V. C. and I. Petkov (1975). “Skin manifestations associated with tumours of the brain.” Br J Dermatol 92(6): 675–678.

https://doi.org/10.1111/j.1365-2133.1975.tb03148.x DOI: https://doi.org/10.1111/j.1365-2133.1975.tb03148.x

Afifi, Y., F. Aubin, E. Puzenat, A. Degouy, D. Aubrion, B. Hassam and P. Humbert (2004). “[Pruritus sine materia: a prospective study of 95 patients].” Rev Med Interne 25(7): 490–493.

https://doi.org/10.1016/j.revmed.2003.12.015 DOI: https://doi.org/10.1016/j.revmed.2003.12.015

Agrawal, D., K. Sardana, S. R. Mathachan and A. Ahuja (2023). “A Case of Recalcitrant Prurigo Nodularis with Heightened Expression of STAT 3 and STAT 6 and its Dramatic Response to Tofacitinib.” Indian Dermatol Online J 14(4): 564–566.

https://doi.org/10.4103/idoj.idoj_508_22 DOI: https://doi.org/10.4103/idoj.idoj_508_22

Aguilar-Bernier, M., J. Bassas-Vila, C. Sanz-Munoz and A. Miranda-Romero (2005). “Successful treatment of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis.” Br J Dermatol 152(4): 808–809.

https://doi.org/10.1111/j.1365-2133.2005.06498.x DOI: https://doi.org/10.1111/j.1365-2133.2005.06498.x

Ahmed, A., L. Solman and H. C. Williams (2018). “Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.” Br J Dermatol 178(3): 659–662.

https://doi.org/10.1111/bjd.16046 DOI: https://doi.org/10.1111/bjd.16046

Al-Ansari, R. Y., M. Al-Sharari and T. Al-Saadi (2021). “Palms and soles itchiness as a side effect of COVID-19 vaccination.” J Infect Public Health 14(10): 1389–1391.

https://doi.org/10.1016/j.jiph.2021.08.006 DOI: https://doi.org/10.1016/j.jiph.2021.08.006

Alsakaan, N. A. G., S. Abd-Elsalam, M. M. Fawzy and N. M. Elwan (2022). “Efficacy and safety of oral methotrexate versus oral mini pulse betamethasone therapy in the treatment of lichen planus: a comparative study.” J Dermatolog Treat 33(7): 3039–3046.

https://doi.org/10.1080/09546634.2022.2104446 DOI: https://doi.org/10.1080/09546634.2022.2104446

Ambros-Rudolph, C. M., R. R. Mullegger, S. A. Vaughan-Jones, H. Kerl and M. M. Black (2006). “The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients.” J Am Acad Dermatol 54(3): 395–404.

https://doi.org/10.1016/j.jaad.2005.12.012 DOI: https://doi.org/10.1016/j.jaad.2005.12.012

Amirkhanlou, S., A. Rashedi, J. Taherian, A. A. Hafezi and S. Parsaei (2016). “Comparison of Gabapentin and Ketotifen in Treatment of Uremic Pruritus in Hemodialysis Patients.” Pak J Med Sci 32(1): 22–26.

https://doi.org/10.12669/pjms.321.8547 DOI: https://doi.org/10.12669/pjms.321.8547

Andersen, H. H., J. B. Marker, E. A. Hoeck, J. Elberling and L. Arendt-Nielsen (2017). “Antipruritic effect of pretreatment with topical capsaicin 8% on histamine- and cowhage-evoked itch in healthy volunteers: a randomized, vehicle-controlled, proof-of-concept trial.” Br J Dermatol 177(1): 107–116.

https://doi.org/10.1111/bjd.15335 DOI: https://doi.org/10.1111/bjd.15335

Andersson, N., H. E. Poulsen and J. T. Andersen (2020). “Desloratadine Use During Pregnancy and Risk of Adverse Fetal Outcomes: A Nationwide Cohort Study.” J Allergy Clin Immunol Pract 8(1598–1605).

https://doi.org/10.1016/j.jaip.2020.02.017 DOI: https://doi.org/10.1016/j.jaip.2020.02.017

Andersson, N. W., C. Torp-Pedersen and J. T. Andersen (2020). “Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes.” JAMA Pediatr 174(8): e201316.

https://doi.org/10.1001/jamapediatrics.2020.1316 DOI: https://doi.org/10.1001/jamapediatrics.2020.1316

Andoh, T., Y. Asakawa and Y. Kuraishi (2018). “Non-myelinated C-fibers, but not myelinated A-fibers, elongate into the epidermis in dry skin with itch.” Neurosci Lett 672: 84–89.

https://doi.org/10.1016/j.neulet.2018.02.034 DOI: https://doi.org/10.1016/j.neulet.2018.02.034

André, F. and B. C. Böckle (2022). “Sjögren’s syndrome.” J Dtsch Dermatol Ges 20(7): 980–1002.

https://doi.org/10.1111/ddg.14823 DOI: https://doi.org/10.1111/ddg.14823

Ang-Tiu, C. U., C. F. Meghrajani and C. C. Maano (2012). “Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials.” Expert Rev Clin Pharmacol 5(1): 91–97.

https://doi.org/10.1586/ecp.11.68 DOI: https://doi.org/10.1586/ecp.11.68

Aperis, G., C. Paliouras, A. Zervos, A. Arvanitis and P. Alivanis (2010). “The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients.” J Ren Care 36(4): 180–185.

https://doi.org/10.1111/j.1755-6686.2010.00190.x DOI: https://doi.org/10.1111/j.1755-6686.2010.00190.x

Apfelbacher, C. J., E. J. van Zuuren, Z. Fedorowicz, A. Jupiter, U. Matterne and E. Weisshaar (2013). “Oral H1 antihistamines as monotherapy for eczema.” Cochrane Database Syst Rev 2: CD007770.

https://doi.org/10.1002/14651858.CD007770.pub2 DOI: https://doi.org/10.1002/14651858.CD007770.pub2

Appleby, V. J., J. M. Hutchinson and M. H. Davies (2015). “Safety and efficacy of long-term nasobiliary drainage to treat intractable pruritus in cholestatic liver disease.” Frontline Gastroenterol 6(4): 252–254.

https://doi.org/10.1136/flgastro-2014-100489 DOI: https://doi.org/10.1136/flgastro-2014-100489

Aquino, T. M. O., K. A. C. Luchangco, E. V. Sanchez and V. M. e. a. Verallo-Rowell (2020). “A randomized controlled study of 6% gabapentin topical formulation for chronic kidney disease-associated pruritus.” Int J Dermatol 59(8): 955–961.

https://doi.org/10.1111/ijd.14953 DOI: https://doi.org/10.1111/ijd.14953

Argoff, C. E., N. Katz and M. Backonja (2004). “Treatment of postherpetic neuralgia: a review of therapeutic options.” J Pain Symptom Manage 28(4): 396–411.

https://doi.org/10.1016/j.jpainsymman.2004.01.014 DOI: https://doi.org/10.1016/j.jpainsymman.2004.01.014

Armstrong, A. W., M. Augustin, J. L. Beaumont and T. P. e. a. Pham (2024). “Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.” Dermatol Ther (Heidelb) 14(8): 2235–2248.

https://doi.org/10.1007/s13555-024-01224-x DOI: https://doi.org/10.1007/s13555-024-01224-x

Arrese, J. E., L. Dominguez-Soto, M. T. Hojyo-Tomoka, E. Vega-Memije, R. Cortes-Franco, E. Guevara and G. E. Pierard (2001). “Effectors of inflammation in actinic prurigo.” J Am Acad Dermatol 44(6): 957–961.

https://doi.org/10.1067/mjd.2001.113477 DOI: https://doi.org/10.1067/mjd.2001.113477

Ashmore, S. D., C. H. Jones, C. G. Newstead, M. J. Daly and H. Chrystyn (2000). “Ondansetron therapy for uremic pruritus in hemodialysis patients.” Am J Kidney Dis 35(5): 827–831.

https://doi.org/10.1016/S0272-6386(00)70251-4 DOI: https://doi.org/10.1016/S0272-6386(00)70251-4

Ataei, S., L. Kord, A. Larki, F. Yasrebifar, M. Mehrpooya, M. Seyedtabib and M. Hasanzarrini (2019). “Comparison of Sertraline with Rifampin in the treatment of Cholestatic Pruritus: A Randomized Clinical Trial.” Rev Recent Clin Trials 14(3): 217–223.

https://doi.org/10.2174/1574887114666190328130720 DOI: https://doi.org/10.2174/1574887114666190328130720

Augustin, M., C. Garbe, K. Hagenström, J. Petersen, M. P. Pereira and S. Ständer (2021). “Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: A population-based claims data analysis.” J Eur Acad Dermatol Venereol 35(11): 2270–2276.

https://doi.org/10.1111/jdv.17485 DOI: https://doi.org/10.1111/jdv.17485

Augustin, M., J. Lambert, C. Zema and E. H. Z. e. a. Thompson (2020). “Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.” JAMA Dermatol 156(12): 1344-1353.

https://doi.org/10.1001/jamadermatol.2020.3617 DOI: https://doi.org/10.1001/jamadermatol.2020.3617

Avgerinou, G., D.-K. Papafragkaki, A. Nasiopoulou, A. Arapaki, A. Katsambas and P. G. Stavropoulos (2012). “Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus.” J Eur Acad Dermatol Venereol 26: 762-767.

https://doi.org/10.1111/j.1468-3083.2011.04161.x DOI: https://doi.org/10.1111/j.1468-3083.2011.04161.x

Badiee Aval, S., Y. Ravanshad, A. Azarfar, H. Mehrad-Majd, S. Torabi and S. Ravanshad (2018). “A Systematic Review and Meta-analysis of Using Acupuncture and Acupressure for Uremic Pruritus.” Iran J Kidney Dis 12(2): 78-83.

Baldo, A., E. Sammarco, R. Plaitano, V. Martinelli and Monfrecola (2002). “Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera.” Br J Dermatol 147(5): 979-981.

https://doi.org/10.1046/j.1365-2133.2002.04983.x DOI: https://doi.org/10.1046/j.1365-2133.2002.04983.x

Baltas, E., Z. Csoma, L. Bodai, F. Ignacz, A. Dobozy and L. Kemeny (2006). “Treatment of atopic dermatitis with the xenon chloride excimer laser.” J Eur Acad Dermatol Venereol 20(6): 657-660.

https://doi.org/10.1111/j.1468-3083.2006.01495.x DOI: https://doi.org/10.1111/j.1468-3083.2006.01495.x

Banerji, D., R. Fox, M. Seleznick and R. Lockey (1988). “Controlled antipruritic trial of nalmefene in chronic urticaria and atopic dermatitis.” J Allergy Clin Immunol 81: 252 (Abstr.).

https://doi.org/10.1016/0091-6749(88)90571-4 DOI: https://doi.org/10.1016/0091-6749(88)90571-4

Baschong, A., F. Spiess, P. C. Cattin, A. Navarini and S. M. Mueller (2021). “Itch reduction using immersive virtual reality-An experimental pilot study.” Dermatol Ther 34(4): e15001.

https://doi.org/10.1111/dth.15001 DOI: https://doi.org/10.1111/dth.15001

Bathe, A., U. Matterne, M. Dewald, T. Grande and E. Weisshaar (2009). “Educational multidisciplinary training programme for patients with chronic pruritus.” Acta Derm Venereol 89(5): 498-501.

https://doi.org/10.2340/00015555-0684 DOI: https://doi.org/10.2340/00015555-0684

Bathe, A., E. Weisshaar and U. Matterne (2013). “Chronic pruritus-more than a symptom: a qualitative investigation into patients’ subjective illness perceptions.” J Adv Nurs 69(2): 316-326.

https://doi.org/10.1111/j.1365-2648.2012.06009.x DOI: https://doi.org/10.1111/j.1365-2648.2012.06009.x

Bauer, A., M.-L. Schuttelaar, K. Baranowsk, U. Plohberger, L. Sørensen and M. Worm (2024). “654 - Delgocitinib cream reduces itch and pain in adults with moderate to severe chronic hand eczema: pooled analyses of the phase 3 DELTA-1 and -2 trials.” BJD 191(Suppl 2).

https://doi.org/10.1093/bjd/ljae266.033 DOI: https://doi.org/10.1093/bjd/ljae266.033

Bauer, M., R. Schwameis, T. Scherzer, I. Lang-Zwosta, K. Nishino and M. Zeitlinger (2015). “A double-blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain.” J Dermatolog Treat 26(4): 367-372.

https://doi.org/10.3109/09546634.2014.992384 DOI: https://doi.org/10.3109/09546634.2014.992384

Baumann, U., E. Sturm and F. e. a. Lacaille (2021). “Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.” Clin Res Hepatol Gastroenterol 45(5): 101751.

https://doi.org/10.1016/j.clinre.2021.101751 DOI: https://doi.org/10.1016/j.clinre.2021.101751

Bellmann, R., C. Feistritzer, H. Zoller, I. W. Graziadei, H. Schwaighofer, A. Propst, C. J. Wiedermann and M. Joannidis (2004). “Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: a report of two cases.” ASAIO J 50(4): 387-391.

https://doi.org/10.1097/01.MAT.0000132552.58214.00 DOI: https://doi.org/10.1097/01.MAT.0000132552.58214.00

Bellmann, R., I. W. Graziadei, C. Feistritzer, H. Schwaighofer, F. Stellaard, E. Sturm, C. J. Wiedermann and M. Joannidis (2004). “Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis.” Liver Transpl 10(1): 107-114.

https://doi.org/10.1002/lt.20001 DOI: https://doi.org/10.1002/lt.20001

Belloni Fortina, A. and E. Fontana (2014). “Update on antihistamine treatment for chronic urticaria in children.” Curr Treat Options Allergy 1: 287.

https://doi.org/10.1007/s40521-014-0023-z DOI: https://doi.org/10.1007/s40521-014-0023-z

Bergasa, N. V. (2005). “The pruritus of cholestasis.” J Hepatol 43(6): 1078-1088.

https://doi.org/10.1016/j.jhep.2005.09.004 DOI: https://doi.org/10.1016/j.jhep.2005.09.004

Bergasa, N. V., D. W. Alling, T. L. Talbot, M. G. Swain, C. Yurdaydin, M. L. Turner, J. M. Schmitt, E. C. Walker and E. A. Jones (1995). “Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial.” Ann Intern Med 123(3): 161-167.

https://doi.org/10.7326/0003-4819-123-3-199508010-00001 DOI: https://doi.org/10.7326/0003-4819-123-3-199508010-00001

Bergasa, N. V., D. W. Alling, T. L. Talbot, M. C. Wells and E. A. Jones (1999). “Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study.” J Am Acad Dermatol 41(3 Pt 1): 431-434.

https://doi.org/10.1016/S0190-9622(99)70117-9 DOI: https://doi.org/10.1016/S0190-9622(99)70117-9

Bergasa, N. V., M. J. Link, M. Keogh, G. Yaroslavsky, R. N. Rosenthal and M. McGee (2001). “Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease.” Am J Gastroenterol 96(5): 1563-1570.

https://doi.org/10.1111/j.1572-0241.2001.03778.x DOI: https://doi.org/10.1111/j.1572-0241.2001.03778.x

Bergasa, N. V., M. McGee, I. H. Ginsburg and D. Engler (2006). “Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial.” Hepatology 44(5): 1317-1323.

https://doi.org/10.1002/hep.21370 DOI: https://doi.org/10.1002/hep.21370

Bergasa, N. V., J. K. Mehlman and E. A. Jones (2000). “Pruritus and fatigue in primary biliary cirrhosis.” Baillieres Best Pract Res Clin Gastroenterol 14(4): 643-655.

https://doi.org/10.1053/bega.2000.0109 DOI: https://doi.org/10.1053/bega.2000.0109

Bergasa, N. V., J. M. Schmitt, T. L. Talbot, D. W. Alling, M. G. Swain, M. L. Turner, J. B. Jenkins and E. A. Jones (1998). “Open-label trial of oral nalmefene therapy for the pruritus of cholestasis.” Hepatology 27(3): 679-684.

https://doi.org/10.1002/hep.510270307 DOI: https://doi.org/10.1002/hep.510270307

Bergasa, N. V., T. L. Talbot, D. W. Alling, J. M. Schmitt, E. C. Walker, B. L. Baker, J. C. Korenman, Y. Park, J. H. Hoofnagle and E. A. Jones (1992). “A controlled trial of naloxone infusions for the pruritus of chronic cholestasis.” Gastroenterology 102(2): 544-549.

https://doi.org/10.1016/0016-5085(92)90102-5 DOI: https://doi.org/10.1016/0016-5085(92)90102-5

Berger, T. G., M. Shive and G. M. Harper (2013). “Pruritus in the older patient: a clinical review.” Jama 310: 2443-2450.

https://doi.org/10.1001/jama.2013.282023 DOI: https://doi.org/10.1001/jama.2013.282023

Berger, T. G. and M. Steinhoff (2011). “Pruritus and renal failure.” Semin Cutan Med Surg 30(2): 99-100.

https://doi.org/10.1016/j.sder.2011.04.005 DOI: https://doi.org/10.1016/j.sder.2011.04.005

Bergqvist, C., C. Fiani, A. Simantov, C. Lebre, C. Hua, N. Ortonne, P. Wolkenstein and O. Chosidow (2021). “Combined Methotrexate and Alitretinoin for the treatment of difficult-to-treat generalized prurigo nodularis: a case series.” J Eur Acad Dermatol Venereol 35(8): e516-e519.

https://doi.org/10.1111/jdv.17262 DOI: https://doi.org/10.1111/jdv.17262

Bernhard, J. D. (1994). Itch: Mechanisms and management of pruritus. New York, McGraw-Hill.

Bernstein, J. E., L. C. Parish, M. Rapaport, M. M. Rosenbaum and H. H. Roenigk, Jr. (1986). “Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris.” J Am Acad Dermatol 15(3): 504-507.

https://doi.org/10.1016/S0190-9622(86)70201-6 DOI: https://doi.org/10.1016/S0190-9622(86)70201-6

Berth-Jones, J., I. Pollock, R. M. Heran, S. Lewis-Jones, M. Goodfield, C. E. Griiffiths, R. Gulati, P. McHenry, A. Abdullah, J. Ott, A. Wright, B. Walker, M. T. Stevens and A. M. Edwards (2015). “A randomised, controlled trial of a 4% cutaneous emulsion of sodium cromoglicate in treatment of atopic dermatitis in children.” J Dermatol Treat 26: 291-296.

https://doi.org/10.3109/09546634.2014.946380 DOI: https://doi.org/10.3109/09546634.2014.946380

Berth-Jones, J., S. G. Smith and R. A. Graham-Brown (1995). “Nodular prurigo responds to cyclosporin.” Br J Dermatol 132(5): 795-799.

https://doi.org/10.1111/j.1365-2133.1995.tb00729.x DOI: https://doi.org/10.1111/j.1365-2133.1995.tb00729.x

Beuers, U., A. E. Kremer, R. Bolier and R. P. Elferink (2014). “Pruritus in cholestasis: facts and fiction.” Hepatology 60(1): 399-407.

https://doi.org/10.1002/hep.26909 DOI: https://doi.org/10.1002/hep.26909

Bieber, T., E. L. Simpson, J. I. Silverberg, T. Diamant and C. Paul, et al. (2021). “Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.” N Engl J Med 384(12): 1101-1112.

https://doi.org/10.1056/NEJMoa2019380 DOI: https://doi.org/10.1056/NEJMoa2019380

Biondi, M., T. Arcangeli and R. M. Petrucci (2000). “Paroxetine in a case of psychogenic pruritus and neurotic excoriations.” Psychother Psychosom 69(3): 165-166.

https://doi.org/10.1159/000012386 DOI: https://doi.org/10.1159/000012386

Bissonnette, R., R. B. Warren, A. Pinter and T. e. a. Agner (2024). “Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.” Lancet 404(10451): 461-473. DOI: https://doi.org/10.1093/bjd/ljae266.032

https://doi.org/10.1016/S0140-6736(24)01027-4 DOI: https://doi.org/10.1016/S0140-6736(24)01027-4

Blachley, J. D., D. M. Blankenship, A. Menter, T. F. Parker, 3rd and J. P. Knochel (1985). “Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy.” Am J Kidney Dis 5(5): 237-241.

https://doi.org/10.1016/S0272-6386(85)80115-3 DOI: https://doi.org/10.1016/S0272-6386(85)80115-3

Blauvelt, A., M. de Bruin-Weller, M. Gooderham and J. C. e. a. Cather (2017). “Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.” Lancet 389(10086): 2287-2303.

https://doi.org/10.1016/S0140-6736(17)31191-1 DOI: https://doi.org/10.1016/S0140-6736(17)31191-1

Blauvelt, A., K. Papp, A. Gottlieb, A. Jarell and K. Reich, et al. (2020). “A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.” Br J Dermatol 182(6): 1348-1358.

https://doi.org/10.1111/bjd.18851 DOI: https://doi.org/10.1111/bjd.18851

Blauvelt, A., H. D. Teixeira and E. L. Simpson (2021). “Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis - A Randomized Clinical Trial.” JAMA Dermatol 157(9): 1047-1055.

https://doi.org/10.1001/jamadermatol.2021.3023 DOI: https://doi.org/10.1001/jamadermatol.2021.3023

Bonnel, R. A., L. La Grenade, C. B. Karwoski and J. G. Beitz (2003). “Allergic contact dermatitis from topical doxepin: Food and Drug Administration’s postmarketing surveillance experience.” J Am Acad Dermatol 48(2): 294-296.

https://doi.org/10.1067/mjd.2003.46 DOI: https://doi.org/10.1067/mjd.2003.46

Booken, N., M. Heck, J. P. Nicolay, C. D. Klemke, S. Goerdt and J. Utikal (2011). “Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma.” Br J Dermatol 164(3): 665-667.

https://doi.org/10.1111/j.1365-2133.2010.10108.x DOI: https://doi.org/10.1111/j.1365-2133.2010.10108.x

Bornhövd, E., W. H. C. Burgdorf and A. Wallenberg (2001). “Macrolactam immunomodulators for topical treatment of inflammatory skin diseases.” J Am Acad Dermatol 45(5): 736-743.

https://doi.org/10.1067/mjd.2001.117525 DOI: https://doi.org/10.1067/mjd.2001.117525

Bosecker, P., S. Ständer, G. Heuft, L. Dieckmann and G. Schneider (2011). “Konzept und Evaluation einer einstündigen psychoedukativen Gruppenintervention für Patienten mit chronischem Pruritus.” Z Psychosom Med Psychother 57(377-386).

https://doi.org/10.13109/zptm.2011.57.4.377 DOI: https://doi.org/10.13109/zptm.2011.57.4.377

Brasileiro, L. E. E., D. P. Barreto and E. A. Nunes (2016). “Psychotropics in different causes of itch: systematic review with controlled studies.” An Bras Dermatol 9(6): 791-798.

https://doi.org/10.1590/abd1806-4841.20164878 DOI: https://doi.org/10.1590/abd1806-4841.20164878

Brenaut, E., P. Marcorelles, S. Genestet, D. Ménard and L. Misery (2015). “Pruritus: an underrecognized symptom of small-fiber neuropathies.” J Am Acad Dermatol 72(2): 328-332.

https://doi.org/10.1016/j.jaad.2014.10.034 DOI: https://doi.org/10.1016/j.jaad.2014.10.034

Breneman, D. L., J. S. Cardone, R. F. Blumsack, R. M. Lather, E. A. Searle and V. E. Pollack (1992). “Topical capsaicin for treatment of hemodialysis-related pruritus.” J Am Acad Dermatol 26(1): 91-94.

https://doi.org/10.1016/0190-9622(92)70013-6 DOI: https://doi.org/10.1016/0190-9622(92)70013-6

Breternitz, M., D. Kowatzki, M. Langenauer, P. Elsner and J. W. Fluhr (2008). “Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation.” Skin Pharmacol Physiol 21(1): 39-45.

https://doi.org/10.1159/000111134 DOI: https://doi.org/10.1159/000111134

Britt, H., Y. Pan, G. C. Miller, L. Valenti, J. Charles, S. Knox, J. Henderson, C. Bayram and C. Harrison (2004). “Presentations of ‘itch’ in Australian general practice.” Aust Fam Physician 33(7): 488.

Brunner, W. (1995). “[Pruritus--also a challenge in internal medicine].” Schweiz Med Wochenschr 125(46): 2244-2250.

Butala, S., L. Castelo-Soccio, R. Seshadri and E. L. e. a. Simpson (2023). “Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations.” J Allergy Clin Immunol Pract 11(5): 1361-1373.

https://doi.org/10.1016/j.jaip.2023.03.011 DOI: https://doi.org/10.1016/j.jaip.2023.03.011

Cacciapuoti, S., L. Potestio, L. Gallo and M. L. e. a. Musumeci (2024). “Short-term efficacy of tildrakizumab on difficult-to-treat areas: a real-world experience.” Int J Dermatol.

https://doi.org/10.1111/ijd.17368 DOI: https://doi.org/10.1111/ijd.17368

Cacoub, P., T. Poynard, P. Ghillani, F. Charlotte, M. Olivi, J. C. Piette and P. Opolon (1999). “Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.” Arthritis Rheum 42(10): 2204-2212.

https://doi.org/10.1002/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D DOI: https://doi.org/10.1002/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D

Calikoglu, E. and R. Anadolu (2002). “Management of generalized pruritus in dominant dystrophic epidermolysis bullosa using low-dose oral cyclosporin.” Acta Derm Venereol 82(5): 380-382.

https://doi.org/10.1080/000155502320624168 DOI: https://doi.org/10.1080/000155502320624168

Canavero, S., V. Bonicalzi and B. Massa-Micon (1997). “Central neurogenic pruritus: a literature review.” Acta Neurol Belg 97(4): 244-247.

Cao, T., H. L. Tey and G. Yosipovitch (2018). “Chronic Pruritus in the Geriatric Population.” Dermatol Clin 36(3): 199-211.

https://doi.org/10.1016/j.det.2018.02.004 DOI: https://doi.org/10.1016/j.det.2018.02.004

Cao, T., A. A. Yong, K. B. Tan and H. L. Tey (2015). “Idiopathic aquagenic pruritus: pathogenesis and effective treatment with atenolol.” Dermatol Ther 28(3): 118-121.

https://doi.org/10.1111/dth.12194 DOI: https://doi.org/10.1111/dth.12194

Caravati, C. M., Jr., D. R. Richardson, B. T. Wood and E. P. Cawley (1969). “Cutaneous manifestations of hyperthyroidism.” South Med J 62(9): 1127-1130.

https://doi.org/10.1097/00007611-196909000-00020 DOI: https://doi.org/10.1097/00007611-196909000-00020

Carlsson, C. P. and J. Wallengren (2010). “Therapeutic and experimental therapeutic studies on acupuncture and itch: review of the literature.” J Eur Acad Dermatol Venereol 24(9): 1013-1016 https://doi.org/10.1111/j.1468-3083.2010.03585.x DOI: https://doi.org/10.1111/j.1468-3083.2010.03585.x

Cataldi, M., M. Maurer, M. Taglialatela and M. K. Church (2019). “Cardiac safety of second-generation H(1) -antihistamines when updosed in chronic spontaneous urticaria.” Clin Exp Allergy 49(12): 1615-1623.

https://doi.org/10.1111/cea.13500 DOI: https://doi.org/10.1111/cea.13500

Cedeno-Laurent, F., E. M. Singer, M. Wysocka, B. M. Benoit, C. C. Vittorio, E. J. Kim, G. Yosipovitch and A. H. Rook (2015). “Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.” Clin Immunol 158(1): 1-7.

https://doi.org/10.1016/j.clim.2015.02.014 DOI: https://doi.org/10.1016/j.clim.2015.02.014

Cenzer, I., N. Nkansah-Mahaneyn, M. Wehner, M.-M. Chren, T. Berger, K. Covinsky, K. Berger, K. Abuabara and E. Linos (2020). “A Multi Year Cross Sectional Study of US National Prescribing Patterns of First Generation Sedating Antihistamines in Older Adults with Skin Disease.” Br J Dermatol 182(3): 763-769.

https://doi.org/10.1111/bjd.18042 DOI: https://doi.org/10.1111/bjd.18042

Cevikbas, F. and E. A. Lerner (2020). “Physiology and pathophysiology of itch.” Physiol Rev 100: 945-982.

https://doi.org/10.1152/physrev.00017.2019 DOI: https://doi.org/10.1152/physrev.00017.2019

Chan, K. Y., C. W. Li, H. Wong, T. Yip, M. L. Chan, H. W. Cheng and M. K. Sham (2013). “Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients.” J Palliat Med 16(8): 966-970.

https://doi.org/10.1089/jpm.2012.0504 DOI: https://doi.org/10.1089/jpm.2012.0504

Chan, S., V. Reddy, B. Myers, N. Brownstone, Q. Thibodeaux and J. Koo (2020). “High-dose doxepin for the treatment of chronic, intractable scalp pruritus.” JAAD Case Rep 24: 71-73.

https://doi.org/10.1016/j.jdcr.2020.12.017 DOI: https://doi.org/10.1016/j.jdcr.2020.12.017

Chanarin, I. and L. Szur (1975). “Letter: Relief of intractable pruritus in polycythaemia rubra vera with cholestyramine.” Br J Haematol 29(4): 669-670.

https://doi.org/10.1111/j.1365-2141.1975.tb02753.x DOI: https://doi.org/10.1111/j.1365-2141.1975.tb02753.x

Che-Yi, C., C. Y. Wen, K. Min-Tsung and H. Chiu-Ching (2005). “Acupuncture in haemodialysis patients at the Quchi (LI11) acupoint for refractory uraemic pruritus.” Nephrol Dial Transplant 20(9): 1912-1915.

https://doi.org/10.1093/ndt/gfh955 DOI: https://doi.org/10.1093/ndt/gfh955

Chen, Y. C., W. T. Chiu and M. S. Wu (2006). “Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus.” Am J Kidney Dis 48(1): 69-76.

https://doi.org/10.1053/j.ajkd.2006.03.082 DOI: https://doi.org/10.1053/j.ajkd.2006.03.082

Chi, C. C., G. Kirtschig, W. Aberer, J. P. Gabbud, J. Lipozenčić, S. Kárpáti, U. F. Haustein, F. Wojnarowska and T. Zuberbier (2017). “Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy.” J Eur Acad Dermatol Venereol 31(5): 761-773.

https://doi.org/10.1111/jdv.14101 DOI: https://doi.org/10.1111/jdv.14101

Chi, C. C., G. Kirtschig, M. Baldo, F. Brackenbury, F. Lewis and F. Wojnarowska (2011). “Topical interventions for genital lichen sclerosus.” Cochrane Database Syst Rev(2): CD008240.

https://doi.org/10.1002/14651858.CD008240 DOI: https://doi.org/10.1002/14651858.CD008240

Chi, C. C., S. H. Wang, R. Mayon-White and F. Wojnarowska (2013). “Pregnancy outcomes after material exposure to topical corticosteroids. A UK population-based cohort study.” JAMA Dermatol 149: 1274-1280.

https://doi.org/10.1001/jamadermatol.2013.5768 DOI: https://doi.org/10.1001/jamadermatol.2013.5768

Chi, C. C., W. H. Wang, F. Wojnarowska, G. Kirtschig, E. Davies and C. Bennett (2015). “Safety of topical corticosteroids in pregnancy.” Cochrane Database Syst Rev (10:): CD007346.

https://doi.org/10.1002/14651858.CD007346.pub3 DOI: https://doi.org/10.1002/14651858.CD007346.pub3

Chu, A. W. L., M. M. Wong, D. G. Rayner and G. H. e. a. Guyatt (2023). “Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.” J Allergy Clin Immunol 152(6): 1470-1492.

https://doi.org/10.1016/j.jaci.2023.08.029 DOI: https://doi.org/10.1016/j.jaci.2023.08.029

Chu, D. K., L. Schneider and R. N. e. a. Asiniwasis (2024). “Atopic Dermatitis (Eczema) Guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- And Institute of Medicine-Based Recommendations.” Ann Allergy Asthma Immunol 132(3): 274-312.

https://doi.org/10.1016/j.anai.2023.11.009 DOI: https://doi.org/10.1016/j.anai.2023.11.009

Church, M. K., K. Weller, P. Stock and M. Maurer (2011). “Chronic spontaneous urticaria in children: itching for insight.” Pediatr Allergy Immunol 22: 1-8.

https://doi.org/10.1111/j.1399-3038.2010.01120.x DOI: https://doi.org/10.1111/j.1399-3038.2010.01120.x

Cohen, A. D., I. D. Andrews, E. Medvedovsky, R. Peleg and D. A. Vardy (2014). “Similarities between neuropathic pruritus sites and lichen simplex chronicus sites.” Isr Med Assoc J 16(2): 88-90.

Cohen, A. D., R. Masalha, E. Medvedovsky and D. A. Vardy (2003). “Brachioradial pruritus: a symptom of neuropathy.” J Am Acad Dermatol 48(6): 825-828.

https://doi.org/10.1067/mjd.2003.494 DOI: https://doi.org/10.1067/mjd.2003.494

Corpechot, C., O. Chazouillères, A. Rousseau, A. Le Gruyer, F. Habersetzer, P. Mathurin, O. Goria, P. Potier, A. Minello, C. Silvain, A. Abergel, M. Debette-Gratien, D. Larrey, O. Roux, J. P. Bronowicki, J. Boursier, V. de Ledinghen, A. Heurgue-Berlot, E. Nguyen-Khac, F. Zoulim, I. Ollivier-Hourmand, J. P. Zarski, G. Nkontchou, S. Lemoinne, L. Humbert, D. Rainteau, G. Lefèvre, L. de Chaisemartin, S. Chollet-Martin, F. Gaouar, F. H. Admane, T. Simon and R. Poupon (2018). “A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.” N Engl J Med 378(23): 2171-2181.

https://doi.org/10.1056/NEJMoa1714519 DOI: https://doi.org/10.1056/NEJMoa1714519

Costanzo, A., M. Llamas-Velasco, G. Fabbrocini and A. e. a. Cuccia (2023). “Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice.” J Eur Acad Dermatol Venereol 37(10): 2004-2015.

https://doi.org/10.1111/jdv.19229 DOI: https://doi.org/10.1111/jdv.19229

Craig-Muller, S. A. and J. S. Reichenberg (2015). “The Other Itch That Rashes: a Clinical and Therapeutic Approach to Pruritus and Skin Picking Disorders.” Curr Allergy Asthma Rep 15(6): 31.

https://doi.org/10.1007/s11882-015-0532-2 DOI: https://doi.org/10.1007/s11882-015-0532-2

Curto, L., L. Carnero, D. López-Aventin, G. Traveria, G. Roura and A. M. Giménez-Arnau (2014). “Fast itch relief in an experimental model for methylprednisolone aceponate topical corticosteroid activity, based on allergic contact eczema to nickel sulphate.” J Eur Acad Dermatol Venereol 28(10): 1356-1362.

https://doi.org/10.1111/jdv.12292 DOI: https://doi.org/10.1111/jdv.12292

Cury Martins, J., C. Martins, V. Aoki, A. F. T. Gois, H. A. Ishii and E. M. K. da Silva (2015). “Topical tacrolimus for atopic dermatitis.” Cochrane Database Syst Rev(7): CD009864.

https://doi.org/10.1002/14651858.CD009864.pub2 DOI: https://doi.org/10.1002/14651858.CD009864.pub2

D’Onghia, M., J. Ciaffi, L. Calabrese and L. Tognetti, et al. (2024). “Fibromyalgia and Skin Disorders: A Systematic Review.” J Clin Med 13(15): 4404.

https://doi.org/10.3390/jcm13154404 DOI: https://doi.org/10.3390/jcm13154404

D’Erme, A., F. Zanieri, E. Campolmi, U. Santosuosso, S. Betti, A. Agnoletti, A. Cossidente and T. Lotti (2014). “Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study.” J Eur Acad Dermatol Venereol 28: 246-249.

https://doi.org/10.1111/j.1468-3083.2012.04690.x DOI: https://doi.org/10.1111/j.1468-3083.2012.04690.x

Dalgard, F., A. G. Dawn and G. Yosipovitch (2007). “Are itch and chronic pain associated in adults? Results of a large population survey in Norway.” Dermatology 214(4): 305-309.

https://doi.org/10.1159/000100881 DOI: https://doi.org/10.1159/000100881

Dalgard, F., L. Lien and I. Dalen (2007). “Itch in the community: associations with psychosocial factors among adults.” J Eur Acad Dermatol Venereol 21(9): 1215-1219.

https://doi.org/10.1111/j.1468-3083.2007.02234.x DOI: https://doi.org/10.1111/j.1468-3083.2007.02234.x

Dalgard, F., A. Svensson, J. O. Holm and J. Sundby (2004). “Self-reported skin morbidity in Oslo. Associations with sociodemographic factors among adults in a cross-sectional study.” Br J Dermatol 151(2): 452-457.

https://doi.org/10.1111/j.1365-2133.2004.06058.x DOI: https://doi.org/10.1111/j.1365-2133.2004.06058.x

Dalgard, F. J., A. Svensson, J. A. Halvorsen, U. Gieler, C. Schut, L. Tomas-Aragones, L. Lien, F. Poot, G. B. E. Jemec, L. Misery, C. Szabo, D. Linder, F. Sampogna, S. Spillekom-van Koulil, F. Balieba, J. Szepietowski, A. Lvov, S. E. Marron, I. K. Altunay, A. Y. Finlay, S. S. Salek and J. Kupfer (2020). “Itch and Mental Health in Dermatological Patients Across Europe: A Cross Sectional Study in 13 Countries.” J Invest Dermatol 140(3): 568-573.

https://doi.org/10.1016/j.jid.2019.05.034 DOI: https://doi.org/10.1016/j.jid.2019.05.034

Daly, B. M. and S. Shuster (2000). “Antipruritic action of thalidomide.” Acta Derm Venereol 80(1): 24-25.

https://doi.org/10.1080/000155500750012450 DOI: https://doi.org/10.1080/000155500750012450

Darsow, U., A. Wollenberg, D. Simon, A. Taieb, T. Werfel, A. Oranje, C. Gelmetti, A. Svensson, M. Deleuran, A. M. Calza, F. Giusti, J. Lubbe, S. Seidenari and J. Ring (2010). “ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis.” J Eur Acad Dermatol Venereol 24(3): 317-328.

https://doi.org/10.1111/j.1468-3083.2009.03415.x DOI: https://doi.org/10.1111/j.1468-3083.2009.03415.x

Daunton, A., C. Bridgett and J. M. R. Goulding (2016). “Habit reversal for refractory atopic dermatitis: a review.” Br J Dermatol 174(657-659).

https://doi.org/10.1111/bjd.14176 DOI: https://doi.org/10.1111/bjd.14176

Davis, D. M. R., A. M. Drucker and A. e. a. Alikhan (2024). “Executive Summary: Guidelines of Care for the Management of Atopic Dermatitis in Adults With Phototherapy and Systemic Therapies.” J Am Acad Dermatol 90(2): 342-345.

https://doi.org/10.1016/j.jaad.2023.08.103 DOI: https://doi.org/10.1016/j.jaad.2023.08.103

Davis, M. P., J. L. Frandsen, D. Walsh, S. Andresen and S. Taylor (2003). “Mirtazapine for pruritus.” J Pain Symptom Manage 25(3): 288-291.

https://doi.org/10.1016/S0885-3924(02)00645-0 DOI: https://doi.org/10.1016/S0885-3924(02)00645-0

Dawn, A. and G. Yosipovitch (2006). “Treating itch in psoriasis.” Dermatol Nurs 18(3): 227-233.

De Marchi, S., E. Cecchin, D. Villalta, G. Sepiacci, G. Santini and E. Bartoli (1992). “Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia.” N Engl J Med 326(15): 969-974.

https://doi.org/10.1056/NEJM199204093261501 DOI: https://doi.org/10.1056/NEJM199204093261501

de Vries, E., R. Bolier, J. Goet, A. Parés, J. Verbeek, M. de Vree, J. Drenth, K. van Erpecum, K. van Nieuwkerk, F. van der Heide, N. Mostafavi, J. Helder, C. Ponsioen, O. E. R., H. van Buuren, U. Beuers and N. A. f. t. S. o. t. L.-C. W. Group (2021). “Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.” Gastroenterology 160(3): 734-743.e736.

https://doi.org/10.1053/j.gastro.2020.10.001 DOI: https://doi.org/10.1053/j.gastro.2020.10.001

de Wolf, J. T., D. W. Hendriks, R. C. Egger, M. T. Esselink, M. R. Halie and E. Vellenga (1991). “Alpha-interferon for intractable pruritus in polycythaemia vera.” Lancet 337(8735): 241.

https://doi.org/10.1016/0140-6736(91)92206-H DOI: https://doi.org/10.1016/0140-6736(91)92206-H

Decock, S., R. Roelandts, W. V. Steenbergen, W. Laleman, D. Cassiman, C. Verslype, J. Fevery, J. V. Pelt and F. Nevens (2012). “Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study.” J Hepatol 57(3): 637-641.

https://doi.org/10.1016/j.jhep.2012.04.023 DOI: https://doi.org/10.1016/j.jhep.2012.04.023

Demierre, M. F. and J. Taverna (2006). “Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma.” J Am Acad Dermatol 55(3): 543-544.

https://doi.org/10.1016/j.jaad.2006.04.025 DOI: https://doi.org/10.1016/j.jaad.2006.04.025

Demirtas, S., C. Houssais, J. Tanniou, L. Misery, E. Brenaut and S. e. a. Demirtas (2020). “Effectiveness of a music intervention on pruritus: an open randomized prospective study.” J Eur Acad Dermatol Venereol 34(6): 1280-1285.

https://doi.org/10.1111/jdv.16149 DOI: https://doi.org/10.1111/jdv.16149

Deng, J., V. Parthasarathy, W. Adawi, Z. Bordeaux, N. Sutaria, A. Gami, M. Taylor, K. K. Lee, M. Marani, I. Brown, A. Kambala, H. L. Cornman, A. Alajmi, T. Pritchard, O. O. Oladipo, Y. R. Semenov and S. G. Kwatra (2022). “Risk of hematological cancer in pruritus patients with undifferentiated pruritus.” JAMA Dermatol 158(7): 791-795.

https://doi.org/10.1001/jamadermatol.2022.1562 DOI: https://doi.org/10.1001/jamadermatol.2022.1562

Der-Petrossian, M., A. Seeber, H. Honigsmann and A. Tanew (2000). “Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis.” Br J Dermatol 142(1): 39-43.

https://doi.org/10.1046/j.1365-2133.2000.03239.x DOI: https://doi.org/10.1046/j.1365-2133.2000.03239.x

Dermatol, B. J. (2024). “Correction to: Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.” Br J Dermatol 191(6): e26-e27.

https://doi.org/10.1093/bjd/ljae338

Derry, S., A. Sven-Rice, P. Cole, T. Tan and R. Moore (2013). “Topical capsaicin (high concentration) for chronic neuropathic pain in adults.” Cochrane Database Syst Rev 28(2): CD007393.

https://doi.org/10.1002/14651858.CD007393.pub3 DOI: https://doi.org/10.1002/14651858.CD007393.pub3

Desai, N. S., G. B. Poindexter, Y. M. Monthrope, S. E. Bendeck, R. A. Swerlick and S. C. Chen (2008). “A pilot quality-of-life instrument for pruritus.” J Am Acad Dermatol 59: 234-244.

https://doi.org/10.1016/j.jaad.2008.04.006

Desai, N. S., G. B. Poindexter, Y. M. Monthrope, S. E. Bendeck, R. A. Swerlick and S. C. Chen (2008). “A pilot quality-of-life instrument for pruritus.” J Am Acad Dermatol 59(2): 234-244.

https://doi.org/10.1016/j.jaad.2008.04.006 DOI: https://doi.org/10.1016/j.jaad.2008.04.006

Dhand, A. and M. J. Aminoff (2014). “The neurology of itch.” Brain 137(Pt 2): 313-322.

https://doi.org/10.1093/brain/awt158 DOI: https://doi.org/10.1093/brain/awt158

Diehn, F. and A. Tefferi (2001). “Pruritus in polycythaemia vera: prevalence, laboratory correlates and management.” Br J Haematol 115(3): 619-621.

https://doi.org/10.1046/j.1365-2141.2001.03161.x DOI: https://doi.org/10.1046/j.1365-2141.2001.03161.x

Domagala, A., J. Szepietowski and A. Reich (2017). “Antihistamines in the treatment of pruritus in psoriasis.” Adv Dermatol Allergol 34(5): 457-463.

https://doi.org/10.5114/ada.2017.71112 DOI: https://doi.org/10.5114/ada.2017.71112

Domínguez, O., A. M. Plaza and M. Alvaro (2020). “Relationship Between Atopic Dermatitis and Food Allergy.” Curr Pediatr Rev 16(2): 115-122.

https://doi.org/10.2174/1573396315666191111122436 DOI: https://doi.org/10.2174/1573396315666191111122436

Doria, C., L. Mandala, J. Smith, C. H. Vitale, A. Lauro, S. Gruttadauria, I. R. Marino, C. S. Foglieni, M. Magnone and V. L. Scott (2003). “Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus.” Liver Transpl 9(4): 437-443.

https://doi.org/10.1053/jlts.2003.50055 DOI: https://doi.org/10.1053/jlts.2003.50055

Doyle, C. and R. E. Watchorn (2022). “Persistent pruritus following COVID-19 vaccination.” Ir J Med Sci 192(1): 185-186.

https://doi.org/10.1007/s11845-022-02959-2 DOI: https://doi.org/10.1007/s11845-022-02959-2

Draelos, Z. D., L. F. Stein Gold, D. F. Murrell, M. H. Hughes and L. T. Zane (2016). “Post Hoc analysis of the effect of crisaborole topical ointment 2% on atopic dermatitis: Associated pruritus from phase 1 and 2 clinical studies.” J Drugs Dermatol 15(2): 172-176.

Drake, L. A., J. D. Fallon and A. Sober (1994). “Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group.” J Am Acad Dermatol 31(4): 613-616.

https://doi.org/10.1016/S0190-9622(94)70225-X DOI: https://doi.org/10.1016/S0190-9622(94)70225-X

Drake, L. A. and L. E. Millikan (1995). “The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group.” Arch Dermatol 131(12): 1403-1408.

https://doi.org/10.1001/archderm.1995.01690240065010 DOI: https://doi.org/10.1001/archderm.1995.01690240065010

Dugas-Breit, S., P. Schopf, M. Dugas, H. Schiffl, F. Rueff and B. Przybilla (2005). “Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus.” J Dtsch Dermatol Ges 3(5): 343-347.

https://doi.org/10.1111/j.1610-0387.2005.05706.x DOI: https://doi.org/10.1111/j.1610-0387.2005.05706.x

Düll, M. M. and A. E. Kremer (2019). “Treatment of pruritus secondary to liver disease.” Curr Gastroenterol Rep 21(9): 48.

https://doi.org/10.1007/s11894-019-0713-6 DOI: https://doi.org/10.1007/s11894-019-0713-6

Duque, M. I., S. Thevarajah, Y. H. Chan, A. B. Tuttle, B. I. Freedman and G. Yosipovitch (2006). “Uremic pruritus is associated with higher kt/V and serum calcium concentration.” Clin Nephrol 66(3): 184-191.

https://doi.org/10.5414/CNP66184 DOI: https://doi.org/10.5414/CNP66184

Duque, M. I., G. Yosipovitch, A. B. Fleischer, Jr., J. Willard and B. I. Freedman (2005). “Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study.” J Am Acad Dermatol 52(3 Pt 1): 519-521.

https://doi.org/10.1016/j.jaad.2004.08.050 DOI: https://doi.org/10.1016/j.jaad.2004.08.050

Dvorak, M., A. Watkinson, F. McGlone and R. Rukwied (2003). “Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin.” Inflamm Res 52(6): 238-245.

https://doi.org/10.1007/s00011-003-1162-z DOI: https://doi.org/10.1007/s00011-003-1162-z

EASL (2009). “Clinical Practice Guideline: Management of cholestatic liver disease.” J Hepatol 51(2): 237-267.

https://doi.org/10.1016/j.jhep.2009.04.009 DOI: https://doi.org/10.1016/j.jhep.2009.04.009

Easton, P. and P. R. Galbraith (1978). “Cimetidine treatment of pruritus in polycythemia vera.” N Engl J Med 299(20): 1134.

https://doi.org/10.1056/NEJM197811162992015 DOI: https://doi.org/10.1056/NEJM197811162992015

Ebata, T. (2016). “Drug-Induced Itch Management.” Curr Probl Dermatol 50: 155-163.

https://doi.org/10.1159/000446084 DOI: https://doi.org/10.1159/000446084

Eberlein, B., C. Eicke, H. W. Reinhardt and J. Ring (2008). “Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study).” J Eur Acad Dermatol Venereol 22(1): 73-82.

https://doi.org/10.1111/j.1468-3083.2007.02351.x DOI: https://doi.org/10.1111/j.1468-3083.2007.02351.x

Egli, F., A. Wieczorek, M. Niemoller and K. Rhyner (1988). “[Polycythemia vera: clinical aspects and course in 86 patients].” Schweiz Med Wochenschr 118(52): 1969-1975.

Ehlers, A., U. Stangier and U. Gieler (1995). “Treatment of atopic dermatitis: A comparison of psychological and dermatological approaches to relapse prevention.” J Consult Clin Psychol 63(4): 624-635. DOI: https://doi.org/10.1037//0022-006X.63.4.624

https://doi.org/10.1037/0022-006X.63.4.624 DOI: https://doi.org/10.1037/0022-006X.63.4.624

Ehrchen, J. and S. Stander (2008). “Pregabalin in the treatment of chronic pruritus.” J Am Acad Dermatol 58(2 Suppl): S36-37.

https://doi.org/10.1016/j.jaad.2007.07.017 DOI: https://doi.org/10.1016/j.jaad.2007.07.017

Ellis, A. G., C. Flohr and A. M. Drucker (2019). “Network meta-analyses of systemic treatments for psoriasis: a critical appraisal: Original Articles: Jabbar-Lopez ZK, Yiu ZZN, Ward V et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol 2017; 137:1646-54.

Ellis, C. N., B. Berberian, V. I. Sulica, W. A. Dodd, M. T. Jarratt, H. I. Katz, S. Prawer, G. Krueger, I. H. Rex, Jr. and J. E. Wolf (1993). “A double-blind evaluation of topical capsaicin in pruritic psoriasis.” J Am Acad Dermatol 29(3): 438-442.

https://doi.org/10.1016/0190-9622(93)70208-B DOI: https://doi.org/10.1016/0190-9622(93)70208-B

Elman, S., L. S. Hynan, V. Gabriel and M. J. Mayo (2010). “The 5-D itch scale: a new measure of pruritus.” Br J Dermatol 162(3): 587-593.

https://doi.org/10.1111/j.1365-2133.2009.09586.x DOI: https://doi.org/10.1111/j.1365-2133.2009.09586.x

Elmariah, S. B. and E. A. Lerner (2011). “Topical therapies for pruritus.” Semin Cutan Med Surg 30(2): 118-126.

https://doi.org/10.1016/j.sder.2011.04.008 DOI: https://doi.org/10.1016/j.sder.2011.04.008

Elsayed, M. M., I. E. Elgohary, H. H. S. Abdelhamid and S. A. Zaki (2023). “The effectiveness of sertraline in alleviating uremic pruritus in hemodialysis patients: a randomized clinical trial.” BMC Nephrol 24: 155.

https://doi.org/10.1186/s12882-023-03212-3 DOI: https://doi.org/10.1186/s12882-023-03212-3

Engelhardt, H., R. A. Smits, R. Leurs, E. Haaksma and I. J. de Esch (2009). “A new generation of anti-histamines: Histamine H4 receptor antagonists on their way to the clinic.” Curr Opin Drug Discov Devel 12: 628-643.

Epstein, M. P. and M. M. Kaplan (2004). “A pilot study of etanercept in the treatment of primary sclerosing cholangitis.” Dig Dis Sci 49(1): 1-4.

https://doi.org/10.1023/B:DDAS.0000011827.87103.2e DOI: https://doi.org/10.1023/B:DDAS.0000011827.87103.2e

Ersser, S. J., F. Cowdell, S. Latter, E. Gardiner, C. Flohr, A. R. Thompson, K. Jackson, H. Farasat, F. Ware and A. Drury (2014). “Psychological and educational interventions for atopic eczema in children.” Cochrane Database Syst Rev 2014(1): CD004054.

https://doi.org/10.1002/14651858.CD004054.pub3 DOI: https://doi.org/10.1002/14651858.CD004054.pub3

Evers, A. W., P. Duller, E. M. de Jong, M. E. Otero, C. M. Verhaak, P. G. van der Valk, P. C. van de Kerkhof and F. W. Kraaimaat (2009). “Effectiveness of a multidisciplinary itch-coping training programme in adults with atopic dermatitis.” Acta Derm Venereol 89(1): 57-63.

https://doi.org/10.2340/00015555-0556 DOI: https://doi.org/10.2340/00015555-0556

Evers, A. W. M., C. Schut, U. Gieler, S. Spillekom-van-Koulil and S. van Beugen (2016). Psychological itch management. Itch - Management in Clinical Practice. J. C. Szepietowski and E. Weisshaar. Basel, Karger. 50: 64-70.

https://doi.org/10.1159/000446045 DOI: https://doi.org/10.1159/000446045

Fang, H.-Y. and C.-H. Lian (2023). “The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.” J Dermatol 50(8): 1084-1087.

https://doi.org/10.1111/1346-8138.16803 DOI: https://doi.org/10.1111/1346-8138.16803

Fardel, M. A., E. Brenaut, D. Guellec, M. Etienne, M. Fouchard, R. Seizeur and L. Misery (2022). “Pruritus and brain tumours: A prospective and descriptive study.” Skin Health Dis 3(3): e202.

https://doi.org/10.1002/ski2.202 DOI: https://doi.org/10.1002/ski2.202

Feng, W. W., B. Yuan, F. Y. Shen, W. Y. Fan, D. S. Mei, B. Y. Bao, Q. J. Chen and W. W. e. a. Feng (2020). “Efficacy of uremic pruritus treatment in patients undergoing hemodialysis, a network meta-analysis for randomized clinical trials.” Nephrol Ther 17(1): 30-34.

https://doi.org/10.1016/j.nephro.2020.09.006 DOI: https://doi.org/10.1016/j.nephro.2020.09.006

Ferrandiz, C., J. M. Carrascosa, M. Just, I. Bielsa and M. Ribera (1997). “Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis.” Dermatology 195(4): 359-361.

https://doi.org/10.1159/000245988 DOI: https://doi.org/10.1159/000245988

Ferreira, B. R., O. M. Katamanin, M. Jafferany and L. Misery (2024). “Psychodermatology of Chronic Pruritus: An Overview of the Link Between Itch and Distress.” Dermatol Ther (Heidelb) 14(7): 1799-1809.

https://doi.org/10.1007/s13555-024-01214-z DOI: https://doi.org/10.1007/s13555-024-01214-z

Fett, N., K. Haynes, K. J. Robert and D. J. Margolis (2014). “Five-year malignancy incidence in patients with chronic pruritus: a population-based cohort study aimed at limiting unnecessary screening practices.” J Am Acad Dermatol 70: 651-658.

https://doi.org/10.1016/j.jaad.2013.11.045 DOI: https://doi.org/10.1016/j.jaad.2013.11.045

Finelli, C., L. Gugliotta, B. Gamberi, N. Vianelli, G. Visani and S. Tura (1993). “Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa.” Am J Hematol 43(4): 316-318.

https://doi.org/10.1002/ajh.2830430419 DOI: https://doi.org/10.1002/ajh.2830430419

Fishbane, S., A. Jamal, C. Munera, W. Wen and F. Menzaghi (2020). “A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.” NEJM 382(3): 222-232.

https://doi.org/10.1056/NEJMoa1912770 DOI: https://doi.org/10.1056/NEJMoa1912770

Fitzsimons, E. J., J. H. Dagg and E. J. McAllister (1981). “Pruritus of polycythaemia vera: a place for pizotifen?” Br Med J (Clin Res Ed) 283(6286): 277.

https://doi.org/10.1136/bmj.283.6286.277 DOI: https://doi.org/10.1136/bmj.283.6286.277

Fjellner, B. and O. Hagermark (1979). “Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement.” Acta Derm Venereol 59(6): 505-512.

https://doi.org/10.2340/0001555559505512 DOI: https://doi.org/10.2340/0001555559505512

Fjellner, B. and O. Hagermark (1982). “Potentiation of histamine-induced itch and flare responses in human skin by the enkephalin analogue FK-33-824, beta-endorphin and morphine.” Arch Dermatol Res 274(1-2): 29-37.

https://doi.org/10.1007/BF00510355 DOI: https://doi.org/10.1007/BF00510355

Fleischer, A. B., Jr. (2000). The clinical management of itching. New York, London, Parthenon Publishing.

Fleischer, A. B., Jr. and M. Boguniewicz (2010). “An approach to pruritus in atopic dermatitis: a critical systematic review of the tacrolimus ointment literature.” J Drugs Dermatol 9(5): 488-498.

Foroutan, N., A. Etminan, N. Nikvarz and M. Shojai Shahrokh Abadi (2017). “Comparison of pregabalin with doxepin in the management of uremic pruritus: a randomized single blind clinical trial.” Hemodial Int 21(1): 63-71.

https://doi.org/10.1111/hdi.12455 DOI: https://doi.org/10.1111/hdi.12455

Fouchard, M., E. Brenaut, S. Genestet, A. S. Ficheux, P. Marcorelles and L. Misery (2023). “Observational case-control study of small-fiber neuropathies, with regards on smoking and vitamin D deficiency and other possible causes.” Front Med (Lausanne) 9: 1051967.

https://doi.org/10.3389/fmed.2022.1051967 DOI: https://doi.org/10.3389/fmed.2022.1051967

Francos, G. C., Y. C. Kauh, S. D. Gittlen, E. S. Schulman, A. Besarab, S. Goyal and J. F. Burke, Jr. (1991). “Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus.” Int J Dermatol 30(12): 884-889.

https://doi.org/10.1111/j.1365-4362.1991.tb04360.x DOI: https://doi.org/10.1111/j.1365-4362.1991.tb04360.x

Freitas, E., M. Gooderham and T. Torres (2022). “New Topical Therapies in Development for Atopic Dermatitis.” Drugs 82(8): 843-853.

https://doi.org/10.1007/s40265-022-01722-2 DOI: https://doi.org/10.1007/s40265-022-01722-2

Frese, T., K. Herrmann and H. Sandholzer (2011). “Pruritus as reason for encounter in general practice.” J Clin Med Res 3(5): 223-229.

https://doi.org/10.4021/jocmr632w DOI: https://doi.org/10.4021/jocmr632w

Friedlander, M. S. H. and S. Admani (2021). “Aquagenic pruritus in an adolescent effectively managed with β-alanine supplementation.” Pediatr Dermatol 38(1): 320-321.

https://doi.org/10.1111/pde.14440 DOI: https://doi.org/10.1111/pde.14440

Fujino, H., M. Tanaka, M. Imamura, K. Morio, A. Ono and T. e. a. Nakahara (2019). “Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.” BMC gastroenterology 19(1): 169.

https://doi.org/10.1186/s12876-019-1092-z DOI: https://doi.org/10.1186/s12876-019-1092-z

Gael, M., T.-. Adam, M. Mariano-Bourin and A.-C. Bursztejn (2022). “Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors.” J Eur Acad Dermatol Venereol 36(9): 1541-1551.

https://doi.org/10.1111/jdv.18221 DOI: https://doi.org/10.1111/jdv.18221

Gaig, P., M. Olona, D. Muñoz Lejarazu, M. T. Caballero, F. J. Dominguez, S. Echechipia, J. L. Garcia Abujeta, M. A. Gonzalo, R. Lleonart, C. Martinez Cócera, A. Rodriguez and M. Ferrer (2004). “Epidemiology of urticaria in Spain.” J Investig Allergol Clin Immunol 14: 214-220.

Gal-Oz, A., O. Rogowski, M. Swartzon and S. Kivity (2010). “Ethyl chloride as an antipruritic agent: a double-blind placebo-controlled prospective study.” Dermatology 221(4): 373-377.

https://doi.org/10.1159/000321720 DOI: https://doi.org/10.1159/000321720

Gambichler, T., J. Hyun, A. Sommer, M. Stucker, P. Altmeyer and A. Kreuter (2006). “A randomised controlled trial on photo(chemo)therapy of subacute prurigo.” Clin Exp Dermatol 31(3): 348-353.

https://doi.org/10.1111/j.1365-2230.2006.02081.x DOI: https://doi.org/10.1111/j.1365-2230.2006.02081.x

Garg, S., J. Zhao, K. Tegtmeyer, P. Shah and P. A. Lio (2021). “US Prescription trends of antihistamines for atopic dermatitis, 2011-2016.” Pediatr Dermatol 38(1): 324-326.

https://doi.org/10.1111/pde.14445 DOI: https://doi.org/10.1111/pde.14445

Garritsen, F. M., M. W. Brouwer, J. Limpens and P. I. Spuls (2014). “Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research.” Br J Dermatol 170(3): 501-513.

https://doi.org/10.1111/bjd.12645 DOI: https://doi.org/10.1111/bjd.12645

Gaspari, A. (2002). “Thalidomide neurotoxicity in dermatological patients: the next “STEP”.” J Invest Dermatol 119(5): 987-988.

https://doi.org/10.1046/j.1523-1747.2002.19538.x DOI: https://doi.org/10.1046/j.1523-1747.2002.19538.x

Ghent, C. N. and S. G. Carruthers (1988). “Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial.” Gastroenterology 94(2): 488-493.

https://doi.org/10.1016/0016-5085(88)90442-8 DOI: https://doi.org/10.1016/0016-5085(88)90442-8

Gholyaf, M., V. Sheikh, F. Yasrebifar, Y. Mohammadi, M. Mirjalili and M. Mehrpooya (2020). “Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study.” Int Urol Nephrol 52(6): 1155-1165.

https://doi.org/10.1007/s11255-020-02473-3 DOI: https://doi.org/10.1007/s11255-020-02473-3

Ghorbani, A. R., A. Feily, A. Khalili and B. Dormanesh (2011). “Lack of efficacy of topical calcineurin inhibitor pimecrolimus 1% on pruritus of severely uremic patients: a randomized double-blind study in 60 patients.” Dermatitis 22(3): 167-168.

https://doi.org/10.2310/6620.2011.10110 DOI: https://doi.org/10.2310/6620.2011.10110

Ghura, H. S., A. D. Patterson and A. J. Carmichael (1998). “Naltrexone in the treatment of renal itch.” Br J Dermatol 139 (suppl 51): 139.

Gibson, W., B. M. Wand and N. E. O’Connell (2017). “Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults.” Cochrane Database Syst Rev 14(9): CD011976.

https://doi.org/10.1002/14651858.CD011976.pub2 DOI: https://doi.org/10.1002/14651858.CD011976.pub2

Gieler, U., J. Kupfer, V. Niemeier, B. Brosig and U. Stangier (2000). “Atopic eczema prevention programs - a new therapeutic concept for secondary prevention.” Dermatol Psychosom 1: 138-147.

https://doi.org/10.1159/000057969 DOI: https://doi.org/10.1159/000057969

Gilbert, H. S., R. R. Warner and L. R. Wasserman (1966). “A study of histamine in myeloproliferative disease.” Blood 28(6): 795-806.

https://doi.org/10.1182/blood.V28.6.795.795 DOI: https://doi.org/10.1182/blood.V28.6.795.795

Gilchrest, B. A., J. W. Rowe, R. S. Brown, T. I. Steinman and K. A. Arndt (1977). “Relief of uremic pruritus with ultraviolet phototherapy.” N Engl J Med 297(3): 136-138.

https://doi.org/10.1056/NEJM197707212970304 DOI: https://doi.org/10.1056/NEJM197707212970304

Gilchrest, B. A., J. W. Rowe, R. S. Brown, T. I. Steinman and K. A. Arndt (1979). “Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action.” Ann Intern Med 91(1): 17-21.

https://doi.org/10.7326/0003-4819-91-1-17 DOI: https://doi.org/10.7326/0003-4819-91-1-17

Girling, J. C. (2006). Obstetric cholestasis. Guideline no. 43. London, Royal College of Obstetricians and Gynaecologists (RCOG).

Gisslinger, H., C. Klade, P. Georgiev, D. Krochmalczyk and L. Gercheva-Kyuchukova, et al. (2020). “Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.” Lancet Haematol 7(3): e196-e208.

https://doi.org/10.2139/ssrn.3426089 DOI: https://doi.org/10.2139/ssrn.3426089

Gokdemir, G. and T. Doruk (2011). “Treatment of generalized pruritus: comparison of narrowband ultraviolet-B with oral cetirizine.” J Eur Acad Dermatol Venereol 25: 1484-1485.

https://doi.org/10.1111/j.1468-3083.2010.03948.x DOI: https://doi.org/10.1111/j.1468-3083.2010.03948.x

Golembesky, A., M. Cooney and R. e. a. Boev (2018). “Safety of Cetirizine in pregnancy.” J Obstet Gynaecol 38(940-945).

https://doi.org/10.1080/01443615.2018.1441271 DOI: https://doi.org/10.1080/01443615.2018.1441271

Gonzalez-Estrada, A. and S. A. Geraci (2016). “Allergy medications during pregnancy.” Am J Med Sci 352(3): 326-331.

https://doi.org/10.1016/j.amjms.2016.05.030 DOI: https://doi.org/10.1016/j.amjms.2016.05.030

Gordon, K. B., P. Foley, J. G. Krueger and A. e. a. Pinter (2021). “Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.” Lancet 397(10273): 475-486.

https://doi.org/10.1016/S0140-6736(21)00126-4 DOI: https://doi.org/10.1016/S0140-6736(21)00126-4

Gottlieb, A. B., K. Gordon, S. Hsu, B. Elewski, L. F. Eichenfield, L. Kircik, S. Rastogi, R. Pillai and R. Israel (2018). “Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.” J Eur Acad Dermatol Venereol.

https://doi.org/10.1111/jdv.14913 DOI: https://doi.org/10.1111/jdv.14913

Goulis, J., G. Leandro and A. K. Burroughs (1999). “Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis.” Lancet 354(9184): 1053-1060.

https://doi.org/10.1016/S0140-6736(98)11293-X DOI: https://doi.org/10.1016/S0140-6736(98)11293-X

Goutos, I. (2013). “Neuropathic mechanisms in the pathophysiology of burns pruritus: redefining directions for therapy and research.” J Burn Care Res 34(1): 82-93.

https://doi.org/10.1097/BCR.0b013e3182644c44 DOI: https://doi.org/10.1097/BCR.0b013e3182644c44

Grattan, C. E. H. and D. H. Radia (2016). Mastocytosis. Rook’s textbook of dermatology. J. B. C. Griffiths, T. Bleiker, R. Chalmers, & D. Creamer. Chichester, West Sussex; Hoboken, NJ, John Wiley & Sons Inc.

https://doi.org/10.1002/9781118441213.rtd0047 DOI: https://doi.org/10.1002/9781118441213.rtd0047

Gray, P., J. Kirby, M. T. Smith, P. J. Cabot, B. Williams, J. Doecke and T. Cramond (2011). “Pregabalin in severe burn injury pain. A double-blind, randomised placebo-controlled trial.” Pain 152(6): 1279-1288.

https://doi.org/10.1016/j.pain.2011.01.055 DOI: https://doi.org/10.1016/j.pain.2011.01.055

Gray, S. L., M. L. Anderson and S. e. a. Dublin (2015). “Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.” JAMA Intern Med 175: 401-407.

https://doi.org/10.1001/jamainternmed.2014.7663 DOI: https://doi.org/10.1001/jamainternmed.2014.7663

Green, B. G. and K. L. Schoen (2007). “Thermal and nociceptive sensations from menthol and their suppression by dynamic contact.” Behav Brain Res 176(2): 284-291.

https://doi.org/10.1016/j.bbr.2006.10.013 DOI: https://doi.org/10.1016/j.bbr.2006.10.013

Greenberg, J. H. (1995). “Allergic contact dermatitis from topical doxepin.” Contact Dermatitis 33(4): 281.

https://doi.org/10.1111/j.1600-0536.1995.tb00494.x DOI: https://doi.org/10.1111/j.1600-0536.1995.tb00494.x

Griffiths, C. E. M., K. Reich, M. Lebwohl and P. e. a. van de Kerkhof (2015). “Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.” Lancet 386(9993): 541-551.

https://doi.org/10.1016/S0140-6736(15)60125-8 DOI: https://doi.org/10.1016/S0140-6736(15)60125-8

Grinnell, M., K. N. Price, A. Shah and D. C. Butler (2022). “Antihistamine safety in older adult dermatologic patients.” J Am Acad Dermatol 87(2): 381-386.

https://doi.org/10.1016/j.jaad.2021.01.027 DOI: https://doi.org/10.1016/j.jaad.2021.01.027

Gu, S., S. Dusza, E. Quigley, H. Haliasos and A. e. a. Markova (2024). “Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients.” Breast Cancer Res Treat 203(2): 271-280.

https://doi.org/10.1007/s10549-023-07143-3 DOI: https://doi.org/10.1007/s10549-023-07143-3

Gunal, A. I., G. Ozalp, T. K. Yoldas, S. Y. Gunal, E. Kirciman and H. Celiker (2004). “Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial.” Nephrol Dial Transplant 19(12): 3137-3139.

https://doi.org/10.1093/ndt/gfh496 DOI: https://doi.org/10.1093/ndt/gfh496

Gurnani, P., T. Miloh, J. Chandar, D. A. Landau, F. Hajjar and G. Yosipovitch (2021). “Systemic causes of non-dermatologic chronic pruritus in the pediatric population and their management: An unexplored area.” Pediatr Dermatol 38: 1051-1060.

https://doi.org/10.1111/pde.14596 DOI: https://doi.org/10.1111/pde.14596

Gutman, A. B., A. M. Kligman, J. Sciacca and W. D. James (2005). “Soak and smear: a standard technique revisited.” Arch Dermatol 141: 1556-1559.

https://doi.org/10.1001/archderm.141.12.1556 DOI: https://doi.org/10.1001/archderm.141.12.1556

Guttman-Yassky, E., A. Blauvelt, L. F. Eichenfield, A. S. Paller, A. Armstrong, W., J. Drew, R. Gopalan and E. L. Simpson (2020). “Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.” JAMA Dermatol 156(4): 411-420.

https://doi.org/10.1001/jamadermatol.2020.0079 DOI: https://doi.org/10.1001/jamadermatol.2020.0079

Guttman-Yassky, E., E. L. Simpson, K. Reich and K. e. a. Kabashima (2023). “An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.” Lancet 401(10372): 204-214.

https://doi.org/10.1016/S0140-6736(22)02037-2 DOI: https://doi.org/10.1016/S0140-6736(22)02037-2

Guttman-Yassky, E., H. D. Teixeira, E. L. Simpson, K. A. Papp and A. L. Pangan, et al. (2021). “Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.” Lancet 397(10290): 2151-2168.

https://doi.org/10.1016/S0140-6736(21)00588-2 DOI: https://doi.org/10.1016/S0140-6736(21)00588-2

Günther, M., C. Kobus, C. Perner, S. Schönenberg, and T. Prell. (2025). Chronic Pruritus in Geriatric Patients: Prevalence, Associated Factors, and Itch-related Quality of Life. Acta Derm Venereol. 105: adv42003.

https://doi.org/10.2340/actadv.v105.42003 DOI: https://doi.org/10.2340/actadv.v105.42003

Haber, R., J. Bachour, A. Salloum, T. Maacaron, F. Khoury, L. Habr, A. Ammoury and N. Joubran (2020). “Comparison of gabapentin and doxepin in the management of uremic pruritus: A randomized crossover clinical trial.” Dermatol Ther 33(6): e14522.

https://doi.org/10.1111/dth.14522 DOI: https://doi.org/10.1111/dth.14522

Hagino, T., H. Saeki, E. Fujimoto and N. Kanda (2024). “Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan.” J Dermatolog Treat 35(1): 2307489.

https://doi.org/10.1080/09546634.2024.2307489 DOI: https://doi.org/10.1080/09546634.2024.2307489

Halvorsen, J. A. and W. Aasebø (2015). “Oral tacrolimus treatment of pruritus in prurigo nodularis.” Acta Derm Venereol 95(7): 866-867.

https://doi.org/10.2340/00015555-2107 DOI: https://doi.org/10.2340/00015555-2107

Halvorsen, J. A., F. Dalgard, M. Thoresen, M. Thoresen, E. Bjertness and L. Lien (2009). “Itch and mental distress: a cross-sectional study among late adolescents.” Acta Derm Venereol 89(1): 39-44.

https://doi.org/10.2340/00015555-0554 DOI: https://doi.org/10.2340/00015555-0554

Hamilton, D. V. and D. J. Gould (1985). “Generalized pruritus as a presentation of idiopathic haemochromatosis.” Br J Dermatol 112(5): 629.

https://doi.org/10.1111/j.1365-2133.1985.tb15277.x DOI: https://doi.org/10.1111/j.1365-2133.1985.tb15277.x

Hansen, C., T. A. Desrosiers and K. e. a. Wisniewski (2020). “Use of anthistamine medications during early pregnancy and selected birth defects: the National Birth Defects Prevention Study.” Birth Defects Res 112: 1234-1252.

https://doi.org/10.1002/bdr2.1749 DOI: https://doi.org/10.1002/bdr2.1749

Hartmann, E. M., H. O. Handwerker and C. Forster (2015). “Gender differences in itch and pain-related sensations provoked by histamine, cowhage and capsaicin.” Acta Derm Venereol 95: 25-30.

https://doi.org/10.2340/00015555-1894 DOI: https://doi.org/10.2340/00015555-1894

Hawley, K., P. Lio, T. Nguyen, A. Qureshi, C. Emesiani and M. Meckfessel (2023). “A Novel 3-Step Over-the-Counter Eczema Regimen Improves Eczema Severity, Itch, and Life Quality: Randomized Study.” J Drugs Dermatol 22(10): SF388641s388621-SF388641s388626.

Hawro, T., J. W. Fluhr, V. Mengeaud, D. Redoulès, M. K. Church, M. Maurer and M. Metz (2014). “Polidocanol inhibits cowhage - but not histamine-induced itch in humans.” Exp Dermatol 23(12): 922-923.

https://doi.org/10.1111/exd.12555 DOI: https://doi.org/10.1111/exd.12555

Hay, R. J., N. E. Johns, H. C. Williams, I. W. Bolliger, R. P. Dellavalle, D. J. Margolis, R. Marks, L. Naldi, M. A. Weinstock, S. K. Wulf, C. J. L. Michaud, C. Murray and M. Naghavi (2014). “The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions.” J Invest Dermatol 134(6): 1527-1534.

https://doi.org/10.1038/jid.2013.446 DOI: https://doi.org/10.1038/jid.2013.446

Hayani, K., M. Weiss and E. Weisshaar (2016). “Clinical Findings and Provision of Care in Haemodialysis Patients with Chronic Itch: New Results from the German Epidemiological Haemodialysis Itch Study.” Acta Derm Venereol 96(3): 361-366.

https://doi.org/10.2340/00015555-2280 DOI: https://doi.org/10.2340/00015555-2280

Haydek, C. G., E. Love, N. K. Mollanazar, R. Valdes Rodriguez, H. Lee, G. Yosipovitch, M. D. Tharp, J. M. Hanifin, K.-H. Chen and C. S. C. (2017). “Validation and Banding of the ItchyQuant: A Self-Report Itch Severity Scale.” J Invest Dermatol 137(1): 57-61.

https://doi.org/10.1016/j.jid.2016.06.633 DOI: https://doi.org/10.1016/j.jid.2016.06.633

He, A., S. R. Feldman and A. B. Fleischer (2018). “An assessment of the use of antihistamines in atopic dermatitis.” J Amer Acad Dermatol 79(1): 92-96.

https://doi.org/10.1016/j.jaad.2017.12.077 DOI: https://doi.org/10.1016/j.jaad.2017.12.077

He, M., L. Wu, D. Huang, V. Yau and S. Yu (2020). “Pruritus in neuromyelitis optica spectrum disorders and multiple sclerosis.” J Clin Neurosci 79(108-112).

https://doi.org/10.1016/j.jocn.2020.07.022 DOI: https://doi.org/10.1016/j.jocn.2020.07.022

He, Q., X. Xie, Q. Chen and W. e. a. Li (2024). “Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.” Front Immunol 15: 1342810.

https://doi.org/10.3389/fimmu.2024.1342810 DOI: https://doi.org/10.3389/fimmu.2024.1342810

He, Y., S. Ji and Q. Yu (2021). “Effectiveness of baricitinib in prurigo-type atopic dermatitis: A case report.” Dermatol Ther 34(2): e14878.

https://doi.org/10.1111/dth.14878 DOI: https://doi.org/10.1111/dth.14878

Hearn, R. M., A. C. Kerr, K. F. Rahim, J. Ferguson and R. S. Dawe (2008). “Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy.” Br J Dermatol 159(4): 931-935.

https://doi.org/10.1111/j.1365-2133.2008.08776.x DOI: https://doi.org/10.1111/j.1365-2133.2008.08776.x

Hedman-Lagerlöf, E., J. Fust, E. Axelsson, M. Bonnert, M. Lalouni, O. Molander, P. Agrell, A. Bergman, N. Lindefors and M. Bradley (2021). “Internet-Delivered Cognitive Behavior Therapy for Atopic Dermatitis: A Randomized Clinical Trial.” JAMA Dermatol 157(7): 796-804.

https://doi.org/10.1001/jamadermatol.2021.1450 DOI: https://doi.org/10.1001/jamadermatol.2021.1450

Heinlin, J., G. Isbary, W. Stolz, F. Zeman, M. Landthaler, G. Morfill, T. Shimizu, J. L. Zimmermann and S. Karrer (2013). “A randomized two-sided placebo-controlled study on the efficacy and safety of atmospheric non-thermal argon plasma for pruritus.” J Eur Acad Dermatol Venereol 27(3): 324-331.

https://doi.org/10.1111/j.1468-3083.2011.04395.x DOI: https://doi.org/10.1111/j.1468-3083.2011.04395.x

Heisig, M., J. Salomon and J. C. Szepietowski (2012). “Chronic pruritus in an elderly patient with dementia successfully treated with paroxetine.” Przegl Dermatol 99: 620-624.

Heratizadeh, A., T. Werfel, A. Wollenberg, S. Abraham, S. Plank-Habibi and C. e. a. Schnopp (2017). “Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial.” J Allergy Clin Immunol Pract 140(845-853).

https://doi.org/10.1016/j.jaci.2017.01.029 DOI: https://doi.org/10.1016/j.jaci.2017.01.029

Hettrick, H. H., K. O’Brien, H. Laznick, J. Sanchez, D. Gorga, W. Nagler and R. Yurt (2004). “Effect of transcutaneous electrical nerve stimulation for the management of burn pruritus: a pilot study.” J Burn Care Rehabil 25(3): 236-240.

https://doi.org/10.1097/01.BCR.0000124745.22170.86 DOI: https://doi.org/10.1097/01.BCR.0000124745.22170.86

Hide, M., T. Suzuki, A. Tanaka and H. Aoki (2019). “Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: A double-blind, randomized, multicenter, placebo-controlled clinical trial.” Allergol Int 68(1): 59-67.

https://doi.org/10.1016/j.alit.2018.06.002 DOI: https://doi.org/10.1016/j.alit.2018.06.002

Hide, M., T. Suzuki, A. Tanaka and H. Aoki (2019). “Long-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: A 12-month, multicenter, open-label clinical trial.” J Dermatol Sci 94(3): 339-345.

https://doi.org/10.1016/j.jdermsci.2019.05.008 DOI: https://doi.org/10.1016/j.jdermsci.2019.05.008

Hirschfield, G. M., C. L. Bowlus, M. J. Mayo and A. E. e. a. Kremer (2024). “A phase 3 trial of seladelpar in primary biliary cholangitis.” N Engl J Med 390(9): 783-794.

https://doi.org/10.1056/NEJMoa2312100 DOI: https://doi.org/10.1056/NEJMoa2312100

Hirschfield, G. M., M. L. Shiffman, A. Gulamhusein and K. V. e. a. Kowdley (2023). “Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.” Hepatology 78(2): 397-415.

https://doi.org/10.1097/HEP.0000000000000395 DOI: https://doi.org/10.1097/HEP.0000000000000395

Hoare, C., A. Li Wan Po and H. Williams (2000). “Systematic review of treatments for atopic eczema.” Health Technol Assess 4(37): 1-191.

https://doi.org/10.3310/hta4370 DOI: https://doi.org/10.3310/hta4370

Hołdrowicz, A. M. and A. Woźniacka (2024). “The Efficacy and Effectiveness of the Biological Treatment of Pruritus in the Course of Atopic Dermatitis.” J Clin Med 13(6): 1754.

https://doi.org/10.3390/jcm13061754 DOI: https://doi.org/10.3390/jcm13061754

Holme, S. A. and A. V. Anstey (2001). “Aquagenic pruritus responding to intermittent photochemotherapy.” Clin Exp Dermatol 26(1): 40-41.

https://doi.org/10.1046/j.1365-2230.2001.00757.x DOI: https://doi.org/10.1046/j.1365-2230.2001.00757.x

Holmes, R. C. (1988). “Polymorphic eruption in pregnancy.” Sem Dermatol 8: 18-22.

Hong, J., J. Buddenkotte, T. G. Berger and M. Steinhoff (2011). “Management of itch in atopic dermatitis.” Semin Cutan Med Surg 30(2): 71-86.

https://doi.org/10.1016/j.sder.2011.05.002 DOI: https://doi.org/10.1016/j.sder.2011.05.002

Hoogenberg, K., R. A. Tupker, L. H. van Essen, A. J. Smit and C. G. Kallenberg (1992). “Successful treatment of ulcerating livedo reticularis with infusions of prostacyclin.” Br J Dermatol 127(1): 64-66.

https://doi.org/10.1111/j.1365-2133.1992.tb14834.x DOI: https://doi.org/10.1111/j.1365-2133.1992.tb14834.x

Horimukai, K., K. Morita, M. Narita, M. Kondo, H. Kitazawa, M. Nozaki and Y. e. a. Shigematsu (2014). “Application of moisturizer to neonates prevents development of atopic dermatitis.” J Allergy Clin Immunol 134(4): 824-830.e826.

https://doi.org/10.1016/j.jaci.2014.07.060 DOI: https://doi.org/10.1016/j.jaci.2014.07.060

Hsu, M. M. and C. C. Yang (2003). “Uraemic pruritus responsive to broadband ultraviolet (UV) B therapy does not readily respond to narrowband UVB therapy.” Br J Dermatol 149(4): 888-889.

https://doi.org/10.1046/j.1365-2133.2003.05590.x DOI: https://doi.org/10.1046/j.1365-2133.2003.05590.x

Hu, M., J. Scheffel, S. Frischbutter, C. Steinert, U. Reidel, M. Spindler, K. Przybyłowicz, M. Hawro, M. Maurer, M. Metz and T. Hawro (2024). “Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas.” Clin Exp Med 24(1): 171.

https://doi.org/10.1007/s10238-024-01407-y DOI: https://doi.org/10.1007/s10238-024-01407-y

Huang, D., J. Lu and F. Tan (2024). “Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study.” Dermatitis 35(1): 77-83.

https://doi.org/10.1089/derm.2023.0132 DOI: https://doi.org/10.1089/derm.2023.0132

Ingrasci, G., L. Tornes, A. Brown, S. Delgado, J. Hernandez and Q. V. Yap (2023). “Chronic pruritus in multiple sclerosis and clinical correlates.” J Eur Acad Dermatol Venereol 37(1): 154-159.

https://doi.org/10.1111/jdv.18561 DOI: https://doi.org/10.1111/jdv.18561

Ingrassia, J. P., M. H. Maqsood, J. M. Gelfand and B. N. e. a. Weber (2024). “Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis.” JAMA Dermatol 160(1): 28-36.

https://doi.org/10.1001/jamadermatol.2023.4090 DOI: https://doi.org/10.1001/jamadermatol.2023.4090

Ireland, P. A., N. Jansson, S. K. R. Spencer, J. Braden and D. Sebaratnam (2024). “Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials.” JAMA Dermatol 160(3): 281-289.

https://doi.org/10.1001/jamadermatol.2023.5509 DOI: https://doi.org/10.1001/jamadermatol.2023.5509

Ishida, J. H., C. E. McCulloch, M. A. Steinman, B. A. Grimes and K. L. Johansen (2018). “Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients.” J Am Soc Nephrol 29(7): 1970-1979.

https://doi.org/10.1681/ASN.2018010096 DOI: https://doi.org/10.1681/ASN.2018010096

Jabbour, S. A. (2003). “Cutaneous manifestations of endocrine disorders: a guide for dermatologists.” Am J Clin Dermatol 4(5): 315-331.

https://doi.org/10.2165/00128071-200304050-00003 DOI: https://doi.org/10.2165/00128071-200304050-00003

Jahn, S., G. von Kobyletzki, S. Behrens, A. Röchling, P. Altmeyer and M. Kerscher (1997). “Erfolgreiche Behandlung des aquagenen Pruritus mit PUVA-Bad-Photochemotherapie.” Z Hautkr 72: 821-824.

Jain, V., A. Giménez-Arnau, K. Hayama and A. e. a. Reich (2024). “Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.” J Allergy Clin Immunol 153(2): 479-486.e474.

https://doi.org/10.1016/j.jaci.2023.10.007 DOI: https://doi.org/10.1016/j.jaci.2023.10.007

Jaworek, A., K. Szafraniec, M. Jaworek, Ł. Matusiak, A. Wojas-Pelc and J. C. Szepietowski (2020). “Itch Relief in Atopic Dermatitis: Comparison of Narrowband Ultraviolet B Radiation and Cyclosporine Treatment.” Acta Derm Venereol 100(17): adv00291.

https://doi.org/10.2340/00015555-3652 DOI: https://doi.org/10.2340/00015555-3652

Jeanmougin, M., J. D. Rain and Y. Najean (1996). “Efficacy of photochemotherapy on severe pruritus in polycythemia vera.” Ann Hematol 73(2): 91-93.

https://doi.org/10.1007/s002770050207 DOI: https://doi.org/10.1007/s002770050207

Jia, H.-X. and Y.-L. He (2020). “Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Am J Ther 27(5): e455-e467.

https://doi.org/10.1097/MJT.0000000000000912 DOI: https://doi.org/10.1097/MJT.0000000000000912

Johannesdottir, S. A., B. K. Farkas, G. R. Vinding, L. Pedersen, A. Lamberg, H. T. Sorensen and A. B. Olesen (2014). “Cancer incidence among patients with a hospital diagnosis of pruritus: a nationwide Danish cohort study.” Br J Dermatol 171(4): 839-846.

https://doi.org/10.1111/bjd.13157 DOI: https://doi.org/10.1111/bjd.13157

Johnke, H. and H. Zachariae (1993). “Thaildomide treatment of prurigo nodularis.” Ugeskr Laeger 155(38): 3028-3030.

Ju, T., A. Vander Does and G. Yosipovitch (2022). “Scalp dysesthesia: a neuropathic phenomenon.” J Eur Acad Dermatol Venereol 36(6): 790-796.

https://doi.org/10.1111/jdv.17985 DOI: https://doi.org/10.1111/jdv.17985

Kabashima, K., T. Matsumura, H. Komazaki and M. Kawashima (2020). “Trial of Nemolizumab and Topical Agents for Atopic Dermatitis With Pruritus.” N Engl J Med 38(2): 141-150.

https://doi.org/10.1056/NEJMoa1917006 DOI: https://doi.org/10.1056/NEJMoa1917006

Kalb, R. E., J. Bagel, N. J. Korman, M. G. Lebwohl, M. Young, E. J. Horn, A. S. Van Vorhees and N. P. Foundation (2009). “Treatment of intertriginous psoriasis: From the Medical Board of the National Psoriasis Foundation.” J Am Acad Derm 60(1): 120-124.

https://doi.org/10.1016/j.jaad.2008.06.041 DOI: https://doi.org/10.1016/j.jaad.2008.06.041

Kamata, Y., M. Tominaga and K. Takamori (2016). “Itch in Atopic Dermatitis Management.” Curr Probl Dermatol 50: 86-93.

https://doi.org/10.1159/000446048 DOI: https://doi.org/10.1159/000446048

Kanavy, H., J. Bahner and N. J. Korman (2012). “Treatment of refractory prurigo nodularis with lenalidomide.” Arch Dermatol 148(7): 794-796.

https://doi.org/10.1001/archdermatol.2011.2918 DOI: https://doi.org/10.1001/archdermatol.2011.2918

Kanitakis, J. (2006). “Brachioradial pruritus: report of a new case responding to gabapentin.” Eur J Dermatol 16(3): 311-312.

Kaplan, A. P. (1984). “Drug-induced skin disease.” J Allergy Clin Immunol 74(4 Pt 2): 573-579.

https://doi.org/10.1016/0091-6749(84)90109-X DOI: https://doi.org/10.1016/0091-6749(84)90109-X

Kaptanoglu, A. F. and T. Oskay (2003). “Ultraviolet B treatment for pruritus in Hodgkin’s lymphoma.” J Eur Acad Dermatol Venereol 17(4): 489-490.

https://doi.org/10.1046/j.1468-3083.2003.00614_15.x DOI: https://doi.org/10.1046/j.1468-3083.2003.00614_15.x

Karaosmanoğlu, N., P. O. Cetinkaya, İ. Yüksel, I. Bilen and C. Mülkoğlu (2024). “Investigating the relationship between chronic pruritus and fibromyalgia: an evaluation of 200 patients.” Arch Dermatol Res 316(8): 545.

https://doi.org/10.1007/s00403-024-03291-8 DOI: https://doi.org/10.1007/s00403-024-03291-8

Karppinen, A., H. Brummer-Korvenkontio, T. Reunala and I. Izquierdo (2012). “Rupatadine 10 mg in the treatment of immediate mosquito-bite allergy.” J Eur Acad Dermatol Venereol 26: 919-922.

https://doi.org/10.1111/j.1468-3083.2012.04543.x DOI: https://doi.org/10.1111/j.1468-3083.2012.04543.x

Kaur, R. and V. R. Sinha (2018). “Antidepressants as antipruritic agents: A review.” Eur Neuropsychopharmacol 28(3): 341-352.

https://doi.org/10.1016/j.euroneuro.2018.01.007 DOI: https://doi.org/10.1016/j.euroneuro.2018.01.007

Kaur, S., I. S. Jabbal and A. K. Bhasin (2022). “Omalizumab as a treatment option for antihistamine-refractory aquagenic urticaria.” BMJ Case Rep 15(7): e251057.

https://doi.org/10.1136/bcr-2022-251057 DOI: https://doi.org/10.1136/bcr-2022-251057

Kaushik, S. B., F. B. Cerci, J. Miracle, A. Pokharel, S. C. Chen, Y. H. Chan, A. Wilkin and G. Yosipovitch (2014). “Chronic pruritus in HIV-positive patients in the southeastern United States: its prevalence and effect on quality of life.” J Am Acad Dermatol 70(4): 659-664.

https://doi.org/10.1016/j.jaad.2013.12.015 DOI: https://doi.org/10.1016/j.jaad.2013.12.015

Keaney, T. C., T. Bhutani, P. Sivanesan, G. D. Bandow, S. B. Weinstein, L. C. Cheung, F. Malick and J. Koo (2012). “Open-label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis.” J Am Acad Dermatol 67(4): 636-641.

https://doi.org/10.1016/j.jaad.2011.10.033 DOI: https://doi.org/10.1016/j.jaad.2011.10.033

Kee, Y. K., H. J. Jeon, J. Oh and D. H. Shin (2024). “Vitamin D and narrowband ultraviolet B phototherapy for chronic kidney disease-associated pruritus.” Kidney Res Clin Pract 43(2): 177-185.

https://doi.org/10.23876/j.krcp.22.153 DOI: https://doi.org/10.23876/j.krcp.22.153

Kemperman, P. M. J. H., N. C. C. Vulink, C. Smit, J. W. Hovius and M. A. de Rie (2024). “Review of literature and clinical practice experience for the therapeutic management of Morgellons disease.” J Eur Acad Dermatol Venereol 38(7): 1300-1304.

https://doi.org/10.1111/jdv.19831 DOI: https://doi.org/10.1111/jdv.19831

Keshari, S., A. D. Sipayung, C.-C. Hsieh, L.-J. Su, Y.-R. Chiang, H.-C. Chang, Y. W.-C., T.-H. Chuang, C.-L. Chen and C.-M. Huang (2019). “IL-6/p-BTK/p-ERK signaling mediates calcium phosphate-induced pruritus.” FASEB J 33: 12036-12046.

https://doi.org/10.1096/fj.201900016RR DOI: https://doi.org/10.1096/fj.201900016RR

Khan, N. J., Wahaj, S. Haider, H. Gilani and N. Iqbal, et al. (2022). “Comparing The Efficacy And Safety Of Pregabalin Vs Gabapentin In Uremic Pruritus In Patients Of Chronic Kidney Injury Undergoing Haemodialysis.” J Ayub Med Coll Abbottabad 34(3): 524-527.

Khanna, R., E. Boozalis, M. Belzberg, J. G. Zampella and S. G. Kwatra (2019). “Mirtazapine for the Treatment of Chronic Pruritus.” Medicines (Basel) 6(3): 73.

https://doi.org/10.3390/medicines6030073 DOI: https://doi.org/10.3390/medicines6030073

Kibsgaard, L., B. Bay, M. Deleuran and C. Vestergaard (2015). “A retrospective consecutive case-series study on the effect of systemic treatment, length of admission time, and co-morbidities in 98 bullous pemphigoid patients admitted to a tertiary centre.” Acta Derm Venereol 95(3): 307-311.

https://doi.org/10.2340/00015555-1925 DOI: https://doi.org/10.2340/00015555-1925

Kilic, A., U. Gul and S. Soylu (2007). “Skin findings in internal malignant diseases.” Int. J Dermatol 46: 1055-1060.

https://doi.org/10.1111/j.1365-4632.2007.03288.x DOI: https://doi.org/10.1111/j.1365-4632.2007.03288.x

Kim, B. S., R. Bissonnette, K. Nograles, C. Munera and N. Shah (2023). “Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.” N Engl J Med 388(6): 511-517.

https://doi.org/10.1056/NEJMoa2210699 DOI: https://doi.org/10.1056/NEJMoa2210699

Kim, H. J., M. Zeidi, D. Bonciani, S. M. Pena, J. Tiao, S. Sahu and V. P. Werth (2018). “Itch in dermatomyositis: the role of increased skin interleukin-31.” Br J Dermatol 179(3): 669-678.

https://doi.org/10.1111/bjd.16498 DOI: https://doi.org/10.1111/bjd.16498

Kim, Y. J., D. J. Lim, M. Y. Lee, W. J. Lee, S. E. Chang and C. H. Won (2021). “Prospective, comparative clinical pilot study of cold atmospheric plasma device in the treatment of atopic dermatitis.” Sci Rep 11: 14461.

https://doi.org/10.1038/s41598-021-93941-y DOI: https://doi.org/10.1038/s41598-021-93941-y

Kimball, A. B., T. Luger, A. Gottlieb, L. Puig, R. Kaufmann, R. Burge, C. Y. Lin and G. Yosipovitch (2018). “Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension.” Acta Derm Venereol 98(98-102).

https://doi.org/10.2340/00015555-2801 DOI: https://doi.org/10.2340/00015555-2801

Kimmel, M., D. M. Alscher, R. Dunst, N. Braun, C. Machleidt, T. Kiefer, C. Stulten, H. van der Kuip, C. Pauli-Magnus, U. Raub, U. Kuhlmann and T. Mettang (2006). “The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients.” Nephrol Dial Transplant 21(3): 749-755.

https://doi.org/10.1093/ndt/gfi204 DOI: https://doi.org/10.1093/ndt/gfi204

Kirby, B. and S. Rogers (1997). “Treatment of PUVA itch with capsaicin.” Br J Dermatol 137(1): 152.

https://doi.org/10.1111/j.1365-2133.1997.tb03723.x DOI: https://doi.org/10.1111/j.1365-2133.1997.tb03723.x

Kishimoto, S., N. Watanabe, Y. Yamamoto, T. Imai, R. Aida, C. Germer, R. Tamagawa-Mineoka, R. Shimizu, S. Hickman, Y. Nakayama, T. Etoh, E. Sahker, M. B. Carnie and T. A. Furukawa (2023). “Efficacy of Integrated Online Mindfulness and Self-compassion Training for Adults With Atopic Dermatitis: A Randomized Clinical Trial.” JAMA Dermatol 159(6): 628-636.

https://doi.org/10.1001/jamadermatol.2023.0975 DOI: https://doi.org/10.1001/jamadermatol.2023.0975

Kleinman, E., J. Laborada, L. Metterle and L. F. Eichenfield (2022). “What’s New in Topicals for Atopic Dermatitis?” Am J Clin Dermatol 23(5): 595-603.

https://doi.org/10.1007/s40257-022-00712-0 DOI: https://doi.org/10.1007/s40257-022-00712-0

Klejtman, T., M. Beylot-Barry, P. Joly, M. A. Richard, S. Debarbieux, L. Misery, P. Wolkenstein, O. Chosidow and S. Ingen-Housz-Oro (2018). “Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases.”.J Eur Acad Dermatol Venereol 32(3): 437-440.

https://doi.org/10.1111/jdv.14646 DOI: https://doi.org/10.1111/jdv.14646

Knolle, E., M. Zadrazil, G. G. Kovacs, S. Medwed, G. Scharbert and M. Schemper (2013). “Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo-controlled study.” Pain 154(12): 2729-2236.

https://doi.org/10.1016/j.pain.2013.08.001 DOI: https://doi.org/10.1016/j.pain.2013.08.001

Ko, M. J., J. Y. Yang, H. Y. Wu, F. C. Hu, S. I. Chen, P. J. Tsai, S. H. Jee and H. C. Chiu (2011). “Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial.” Br J Dermatol 165(3): 633-639.

https://doi.org/10.1111/j.1365-2133.2011.10448.x DOI: https://doi.org/10.1111/j.1365-2133.2011.10448.x

Koh, M. J. and W. S. Chong (2009). “Aquagenic pruritus responding to combined ultraviolet A/narrowband ultraviolet B therapy.” Photodermatol Photoimmunol Photomed 25(3): 169-170.

https://doi.org/10.1111/j.1600-0781.2009.00429.x DOI: https://doi.org/10.1111/j.1600-0781.2009.00429.x

Kong, H. E., S. Francois, S. Smith, G. Lee, B. Bradley, K.-H. Chen, L. P. Lawley, M. Spraker, J. S. Roberts and S. C. Chen (2021). “Tools to study the severity of itch in 8-to 17 year old children : Validation of TweenItchyQOL and ItchyQuant.” Pediatr Dermatol 38: 1118-1126.

https://doi.org/10.1111/pde.14662 DOI: https://doi.org/10.1111/pde.14662

Kong, X., Y. Kong, F. Zhang, T. Wang and J. Yan (2016). “Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study).” Medicine (Baltimore) 95(40): e494.

https://doi.org/10.1097/MD.0000000000004949 DOI: https://doi.org/10.1097/MD.0000000000004949

Kopecky, E. A., S. Jacobson, M. B. Bch, P. Hubley, L. Palozzi, H. M. Clarke and G. Koren (2001). “Safety and pharmacokinetics of EMLA in the treatment of postburn pruritus in pediatric patients: a pilot study.” J Burn Care Rehabil 22(3): 235-242.

https://doi.org/10.1097/00004630-200105000-00010 DOI: https://doi.org/10.1097/00004630-200105000-00010

Koschmieder, S., S. Isfort, D. Wolf, F. H. Heidel and A. Hochhaus, et al. (2023). “Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.” Ann Hematol 102(2): 349-358.

https://doi.org/10.1007/s00277-022-05080-7 DOI: https://doi.org/10.1007/s00277-022-05080-7

Koumaki, D., S. Gregoriou, G. Evangelou and K. Krasagakis (2023). “Pruritogenic Mediators and New Antipruritic Drugs in Atopic Dermatitis.” J Clin Med 12(6): 2091.

https://doi.org/10.3390/jcm12062091 DOI: https://doi.org/10.3390/jcm12062091

Kouwenhoven, T. A., P. C. M. van de Kerkhof and M. Kamsteeg (2017). “Use of oral antidepressants in patients with chronic pruritus: A systematic review.” J Am Acad Dermatol 77(6): 1068-1073.e1067.

https://doi.org/10.1016/j.jaad.2017.08.025 DOI: https://doi.org/10.1016/j.jaad.2017.08.025

Kouwenhoven, T. A., M. E. van Muijen and v. d. K. P. C. M. et. al. (2024). “Effectiveness of Systemic Treatments on Pruritus Associated With Atopic Dermatitis: A Systematic Review in Pediatric Patients.” Pediatr Dermatol 41(1): 34-40.

https://doi.org/10.1111/pde.15468 DOI: https://doi.org/10.1111/pde.15468

Krajnik, M. and Z. Zylicz (2001). “Pruritus in advanced internal diseases. Pathogenesis and treatment.” Neth J Med 58(1): 27-40.

https://doi.org/10.1016/S0300-2977(00)00084-X DOI: https://doi.org/10.1016/S0300-2977(00)00084-X

Kraut, R. Y. (2017). “Treatment of pruritus in a palliative care patient with low-dose paroxetine: a case report.” J Med Case Rep 11(1): 280.

https://doi.org/10.1186/s13256-017-1437-6 DOI: https://doi.org/10.1186/s13256-017-1437-6

Kremer, A. E., R. Bolier, R. van Dijk, R. P. Oude Elferink and U. Beuers (2014). “Advances in pathogenesis and management of pruritus in cholestasis.” Dig Dis 32(5): 637-645.

https://doi.org/10.1159/000360518 DOI: https://doi.org/10.1159/000360518

Kremer, A. E., R. V. Dijk, P. Leckie, F. G. Schaap, E. M. Kuiper, T. Mettang, K. S. Reiners, U. Raap, H. R. Buuren, K. J. Erpecum, N. A. Davies, C. Rust, A. Engert, R. Jalan, R. P. Elferink and U. Beuers (2012). “Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions.” Hepatology.

https://doi.org/10.1002/hep.25748 DOI: https://doi.org/10.1002/hep.25748

Kremer, A. E., M. J. Mayo, G. M. Hirschfield and C. e. a. Levy (2024). “Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.” Hepatology 80(1): 27-37.

https://doi.org/10.1097/HEP.0000000000000728 DOI: https://doi.org/10.1097/HEP.0000000000000728

Kremer, A. E., B. Namer, R. Bolier, M. J. Fischer, R. P. Oude Elferink and U. Beuers (2015). “Pathogenesis and management of pruritus in PBC and PSC.” Dig Dis 33(Suppl 2): 164-175.

https://doi.org/10.1159/000440829 DOI: https://doi.org/10.1159/000440829

Kuhn, A., K. Gensch, M. Haust, S. W. Schneider, G. Bonsmann, N. Gaebelein-Wissing, P. Lehmann, A. Wons, P. Reitmeir, V. Ruland, T. A. Luger and T. Ruzicka (2011). “Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial.” J Am Acad Dermatol 65(1): 54-64, 64 e51-52.

https://doi.org/10.1016/j.jaad.2010.03.037 DOI: https://doi.org/10.1016/j.jaad.2010.03.037

Kumada, H., H. Miyakawa, T. Muramatsu, N. Ando, T. Oh, K. Takamori and H. Nakamoto (2016). “Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial.” Hepatol Res.

https://doi.org/10.1111/hepr.12830 DOI: https://doi.org/10.1111/hepr.12830

Kumagai, H., T. Ebata, K. Takamori, K. Miyasato, T. Muramatsu, H. Nakamoto, M. Kurihara, T. Yanagita and H. Suzuki (2012). “Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients.” Am J Nephrol 36(2): 175-183.

https://doi.org/10.1159/000341268 DOI: https://doi.org/10.1159/000341268

Kumagai, H., T. Ebata, K. Takamori, T. Muramatsu, H. Nakamoto and H. Suzuki (2010). “Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.” Nephrol Dial Transplant 25(4): 1251-1257.

https://doi.org/10.1093/ndt/gfp588 DOI: https://doi.org/10.1093/ndt/gfp588

Kupsa, R., A. Gruber-Wackernagel, A. Hofer, F. Quehenberger, P. Wolf and F. J. Legat (2023). “Narrowband-ultraviolet B vs Broadband-ultraviolet B in Treatment of Chronic Pruritus: A Randomized, Single-blinded, Non-inferiority Study.” Acta Derm Venereol 103: adv9403.

https://doi.org/10.2340/actadv.v103.9403 DOI: https://doi.org/10.2340/actadv.v103.9403

Kursewicz, C., E. Fowler, J. Rosen, D. Castillo, Y. H. Chan, L. Nattkemper and G. Yosipovitch (2020). “Sex differences in the perception of itch and quality of life in patients with chronic pruritus in the United States.” Itch 5(3): p e41.

https://doi.org/10.1097/itx.0000000000000041 DOI: https://doi.org/10.1097/itx.0000000000000041

Kuypers, D. R., K. Claes, P. Evenepoel, B. Maes and Y. Vanrenterghem (2004). “A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy.” Nephrol Dial Transplant 19(7): 1895-1901.

https://doi.org/10.1093/ndt/gfh202 DOI: https://doi.org/10.1093/ndt/gfh202

Kwatra, S. G., Z. A. Bordeaux, V. Parthasarathy and A. L. e. a. Kollhoff (2024). “Efficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin. A Nonrandomized Controlled Trial.” JAMA Dermatol 160(7): 717-724.

https://doi.org/10.1001/jamadermatol.2024.1464 DOI: https://doi.org/10.1001/jamadermatol.2024.1464

Kwatra, S. G., S. Stander, J. D. Bernhard, E. Weisshaar and G. Yosipovitch (2013). “Brachioradial pruritus: a trigger for generalization of itch.” J Am Acad Dermatol 68(5): 870-873.

https://doi.org/10.1016/j.jaad.2012.11.026 DOI: https://doi.org/10.1016/j.jaad.2012.11.026

Kwatra, S. G., G. Yosipovitch, F. J. Legat and A. e. a. Reich (2023). “Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.” N Engl J Med 389(17): 1579-1589.

https://doi.org/10.1056/NEJMoa2301333 DOI: https://doi.org/10.1056/NEJMoa2301333

Kwatra, S. G., G. Yosipovitch, S. Ständer and I. e. a. Guillemin (2024). “Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis.” J Eur Acad Dermatol Venereol 38(10): 1965-1972.

https://doi.org/10.1111/jdv.20099 DOI: https://doi.org/10.1111/jdv.20099

Labib, A., L. A. Nattkemper, A. Vander Does, T. Ju, S. Cacciapuoti, M. Vastarella, G. Fabbrocini and G. Yosipovitch (2022). “LB1043 COVID-19-associated pruritus is non-histaminergic mediated.” J Invest Dermatol 142(8): B38.

https://doi.org/10.1016/j.jid.2022.05.1081 DOI: https://doi.org/10.1016/j.jid.2022.05.1081

Labib, A., J. Rosen and G. Yosipovitch (2022). Skin Manifestations of Diabetes Mellitus. Endotext [Internet]. K. R. Feingold, B. Anawalt and M. R. e. a. Blackman. South Dartmouth (MA), MDText.com, Inc.

Lam, M., J. W. Zhu, M. Tadrous and A. M. Drucker (2021). “Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.” JAMA Dermatol 157(5): 549-558.

https://doi.org/10.1001/jamadermatol.2021.0345 DOI: https://doi.org/10.1001/jamadermatol.2021.0345

Langley, R. G., B. E. Elewski, M. Lebwohl and K. e. a. Reich (2014). “Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials.” N Engl J Med 371(4): 326-338.

https://doi.org/10.1056/NEJMoa1314258 DOI: https://doi.org/10.1056/NEJMoa1314258

Laniosz, V., D. A. Wetter and D. A. Godar (2014). “Dermatologic manifestations of fibromyalgia.” Clin Rheumatol 33(7): 1009-1013.

https://doi.org/10.1007/s10067-014-2488-3 DOI: https://doi.org/10.1007/s10067-014-2488-3

Larson, V. A., O. Tang, S. Ständer, S. Kang and S. G. Kwatra (2018). “Association between itch and cancer in 16,925 patients with pruritus: Experience at a tertiary care center.” J Am Acad Dermatol 80(4): 931-937.

https://doi.org/10.1016/j.jaad.2018.08.044 DOI: https://doi.org/10.1016/j.jaad.2018.08.044

Lavda, A. C., T. L. Webb and A. R. Thompson (2012). “A meta-analysis of the effectiveness of psychological interventions for adults with skin conditions.” Br J Dermatol 167(970-979).

https://doi.org/10.1111/j.1365-2133.2012.11183.x DOI: https://doi.org/10.1111/j.1365-2133.2012.11183.x

Lavery, M. J., C. Stull, M. O. Kinney and G. Yosipovitch (2016). “Nocturnal Pruritus: The Battle for a Peaceful Night’s Sleep.” Int J Mol Sci 17: 425.

https://doi.org/10.3390/ijms17030425 DOI: https://doi.org/10.3390/ijms17030425

Lawson, V., M. S. Lewis-Jones, A. Y. Finlay, P. Reid and R. G. Owens (1998). “The family impact of childhood atopic dermatitis : the dermatitis family impact questionnaire.” Br J Dermatol 138: 107-113.

https://doi.org/10.1046/j.1365-2133.1998.02034.x DOI: https://doi.org/10.1046/j.1365-2133.1998.02034.x

Layton, A. M. and J. A. Cotterill (1991). “Notalgia paraesthetica--report of three cases and their treatment.” Clin Exp Dermatol 16(3): 197-198.

https://doi.org/10.1111/j.1365-2230.1991.tb00345.x DOI: https://doi.org/10.1111/j.1365-2230.1991.tb00345.x

Lebwohl, M., R. B. Warren, H. Sofen and S. e. a. Imafuku (2024). “Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.” Br J Dermatol 190(5): 668-679.

https://doi.org/10.1093/bjd/ljae014 DOI: https://doi.org/10.1093/bjd/ljae014

Lebwohl, M. G., L. H. Kircik, A. Y. Moore and L. e. a. Stein Gold (2022). “Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.” JAMA 328(11): 1073-1084.

https://doi.org/10.1001/jama.2022.15632 DOI: https://doi.org/10.1001/jama.2022.15632

Lebwohl, M. G., K. A. Papp, L. Stein Gold and M. J. e. a. Gooderham (2020). “Trial of Roflumilast Cream for Chronic Plaque Psoriasis.” N Engl J Med 383(3): 229-239.

https://doi.org/10.1056/NEJMoa2000073 DOI: https://doi.org/10.1056/NEJMoa2000073

Lebwohl, M. G., L. Stein Gold, B. Strober and K. A. e. a. Papp (2021). “Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.” N Engl J Med 385(24): 2219-2229.

https://doi.org/10.1056/NEJMoa2103629 DOI: https://doi.org/10.1056/NEJMoa2103629

Lee, E., J. Koo and T. G. Berger (2005). “UVB phototherapy and skin cancer risk: a review of the literature.” Int J Dermatol 44(5): 355-360.

https://doi.org/10.1111/j.1365-4632.2004.02186.x DOI: https://doi.org/10.1111/j.1365-4632.2004.02186.x

Lee, F. J., B. S. Frankum and C. H. Katelaris (2012). “Poor efficacy of oral tacrolimus in the treatment of severe generalized atopic eczema in adults: a small retrospective case series.” Australas J Dermatol 53(4): 295-297.

https://doi.org/10.1111/j.1440-0960.2011.00789.x DOI: https://doi.org/10.1111/j.1440-0960.2011.00789.x

Lee, J. J., S. D. Girouard, V. M. Carlberg and A. Mostaghimi (2016). “Effective use of mirtazapine for refractory pruritus associated with carcinoma en cuirasse.” BMJ Support Palliat Care 2016(1): 119-121.

https://doi.org/10.1136/bmjspcare-2014-000790 DOI: https://doi.org/10.1136/bmjspcare-2014-000790

Lee, J. J., C. Morillo-Hernandez, V. Agarwal, C. J. Standaert and J. C. r. English (2023). “Cervical spine imaging and treatment outcomes in scalp dysesthesia: A retrospective cohort study.” J Am Acad Dermatol 88(3): 655-656.

https://doi.org/10.1016/j.jaad.2020.08.010 DOI: https://doi.org/10.1016/j.jaad.2020.08.010

Lee, S. S., G. Yosipovitch, Y. H. Chan and C. L. Goh (2004). “Pruritus, pain, and small nerve fiber function in keloids: a controlled study.” J Am Acad Dermatol 51(6): 1002-1006.

https://doi.org/10.1016/j.jaad.2004.07.054 DOI: https://doi.org/10.1016/j.jaad.2004.07.054

Legat, F. J. (2018). “The Antipruritic Effect of Phototherapy.” Front Med (Lausanne) 5: 333.

https://doi.org/10.3389/fmed.2018.00333 DOI: https://doi.org/10.3389/fmed.2018.00333

Legat, F. J. (2019). “Is there still a role for UV therapy in itch treatment?” Exp Dermatol 28(12): 1432-1438.

https://doi.org/10.1111/exd.14011 DOI: https://doi.org/10.1111/exd.14011

Legroux-Crespel, E., J. Clèdes and L. Misery (2004). “A comparative study on the effects of naltrexone and loratadine on uremic pruritus.” Dermatology 208(4): 326-330.

https://doi.org/10.1159/000077841 DOI: https://doi.org/10.1159/000077841

Lepping, P., M. Huber and R. W. Freudenmann (2015). “How to approach delusional infestation.” BMJ 350: h1328.

https://doi.org/10.1136/bmj.h1328 DOI: https://doi.org/10.1136/bmj.h1328

Leslie, T. A. (2013). “Itch.” Medicine 41(7): 367-371.

https://doi.org/10.1016/j.mpmed.2013.04.004

Leslie, T. A. (2013). “Itch.” Medicine 41: 367-371.

https://doi.org/10.1016/j.mpmed.2013.04.004 DOI: https://doi.org/10.1016/j.mpmed.2013.04.004

Leslie, T. A. (2015). Antihistamines. Abingdon, Taylor and Francis Group.

https://doi.org/10.1201/b18491-8 DOI: https://doi.org/10.1201/b18491-8

Leslie, T. A. (2016). “Itch management in the elderly.” Curr Prob Dermatol 50: 192-201.

https://doi.org/10.1159/000446094

Leslie, T. A. (2016). “Itch Management in the Elderly.” Curr Probl Dermatol 50: 192-201.

https://doi.org/10.1159/000446094 DOI: https://doi.org/10.1159/000446094

Leslie, T. A. and C. H. Grattan (2017). Antihistamines, sodium cromoglicate, and leukotriene receptor antagonists. Handbook of Dermatology Treatment. M. Arden-Jones, P. Hampton and R. A. Vleugels. London, JP Medical Ltd: 64-67 (in press).

Leslie, T. A., M. W. Greaves and G. Yosipovitch (2015). “Current topical and systemic therapies for itch.” Handb Exp Pharmacol 226: 337-356.

https://doi.org/10.1007/978-3-662-44605-8_18 DOI: https://doi.org/10.1007/978-3-662-44605-8_18

Lewis-Jones, M. S. and A. Y. Finlay (1995). “The Children’s Dermatology Life Quality Index ( CDLQI): initial validation and practical use.” Br J Dermatol 132: 942-949.

https://doi.org/10.1111/j.1365-2133.1995.tb16953.x DOI: https://doi.org/10.1111/j.1365-2133.1995.tb16953.x

Lewis-Jones, S. (2001). “Atopic dermatitis in childhood.” Hosp Med 62: 136-143.

https://doi.org/10.12968/hosp.2001.62.3.1531 DOI: https://doi.org/10.12968/hosp.2001.62.3.1531

Liao, V., H. L. Cornman, E. Ma and S. G. Kwatra (2024). “Prurigo nodularis: new insights into pathogenesis and novel therapeutics.” Br J Dermatol 190(6): 798-810.

https://doi.org/10.1093/bjd/ljae052 DOI: https://doi.org/10.1093/bjd/ljae052

Lim, H. W., S. Vallurupalli, T. Meola and N. A. Soter (1997). “UVB phototherapy is an effective treatment for pruritus in patients infected with HIV.” J Am Acad Dermatol 37(3 Pt 1): 414-417.

https://doi.org/10.1016/S0190-9622(97)70142-7 DOI: https://doi.org/10.1016/S0190-9622(97)70142-7

Lim, V. M., E. L. Maranda, V. Patel, B. J. Simmons and J. J. Jimenez (2016). “A review of the efficacy of Thalidomide and Lenalidomide in the treatment of refractory prurigo nodularis.” Dermatol Ther 6: 397-411.

https://doi.org/10.1007/s13555-016-0122-9 DOI: https://doi.org/10.1007/s13555-016-0122-9

Lim, Y. L., Y. H. Chan, G. Yosipovitch and M. W. Greaves (2008). “Pruritus is a common and significant symptom of acne.” J Eur Acad Dermatol Venereol 22(11): 1332-1336.

https://doi.org/10.1111/j.1468-3083.2008.02828.x DOI: https://doi.org/10.1111/j.1468-3083.2008.02828.x

Lindelof, B., B. Sigurgeirsson, E. Tegner, O. Larko, A. Johannesson, B. Berne, B. Ljunggren, T. Andersson, L. Molin, E. Nylander-Lundqvist and L. Emtestam (1999). “PUVA and cancer risk: the Swedish follow-up study.” Br J Dermatol 141(1): 108-112.

https://doi.org/10.1046/j.1365-2133.1999.02928.x DOI: https://doi.org/10.1046/j.1365-2133.1999.02928.x

Lindh, J. D. and M. Bradley (2015). “Clinical Effectiveness of Moisturizers in Atopic Dermatitis and Related Disorders: A Systematic Review.” Am J Clin Dermatol 16(5): 341-359.

https://doi.org/10.1007/s40257-015-0146-4 DOI: https://doi.org/10.1007/s40257-015-0146-4

Lisante, T. A., C. Nuñez and P. Zhang (2017). “Efficacy and safety of an over-the-counter 1% colloidal oatmeal cream in the management of mild to moderate atopic dermatitis in children: a double-blind, randomized, active-controlled study.” J Dermatolog Treat 28(7): 659-667.

https://doi.org/10.1080/09546634.2017.1303569 DOI: https://doi.org/10.1080/09546634.2017.1303569

Liu, T., Y. Chu, Y. Wang and X. e. a. Zhong (2023). “Successful treatment of prurigo nodularis with tofacitinib: The experience from a single center.” Int J Dermatol 62(5): e293-e295.

https://doi.org/10.1111/ijd.16568 DOI: https://doi.org/10.1111/ijd.16568

Liu, T., R. Gao, L. Li, B. Wu and F. Wu (2023). “Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System.” Int J Dermatol 45(6): 1483-1491.

https://doi.org/10.1007/s11096-023-01634-5 DOI: https://doi.org/10.1007/s11096-023-01634-5

Lodén, M. (2012). “Effect of moisturizers on epidermal barrier function.” Clin Dermatol 30(3): 286-296.

https://doi.org/10.1016/j.clindermatol.2011.08.015 DOI: https://doi.org/10.1016/j.clindermatol.2011.08.015

Lodén, M. (2003). “Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders.” Am J Clin Dermatol 4(11): 771-788.

https://doi.org/10.2165/00128071-200304110-00005 DOI: https://doi.org/10.2165/00128071-200304110-00005

Long, D., R. A. Long, M. P. Grillo and G. Marshman (2006). “Development of a psychological treatment service for pruritic skin conditions.” Australas J Dermatol 47(237-241).

https://doi.org/10.1111/j.1440-0960.2006.00288.x DOI: https://doi.org/10.1111/j.1440-0960.2006.00288.x

Lönndahl, L., M. Holst, M. Bradley, H. Killasli, J. Heilborn, M. A. Hall, E. Theodorsson, J. Holmberg and K. Nordlind (2018). “Substance P antagonist aprepitant shows no additive effect compared with standardized topical treatment alone in patients with atopic dermatitis.” Acta Derm Venereol 98(3): 324-328.

https://doi.org/10.2340/00015555-2852 DOI: https://doi.org/10.2340/00015555-2852

Lopes, J., M. Teixeira and A. Moreira (2020). “Hypnosis for the treatment of chronic refractory pruritus.” Int J Dermatol 59(300-301).

https://doi.org/10.1111/ijd.14908 DOI: https://doi.org/10.1111/ijd.14908

Lotti, T., P. Teofoli and D. Tsampau (1994). “Treatment of aquagenic pruritus with topical capsaicin cream.” J Am Acad Dermatol 30(2 Pt 1): 232-235.

https://doi.org/10.1016/S0190-9622(94)70022-2 DOI: https://doi.org/10.1016/S0190-9622(94)70022-2

Lowney, A. C., M. A. McAleer, S. Kelly and R. J. McQuillan (2014). “Thalidomide therapy for pruritus in the palliative setting - a distinct subset of patients in whom the benefit may outweigh the risk.” Pain Symptom Manag 48: e3-e5.

https://doi.org/10.1016/j.jpainsymman.2014.06.001 DOI: https://doi.org/10.1016/j.jpainsymman.2014.06.001

Lu, P.-H., C.-H. Chung, H.-E. Chuo, I.-H. Lin and P.-H. Lu (2022). “Efficacy of acupoint stimulation as a treatment for uremic pruritus: A systematic review and meta-analysis.” Front Med 9: 1036072.

https://doi.org/10.3389/fmed.2022.1036072 DOI: https://doi.org/10.3389/fmed.2022.1036072

Luger, T., M. Boguniewicz, W. Carr, M. Cork, M. Deleuran, L. Eichenfield, P. Eigenmann, R. Fölster-Holst, C. Gelmetti, H. Gollnick, E. Hamelmann, A. A. Hebert, A. Muraro, A. P. Oranje, A. S. Paller, C. Paul, L. Puig, J. Ring, E. Siegfried, J. M. Spergel, G. Stingl, A. Taieb, A. Torrelo, T. Werfel and U. Wahn (2015). “Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants.” Pediatr Allergy Immunol 26(4): 306-315.

https://doi.org/10.1111/pai.12331 DOI: https://doi.org/10.1111/pai.12331

Luger, T., A. S. Paller, A. D. Irvine, R. Sidbury, L. F. Eichenfield, T. Werfel and T. Bieber (2021). “Topical therapy of atopic dermatitis with a focus on pimecrolimus.” J Eur Acad Dermatol Venereol 35(7): 1505-1518.

https://doi.org/10.1111/jdv.17272 DOI: https://doi.org/10.1111/jdv.17272

Lynde, C. W., G. Sussman, P. L. Dion, L. Guenther, J. Hébert, J. Rao, T. V. Leek and S. Waserman (2020). “Multidisciplinary Real-World Experience With Bilastine, a Second Generation Antihistamine.” J Drugs Dermatol 19(2): 145-154.

https://doi.org/10.36849/JDD.2020.4835 DOI: https://doi.org/10.36849/JDD.2020.4835

Lysy, J., M. Sistiery-Ittah, Y. Israelit, A. Shmueli, N. Strauss-Liviatan, V. Mindrul, D. Keret and E. Goldin (2003). “Topical capsaicin--a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study.” Gut 52(9): 1323-1326.

https://doi.org/10.1136/gut.52.9.1323 DOI: https://doi.org/10.1136/gut.52.9.1323

Macpherson, L. J., S. W. Hwang, T. Miyamoto, A. E. Dubin, A. Patapoutian and G. M. Story (2006). “More than cool: promiscuous relationships of menthol and other sensory compounds.” Mol Cell Neurosci 32(4): 335-343.

https://doi.org/10.1016/j.mcn.2006.05.005 DOI: https://doi.org/10.1016/j.mcn.2006.05.005

Magerl, M., E. Borzova, A. Gimenez-Arnau, C. E. Grattan, F. Lawlor, P. Mathelier-Fusade, M. Metz, A. Mlynek, M. Maurer and Eaaci/Ga2Len/Edf/Unev (2009). “The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations.” Allergy 64(12): 1715-1721.

https://doi.org/10.1111/j.1398-9995.2009.02177.x DOI: https://doi.org/10.1111/j.1398-9995.2009.02177.x

Magerl, W., R. A. Westerman, B. Mohner and H. O. Handwerker (1990). “Properties of transdermal histamine iontophoresis: differential effects of season, gender, and body region.” J Invest Dermatol 94: 347-352.

https://doi.org/10.1111/1523-1747.ep12874474 DOI: https://doi.org/10.1111/1523-1747.ep12874474

Magnolo, N., T. Jaenicke, A. Tsianakas, W. Czech, D. Thaçi, A. Pinter, D. Kerob, S. Salah and T. A. Luger (2023). “Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial.” J Eur Acad Dermatol Venereol Suppl 5: 18-26.

https://doi.org/10.1111/jdv.18949 DOI: https://doi.org/10.1111/jdv.18949

Mahil, S. K., M. C. Ezejimofor, L. S. Exton and L. e. a. Manounah (2020). “Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.” Br J Dermatol 183(4): 638-649.

https://doi.org/10.1111/bjd.19325 DOI: https://doi.org/10.1111/bjd.19325

Mahmudpour, M., J. Roozbeh, G. A. Raiss Jalali, M. Pakfetrat, S. Ezzat Zadegan and M. M. Sagheb (2017). “Therapeutic effect of montelukastfor treatment of uremic pruritus in hemodialysis patients.” Iran J Kidney Dis 11(1): 50-55.

Majeski, C. J., J. A. Johnson, S. N. Davison and G. J. Lauzon (2007). “Itch Severity Scale: a self-report instrument for the measurement of pruritus severity.” Br J Dermatol 156(4): 667-673.

https://doi.org/10.1111/j.1365-2133.2006.07736.x DOI: https://doi.org/10.1111/j.1365-2133.2006.07736.x

Majoie, I. M., J. M. Oldhoff, H. van Weelden, M. Laaper-Ertmann, M. T. Bousema, V. Sigurdsson, E. F. Knol, C. A. Bruijnzeel-Koomen and M. S. de Bruin-Weller (2009). “Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis.” J Am Acad Dermatol 60(1): 77-84.

https://doi.org/10.1016/j.jaad.2008.08.048 DOI: https://doi.org/10.1016/j.jaad.2008.08.048

Malekzad, F., M. Arbabi, N. Mohtasham, P. Toosi, M. Jaberian, M. Mohajer, M. R. Mohammadi, M. R. Roodsari and S. Nasiri (2009). “Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.” J Eur Acad Dermatol Venereol 23(8): 948-950.

https://doi.org/10.1111/j.1468-3083.2009.03129.x DOI: https://doi.org/10.1111/j.1468-3083.2009.03129.x

Maley, A. and R. A. Swerlick (2015). “Azathioprine treatment of intractable pruritus: A retrospective review.” J Am Acad Dermatol 73(3): 439-443.

https://doi.org/10.1016/j.jaad.2015.05.025 DOI: https://doi.org/10.1016/j.jaad.2015.05.025

Mannix, S., E. Edson-Heredia, A. Paller, S., G. Yosipovitch, R. Burge and L. P. D.-. Kleinman (2021). “The experience of itch in children with psoriasis: A qualitative exploration of the itch Numeric Rating Scale.” Pediatr Dermatol 38: 405-412.

https://doi.org/10.1111/pde.14403 DOI: https://doi.org/10.1111/pde.14403

Martinez-Escribano, J. A., E. Quecedo, J. De la Cuadra, J. Frias, P. Sanchez-Pedreno and A. Aliaga (1997). “Treatment of aquagenic urticaria with PUVA and astemizole.” J Am Acad Dermatol 36(1): 118-119.

https://doi.org/10.1016/S0190-9622(97)70344-X DOI: https://doi.org/10.1016/S0190-9622(97)70344-X

Martora, F., A. Villani, G. Fabbrocini and T. Battista (2022). “COVID-19 and cutaneous manifestations: A review of the published literature.” J Cosmet Dermatol 22(1): 4-10.

https://doi.org/10.1111/jocd.15477 DOI: https://doi.org/10.1111/jocd.15477

Mathur, V. S., J. Kumar, P. W. Crawford, H. Hait, T. Sciascia and T. S. Investigators (2017). “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus.” Am J Nephrol 46(6): 450-458.

https://doi.org/10.1159/000484573 DOI: https://doi.org/10.1159/000484573

Maticic, M., M. Poljak, T. Lunder, K. Rener-Sitar and L. Stojanovic (2008). “Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area.” J Eur Acad Dermatol Venereol 22(7): 779-788.

https://doi.org/10.1111/j.1468-3083.2008.02676.x DOI: https://doi.org/10.1111/j.1468-3083.2008.02676.x

Matsuda, K. M., D. Sharma, A. R. Schonfeld and S. G. Kwatra (2016). “Gabapentin and pregabalin for the treatment of chronic pruritus.” J Am Acad Dermatol 75(3): 619-625.

https://doi.org/10.1016/j.jaad.2016.02.1237 DOI: https://doi.org/10.1016/j.jaad.2016.02.1237

Matsuura, J., A. Kimura, T. Kasai, T. Yoshida, M. Nakagawa and T. Mizuno (2015). “A case of neuromyelitis optica with relapse symptoms from paroxysmal pruritus.” Brain Nerve 67(8): 1057-1060.

Matterne, U., C. J. Apfelbacher, A. Loerbroks, T. Schwarzer, M. Buttner, R. Ofenloch, T. L. Diepgen and E. Weisshaar (2011). “Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study.” Acta Derm Venereol 91(6): 674-679.

https://doi.org/10.2340/00015555-1159 DOI: https://doi.org/10.2340/00015555-1159

Matterne, U., C. J. Apfelbacher, L. Vogelgsang, A. Loerbroks and E. Weisshaar (2013). “Incidence and determinants of chronic pruritus: a population-based cohort study.” Acta Derm Venereol 93(5): 532-537.

https://doi.org/10.2340/00015555-1572 DOI: https://doi.org/10.2340/00015555-1572

Matterne, U., M. M. Böhmer, E. Weisshaar, A. Jupiter, B. Carter and C. J. Apfelbacher (2019). “Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema.” Cochrane Database Syst Rev 1: Cd012167.

https://doi.org/10.1002/14651858.CD012167.pub2 DOI: https://doi.org/10.1002/14651858.CD012167.pub2

Maurer, M., W. Berger, A. Giménez-Arnau and K. e. a. Hayama (2022). “Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.” J Allergy Clin Immunol 150(6): 1498-1506.e1492.

https://doi.org/10.1016/j.jaci.2022.08.027 DOI: https://doi.org/10.1016/j.jaci.2022.08.027

Maurer, M., T. B. Casale, S. S. Saini and M. e. a. Ben-Shoshan (2024). “Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.” J Allergy Clin Immunol 154(1): 184-194.

https://doi.org/10.1016/j.jaci.2024.01.028 DOI: https://doi.org/10.1016/j.jaci.2024.01.028

Maurer, M., L. F. Ensina, A. M. Gimenez-Arnau and G. e. a. Sussman (2024). “Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.” Lancet 403(10422): 147-159.

https://doi.org/10.1016/S0140-6736(23)01684-7 DOI: https://doi.org/10.1016/S0140-6736(23)01684-7

Maurer, M., A. M. Giménez-Arnau, G. Sussman, M. Metz, D. R. Baker, A. Bauer, J. A. Bernstein, R. Brehler, C. Y. Chu, W. H. Chung, I. Danilycheva, C. Grattan, J. Hébert, C. Katelaris, M. Makris, R. Meshkova, S. Savic, R. Sinclair, K. Sitz, P. Staubach, B. Wedi, J. Löffler, A. Barve, K. Kobayashi, E. Hua, T. Severin and R. Janocha (2019). “Ligelizumab for Chronic Spontaneous Urticaria.” N Engl J Med 381(14): 1321-1332.

https://doi.org/10.1056/NEJMoa1900408 DOI: https://doi.org/10.1056/NEJMoa1900408

Maurer, M., K. Rosén, H.-J. Hsieh and S. e. a. Saini (2013). “Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.” N Engl J Med 368(10): 924-935.

https://doi.org/10.1056/NEJMoa1215372

Maurer, M., K. Rosén, H. J. Hsieh, S. Saini, C. Grattan, A. Gimenéz-Arnau, S. Agarwal, R. Doyle, J. Canvin, A. Kaplan and T. Casaleet (2013). “Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.” N Engl J Med 368: 924-935.

https://doi.org/10.1056/NEJMoa1215372 DOI: https://doi.org/10.1056/NEJMoa1215372

Maurer, T., A. Poncelet and T. Berger (2004). “Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy.” Arch Dermatol 140(7): 845-849.

https://doi.org/10.1001/archderm.140.7.845 DOI: https://doi.org/10.1001/archderm.140.7.845

Mayo, M. J., I. Handem, S. Saldana, H. Jacobe, Y. Getachew and A. J. Rush (2007). “Sertraline as a first-line treatment for cholestatic pruritus.” Hepatology 45(3): 666-674.

https://doi.org/10.1002/hep.21553 DOI: https://doi.org/10.1002/hep.21553

Mayo, M. J., P. J. Pockros, D. Jones, C. L. Bowlus, C. Levy and I. e. a. Patanwala (2019). “A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis.” Hepatol Commun 3(3): 365‑381.

https://doi.org/10.1002/hep4.1305 DOI: https://doi.org/10.1002/hep4.1305

Mazeh, D., Y. Melamed, A. Cholostoy, V. Aharonovitzch, A. Weizman and G. Yosipovitch (2008). “Itching in the psychiatric ward.” Acta dermato-venereologica 88(2): 128-131.

https://doi.org/10.2340/00015555-0406 DOI: https://doi.org/10.2340/00015555-0406

Mazza, M., G. Guerriero, G. Marano, L. Janiri, P. Bria and S. Mazza (2013). “Treatment of prurigo nodularis with pregabalin.” J Clin Pharm Ther 38(1): 16-18.

https://doi.org/10.1111/jcpt.12005 DOI: https://doi.org/10.1111/jcpt.12005

Mazzatenta, C., G. Peonia and P. Martini (2004). “Pruritus induced by interruption of paroxetine therapy.” Br J Dermatol 150(4): 787.

https://doi.org/10.1111/j.0007-0963.2004.05882.x DOI: https://doi.org/10.1111/j.0007-0963.2004.05882.x

McCormick, A., D. Fleming and J. Charlton (1995). Morbidity Statistics from General Practice. Fourth national study 1991-1992. London, Her Majestic’s Stationery Office.

McCormick, P. A., F. Scott, O. Epstein, A. K. Burroughs, P. J. Scheuer and N. McIntyre (1994). “Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study.” J Hepatol 21(4): 496-499.

https://doi.org/10.1016/S0168-8278(94)80092-8 DOI: https://doi.org/10.1016/S0168-8278(94)80092-8

McGovern, C., T. Quasim, K. Puxty, M. Shaw, W. Ng, C. Gilhooly, N. Arkoulis, M. Basler, A. Macfarlane and L. Paton (2021). “Neuropathic agents in the management of pruritus in burn injuries: a systematic review and meta-analysis.” Trauma Surg Acute Care Open 6(1): e000810.

https://doi.org/10.1136/tsaco-2021-000810 DOI: https://doi.org/10.1136/tsaco-2021-000810

Mehrkash, M., S.-J. Golestaneh, Y. Madihi, F. Paknazar, M. Hadian, M. Akbari and B. Abtahi-Naeini (2021). “Pruritus features in children with end-stage renal disease underwent dialysis: A Cross-Sectional Study.” Int J Pediatr 9970321.

https://doi.org/10.1155/2021/9970321 DOI: https://doi.org/10.1155/2021/9970321

Mehrpooya, M., M. Gholyaf, F. Yasrebifar, Y. Mohammadi and V. Sheikh (2020). “Evaluation of Efficacy of Mirtazapine on Pruritus and Serum Histamine and Serotonin Levels in Patients Undergoing Hemodialysis: A Before-After Pilot Clinical Trial.” Int J Nephrol Renovasc Dis 13: 129-138.

https://doi.org/10.2147/IJNRD.S246393 DOI: https://doi.org/10.2147/IJNRD.S246393

Menage, H. D., P. G. Norris, J. L. Hawk and M. W. Graves (1993). “The efficacy of psoralen photochemotherapy in the treatment of aquagenic pruritus.” Br J Dermatol 129(2): 163-165.

https://doi.org/10.1111/j.1365-2133.1993.tb03520.x DOI: https://doi.org/10.1111/j.1365-2133.1993.tb03520.x

Mendham, J. E. (2004). “Gabapentin for the treatment of itching produced by burns and wound healing in children: a pilot study.” Burns 30(8): 851-853.

https://doi.org/10.1016/j.burns.2004.05.009 DOI: https://doi.org/10.1016/j.burns.2004.05.009

Menter, A., B. E. Strober and D. H. e. a. Kaplan (2019). “Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis With Biologics.” J Am Acad Dermatol 80(4): 1029-1072.

https://doi.org/10.1016/j.jaad.2018.11.057 DOI: https://doi.org/10.1016/j.jaad.2018.11.057

Merkel, T., A. Navarini and S. Mueller (2024). “The impact of phototherapy on itch intensity and itch-related quality of life amongst different skin diseases, skin phototypes and genders - A prospective study with 102 patients.” Photodermatol Photoimmunol Photomed 40(1): e12948.

https://doi.org/10.1111/phpp.12948 DOI: https://doi.org/10.1111/phpp.12948

Merkel, T. A., A. Navarini and S. Mueller (2021). “Differences in phototherapy among skin diseases and genders in real-life conditions-A retrospective analysis of the cumulative doses, numbers of sessions, side effects and costs in 561 patients.” Photodermatol Photoimmunol Photomed 37(5): 464-473.

https://doi.org/10.1111/phpp.12683 DOI: https://doi.org/10.1111/phpp.12683

Mettang, T. (2016). “Uremic itch management.” Curr Prob Dermatol 50: 133-141.

https://doi.org/10.1159/000446056 DOI: https://doi.org/10.1159/000446056

Mettang, T., C. Pauli-Magnus and D. M. Alscher (2002). “Uraemic pruritus--new perspectives and insights from recent trials.” Nephrol Dial Transplant 17(9): 1558-1563.

https://doi.org/10.1093/ndt/17.9.1558 DOI: https://doi.org/10.1093/ndt/17.9.1558

Metz, M., G. Sussman, R. Gagnon and P. e. a. Staubach (2021). “Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.” Nat Med 27(11): 1961-1969.

https://doi.org/10.1038/s41591-021-01537-w DOI: https://doi.org/10.1038/s41591-021-01537-w

Metz, M., U. Wahn, U. Gieler, P. Stock, J. Schmitt and U. Blume-Peytavi (2013). “Chronic pruritus associated with dermatologic disease in infancy and childhood: update from an interdisciplinary group of dermatologists and paediatricians.” Pediatr Allergy Immunol 24(6): 527-539.

https://doi.org/10.1111/pai.12115 DOI: https://doi.org/10.1111/pai.12115

Metze, D., S. Reimann, Z. Szepfalusi, B. Bohle, D. Kraft and T. A. Luger (1997). “Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves.” Br J Dermatol 136(4): 553-559. DOI: https://doi.org/10.1111/j.1365-2133.1997.tb02140.x

https://doi.org/10.1046/j.1365-2133.1997.d01-1234.x DOI: https://doi.org/10.1046/j.1365-2133.1997.d01-1234.x

Millington, G. W. M., A. Collins and C. R. e. a. Lovell (2018). “British Association of Dermatologists’ guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis.” BJD 178: 34-60.

https://doi.org/10.1111/bjd.16186 DOI: https://doi.org/10.1111/bjd.16186

Min, T. K. and S. S. Saini (2024). “The future of targeted therapy in chronic spontaneous urticaria.” Ann Allergy Asthma Immunol 133(4): 367-373.

https://doi.org/10.1016/j.anai.2024.05.020 DOI: https://doi.org/10.1016/j.anai.2024.05.020

Miron, Y., P. E. Miller, C. Hughes, T. Indersmitten, E. A. Lerner and F. Cevikbas (2022). “Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb.” J Allergy Clin Immunol 150(3): 690-700.

https://doi.org/10.1016/j.jaci.2022.01.028 DOI: https://doi.org/10.1016/j.jaci.2022.01.028

Mirzoyev, S. A. and M. D. Davis (2013). “Brachioradial pruritus: Mayo Clinic experience over the past decade.” Br J Dermatol 169(5): 1007-1015.

https://doi.org/10.1111/bjd.12483 DOI: https://doi.org/10.1111/bjd.12483

Misery, L. (2005). “Gabapentin in dermatology.” Dermatology 211(2): 79-80.

https://doi.org/10.1159/000086432 DOI: https://doi.org/10.1159/000086432

Misery, L. (2016). Neuropathic pruritus secondary to brain and spinal cord tumors” in Misery, L., Ständer S. (eds): Pruritus. 2nd ed. London, Springer-Verlag: 215-218.

https://doi.org/10.1007/978-3-319-33142-3_28 DOI: https://doi.org/10.1007/978-3-319-33142-3_28

Misery, L., S. Alexandre, S. Dutray, M. Chastaing, S. G. Consoli, H. Audra, D. Bauer, S. Bertolus, V. Callot, F. Cardinaud, E. Corrin, N. Feton-Danou, R. Malet, S. Touboul and S. M. Consoli (2007). “Functional itch disorder or psychogenic pruritus: suggested diagnosis criteria from the French psychodermatology group.” Acta Derm Venereol 87(4): 341-344.

https://doi.org/10.2340/00015555-0266 DOI: https://doi.org/10.2340/00015555-0266

Misery, L., C. Bodere, S. Genestet, F. Zagnoli and P. Marcorelles (2014). “Small-fibre neuropathies and skin: news and perspectives for dermatologists.” Eur J Dermatol 24(2): 147-153.

https://doi.org/10.1684/ejd.2013.2189 DOI: https://doi.org/10.1684/ejd.2013.2189

Misery, L., E. Brenaut, R. Le Garrec, C. Abasq, S. Genestet, P. Marcorelles and F. Zagnoli (2014). “Neuropathic pruritus.” Nat Rev Neurol 10(7): 408-416.

https://doi.org/10.1038/nrneurol.2014.99 DOI: https://doi.org/10.1038/nrneurol.2014.99

Misery, L., N. Erfan, E. Castela, E. Brenaut, M. Lantéri-Minet, J. P. Lacour and T. Passeron (2015). “Successful treatment of refractory neuropathic pruritus with capsaicin 8% patch: a bicentric retrospective study with long-term follow-up.” Acta Derm Venereol 95(7): 864-865.

https://doi.org/10.2340/00015555-2085 DOI: https://doi.org/10.2340/00015555-2085

Misery, L., S. Genestet and F. Zagnoli (2022). “Neuromyelitis Optica and Skin.” Dermatology 238(5): 823-828.

https://doi.org/10.1159/000522168 DOI: https://doi.org/10.1159/000522168

Misery, L., A. Santerre, A. Batardière, N. Hornez, A. S. Nedelec, F. Le Caër, P. Bourgeois, F. Huet and G. Neufang (2018). “Real-life study of anti-itching effects of a cream containing menthoxypropanediol, a TRPM8 agonist, in atopic dermatitis patients.” J Eur Acad Dermatol Venereol.

https://doi.org/10.1111/jdv.15199 DOI: https://doi.org/10.1111/jdv.15199

Mittal, A., A. Srivastava, M. Balai and A. K. Khare (2016). “A study of postherpetic pruritus.” Indian Dermatol Online J 7(4): 343-344.

https://doi.org/10.4103/2229-5178.185479 DOI: https://doi.org/10.4103/2229-5178.185479

Miyamoto, T., H. Nojima, T. Shinkado, T. Nakahashi and Y. Kuraishi (2002). “Itch-associated response induced by experimental dry skin in mice.” Jpn J Pharmacol 88: 285-292.

https://doi.org/10.1254/jjp.88.285 DOI: https://doi.org/10.1254/jjp.88.285

Mohammad Ali, B. M., D. S. Hegab and H. M. El Saadany (2015). “Use of transcutaneous electrical nerve stimulation for chronic pruritus.” Dermatol Ther 28(4): 210-215.

https://doi.org/10.1111/dth.12242 DOI: https://doi.org/10.1111/dth.12242

Mollanazar, N. K., P. K. Smith and G. Yosipovitch (2015). “Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?” Clin Rev Allergy Immunol 51: 263-292.

https://doi.org/10.1007/s12016-015-8488-5 DOI: https://doi.org/10.1007/s12016-015-8488-5

Monroe, E. W. (1989). “Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis.” J Am Acad Dermatol 21(1): 135-136.

https://doi.org/10.1016/S0190-9622(89)80353-6 DOI: https://doi.org/10.1016/S0190-9622(89)80353-6

Montero, J. L., J. C. Pozo, P. Barrera, E. Fraga, G. Costan, J. L. Dominguez, J. Muntane, A. Rodriguez-Ariza, M. Pleguezuelo, S. Rufian, P. Lopez-Cillero and M. de la Mata (2006). “Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS).” Transplant Proc 38(8): 2511-2513.

https://doi.org/10.1016/j.transproceed.2006.08.052 DOI: https://doi.org/10.1016/j.transproceed.2006.08.052

Moon, I. J., M. R. Yun, H. K. Yoon, K. H. Lee, S. Y. Choi, W. J. Lee, S. E. Chang and C. H. Won (2021). “Treatment of atopic dermatitis using non-thermal atmospheric plasma in an animal model.” Sci Rep 11(1): 16091.

https://doi.org/10.1038/s41598-021-95471-z DOI: https://doi.org/10.1038/s41598-021-95471-z

Morgado-Carrasco, D., J. Riera-Monroig, H. Feola and P. Aguilera (2020). “Treatment of 2 Patients With Aquagenic Pruritus With UVA/Narrow Band UVB Combined Therapy Once a Year.” Actas Dermosifiliogr 111(10): 889-892. DOI: https://doi.org/10.1016/j.adengl.2019.02.027

https://doi.org/10.1016/j.ad.2019.02.026 DOI: https://doi.org/10.1016/j.ad.2019.02.026

Mueller, S. M., H. R. Carruthers, A. A. Navarini, M. Goldust, S. Gysin and P. H. Itin (2020). “Pruritic and antipruritic colors: An exploratory pilot study.” Dermatol Ther 33(3): e13447.

https://doi.org/10.1111/dth.13447 DOI: https://doi.org/10.1111/dth.13447

Mueller, S. M., F. Mueller, J. Reinhardt, P. Itin and A. e. a. Navarini (2019). “Assessment of the impact of sex in intensity, skin flares and central processing of histaminergic itch-A pilot study.” Exp Dermatol 28(12): 1493-1500.

https://doi.org/10.1111/exd.14021 DOI: https://doi.org/10.1111/exd.14021

Mueller, S. M., A. A. Navarini, M. Goldust, B. O., C. E. M. Griffiths and C. E. Kleyn (2020). “Levocetirizine for the treatment of itch in psoriasis patients: An open-label pilot study in a real-world setting.” Dermatol Ther 33(1): e13166.

https://doi.org/10.1111/dth.13166 DOI: https://doi.org/10.1111/dth.13166

Mülkoğlu, C. and B. Nacır (2020). “Notalgia paresthetica: clinical features, radiological evaluation, and a novel therapeutic option.” BMC Neurol 20(1): 191.

https://doi.org/10.1186/s12883-020-01773-6 DOI: https://doi.org/10.1186/s12883-020-01773-6

Muller, C., S. Pongratz, J. Pidlich, E. Penner, A. Kaider, M. Schemper, M. Raderer, W. Scheithauer and P. Ferenci (1998). “Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial.” Eur J Gastroenterol Hepatol 10(10): 865-870.

https://doi.org/10.1097/00042737-199810000-00010 DOI: https://doi.org/10.1097/00042737-199810000-00010

Muller, E. W., J. T. de Wolf, R. Egger, P. W. Wijermans, P. C. Huijgens, M. R. Halie and E. Vellenga (1995). “Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera.” Br J Haematol 89(2): 313-318.

https://doi.org/10.1111/j.1365-2141.1995.tb03306.x DOI: https://doi.org/10.1111/j.1365-2141.1995.tb03306.x

Müller, S., L. Maintz and T. Bieber (2024). “Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs.” Allergy 79(6): 1501-1515.

https://doi.org/10.1111/all.16009 DOI: https://doi.org/10.1111/all.16009

Müller, S., C. Zeidler and S. Ständer (2024). “Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.” Am J Clin Dermatol 25(1): 15-33.

https://doi.org/10.1007/s40257-023-00818-z DOI: https://doi.org/10.1007/s40257-023-00818-z

Mullhaupt, B., G. A. Kullak-Ublick, P. M. Ambuhl, R. Stocker and E. L. Renner (2003). “Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritus.” Hepatol Res 25(4): 442-446.

https://doi.org/10.1016/S1386-6346(02)00310-8 DOI: https://doi.org/10.1016/S1386-6346(02)00310-8

Mullol, J., J. Bousquet, C. Bachert, G. W. Canonica, A. Giménez-Arnau, M. L. Kowalski, F. E. R. Simons, M. Maurer, D. Ryan and G. Scadding (2015). “Update on rupatadine in the management of allergic disorders.” Allergy 70: 1-24.

https://doi.org/10.1111/all.12531 DOI: https://doi.org/10.1111/all.12531

Murase, J. E., M. M. Heller and D. C. Butler (2014). “Safety of dermatological medications in pregnancy and lactation: Part I. Pregnancy.” J Am Acad Dermatol 70: 401-414.

https://doi.org/10.1016/j.jaad.2013.09.010 DOI: https://doi.org/10.1016/j.jaad.2013.09.010

Murphy, B., M. Duffin and J. Tolland (2018). “Aquagenic pruritus successfully treated with omalizumab.” Clin Exp Dermatol 43(7): 858-859.

https://doi.org/10.1111/ced.13415 DOI: https://doi.org/10.1111/ced.13415

Murphy, M., D. Reaich, P. Pai, P. Finn and A. J. Carmichael (2003). “A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch.” Br J Dermatol 148(2): 314-317.

https://doi.org/10.1046/j.1365-2133.2003.05172.x DOI: https://doi.org/10.1046/j.1365-2133.2003.05172.x

Naini, A. E., A. A. Harandi, S. Khanbabapour, S. Shadidi, S. Seirafivan and M. Mosheni (2007). “Gabapentin: a promising drug for the treatment of uremic pruritus.” Saudi J Kidney Dis Transpl 18(3): 378-381.

Nakagawa, H., O. Nemoto, A. Igarashi, H. Saeki, H. Kaino and T. Nagata (2020). “Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.” J Am Acad Dermatol 82(4): 823-831.

https://doi.org/10.1016/j.jaad.2019.12.015 DOI: https://doi.org/10.1016/j.jaad.2019.12.015

Narita, I., Y. Tsubakihara, T. Uchiyama, O. S. and N. Oya, et al. (2022). Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial 5(5): e2210339.

Nasrollahi A., M. A., Ghanei E. et al. (2007). “Montelukast for Treatment of Refractory Pruritus in Patients on Hemodialysis.” Iran J Kidney Dis 1: 73-77.

Nast, A., C. Smith, P. I. Spuls and G. e. a. Avila Valle (2020). “EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations.” J Eur Acad Dermatol Venereol 34(11): 2461-2498.

https://doi.org/10.1111/jdv.16915 DOI: https://doi.org/10.1111/jdv.16915

Nattkemper, L. A., M. E. Martinez-Escala, A. B. Gelman, E. M. Singer, A. H. Rook, J. Guitart and G. Yosipovitch (2016). “ Cutaneous T-Cell Lymphoma and Pruritus: the Expression of IL-31 and its Receptors in the Skin.” Acta Derm Venereol.

https://doi.org/10.2340/00015555-2417 DOI: https://doi.org/10.2340/00015555-2417

Neilly, J. B., A. Martin, N. Simpson and A. C. MacCuish (1986). “Pruritus in diabetes mellitus: investigation of prevalence and correlation with diabetes control.” Diabetes Care 9(3): 273-275.

https://doi.org/10.2337/diacare.9.3.273 DOI: https://doi.org/10.2337/diacare.9.3.273

Nestler, J. E. (1983). “Hemochromatosis and pruritus.” Ann Intern Med 98(6): 1026.

https://doi.org/10.7326/0003-4819-98-6-1026_1 DOI: https://doi.org/10.7326/0003-4819-98-6-1026_1

Neuberger, J. (2003). “Liver Transplantation for Cholestatic Liver Disease.” Curr Treat Options Gastroenterol 6(2): 113-121.

https://doi.org/10.1007/s11938-003-0012-y DOI: https://doi.org/10.1007/s11938-003-0012-y

Nevols, J., L. Watkins and R. Lewis (2023). “A phase IV, randomised, double-blind, controlled, parallel group trial to evaluate the effectiveness and safety of Balneum Plus versus emollient in the treatment of chronic kidney disease-associated pruritus in haemodialysis patients.” Clin Kidney J 16(8): 1307-1315.

https://doi.org/10.1093/ckj/sfad066 DOI: https://doi.org/10.1093/ckj/sfad066

Nieto, A., M. Nieto and Á. Mazón (2021). “The clinical evidence of second-generation H1-antihistamines in the treatment of allergic rhinitis and urticaria in children over 2 years with a special focus on rupatadine.” Expert Opin Pharmacother 22(4): 511-519.

https://doi.org/10.1080/14656566.2020.1830970 DOI: https://doi.org/10.1080/14656566.2020.1830970

Nilsson, H. J., A. Levinsson and J. Schouenborg (1997). “Cutaneous field stimulation (CFS): a new powerful method to combat itch.” Pain 71(1): 49-55.

https://doi.org/10.1016/S0304-3959(97)03339-3 DOI: https://doi.org/10.1016/S0304-3959(97)03339-3

Nilsson, H. J., E. Psouni, R. Carstam and J. Schouenborg (2004). “Profound inhibition of chronic itch induced by stimulation of thin cutaneous nerve fibres.” J Eur Acad Dermatol Venereol 18(1): 37-43.

https://doi.org/10.1111/j.1468-3083.2004.00724.x DOI: https://doi.org/10.1111/j.1468-3083.2004.00724.x

Norén, P., L. Hagströmer, M. Alimohammadi and L. Melin (2018). “The positive effects of habit reversal treatment of scratching in children with atopic dermatitis: a randomized controlled study.” Br J Dermatol 178: 665-673.

https://doi.org/10.1111/bjd.16009 DOI: https://doi.org/10.1111/bjd.16009

Norman, T., J. Guenther, N. Vecerek, B. L. Adler, A. Crew and S. Worswick (2023). “Psychiatric comorbidities on an inpatient dermatology consultation service: A cross-sectional analysis.” Skin Health Dis 3(5): e266.

https://doi.org/10.1002/ski2.266 DOI: https://doi.org/10.1002/ski2.266

Nosbaum, A., C. Pecquet, O. Bayrou, E. Amsler, J. F. Nicolas, F. Bérard and C. Francès (2011). “Treatment with propranolol of 6 patients with idiopathic aquagenic pruritus.” J Allergy Clin Immunol 128(5): 1113.

https://doi.org/10.1016/j.jaci.2011.05.001 DOI: https://doi.org/10.1016/j.jaci.2011.05.001

O’Donoghue, M. and M. D. Tharp (2005). “Antihistamines and their role as antipruritics.” Dermatol Ther 18(4): 333-340.

https://doi.org/10.1111/j.1529-8019.2005.00034.x DOI: https://doi.org/10.1111/j.1529-8019.2005.00034.x

O’Donohue, J. W., C. Haigh and R. Williams (1997). “Ondansetron in the treatment of cholestasis: a randomised controlled trial.” Gastroenterology 112: A1349.

Oaklander, A. (2012). “Common neuropathic itch syndromes.” Acta Derm Venereol 92(2): 118-125.

https://doi.org/10.2340/00015555-1318 DOI: https://doi.org/10.2340/00015555-1318

Oaklander, A. L. (2011). “Neuropathic itch.” Semin Cutan Med Surg 30(2): 87-92.

https://doi.org/10.1016/j.sder.2011.04.006 DOI: https://doi.org/10.1016/j.sder.2011.04.006

Ofenloch, R., K. Grochulska, T. Mettang and E. Weisshaar (2022). “The incidence of chronic itch in hemodialysis patients and factors associated.” Br J Dermatol.

https://doi.org/10.1111/bjd.21024

Ofenloch, R., K. Grochulska, T. Mettang and E. Weisshaar. The incidence of chronic itch in hemodialysis patients and factors associated. Br J Dermatol. 2022 Jun;186(6):1052-1054.

https://doi.org/10.1111/bjd.21024 DOI: https://doi.org/10.1111/bjd.21024

Ohanyan, T., N. Schoepke, S. Eirefelt, G. Hoey, W. Koopmann, T. Hawro, M. Maurer and M. Metz (2018). “Role of substance P and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical aprepitant.” Acta Derm Venereol 98(1): 26-31.

https://doi.org/10.2340/00015555-2780 DOI: https://doi.org/10.2340/00015555-2780

Ozkan, S., Y. Ceylan, O. V. Ozkan and S. R. Yildirim (2015). “Review of a challenging clinical issue: Intrahepatic cholestasis of pregnancy.” World J Gastroenterol 2(237): 7134-7141.

https://doi.org/10.3748/wjg.v21.i23.7134 DOI: https://doi.org/10.3748/wjg.v21.i23.7134

Pacan, P., M. Grzesiak, A. Reich and J. C. Szepietowski (2009). “Is pruritus in depression a rare phenomenon?” Acta Derm Venereol 89: 109-110.

https://doi.org/10.2340/00015555-0576 DOI: https://doi.org/10.2340/00015555-0576

Pakfetrat, M., L. Malekmakan, N. Hashemi and T. Tadayon (2018). “Sertraline can reduce uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran.” Hemodial Int 22(1): 103-109.

https://doi.org/10.1111/hdi.12540 DOI: https://doi.org/10.1111/hdi.12540

Paller, A. S., E. L. Simpson, E. C. Siegfried and M. J. e. a. Cork (2022). “Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.” Lancet 400(10356): 908-919.

https://doi.org/10.1016/S0140-6736(22)01539-2 DOI: https://doi.org/10.1016/S0140-6736(22)01539-2

Paller, A. S., W. L. Tom, M. G. Lebwohl and R. L. e. a. Blumenthal (2016). “Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.” J Am Acad Dermatol 75(3): 494-503.

https://doi.org/10.1016/j.jaad.2016.05.046 DOI: https://doi.org/10.1016/j.jaad.2016.05.046

Palmer, R. B., K. M. Reynolds, W. Banner, G. R. Bond, R. E. Kauffman, I. M. Paul, J. L. Green and R. C. Dart (2020). “Adverse events associated with diphenhydramine in children.” Clin Toxicol (Phila) 58(2): 99-106.

https://doi.org/10.1080/15563650.2019.1609683 DOI: https://doi.org/10.1080/15563650.2019.1609683

Palungwachira, P., K. Vilaisri, K. Musikatavorn and J. Wongpiyabovorn (2021). “A randomized controlled trial of adding intravenous corticosteroids to H1 antihistamines in patients with acute urticaria.” J.Am J Emerg Med 42: 197-197.

https://doi.org/10.1016/j.ajem.2020.02.025 DOI: https://doi.org/10.1016/j.ajem.2020.02.025

Papadopoulos, N. G. and T. Zuberbier (2019). “The safety and tolerability profile of bilastine for chronic urticaria in children.” Clin Transl Allergy 23(9): 55.

https://doi.org/10.1186/s13601-019-0294-3 DOI: https://doi.org/10.1186/s13601-019-0294-3

Papageorgiou, C., E. Lazaridou, K. Lallas, K. Papaioannou, V. Nikolaou, V. Mateeva, K. Efthymiadis, C. Koukoutzeli and K. e. a. Loga (2023). “A retrospective multicentric cohort study of checkpoint inhibitors-induced pruritus with focus on management.” Photodermatol Photoimmunol Photomed 39(5): 506-511.

https://doi.org/10.1111/phpp.12892 DOI: https://doi.org/10.1111/phpp.12892

Papp, K., K. Reich, C. L. Leonardi, L. Kircik, S. Chimenti, R. G. Langley, C. Hu, R. M. Stevens, R. M. Day, K. B. Gordon, N. J. Korman and C. E. Griffiths (2015). “Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).” J Am Acad Dermatol 73(1): 37-49.

https://doi.org/10.1016/j.jaad.2015.03.049 DOI: https://doi.org/10.1016/j.jaad.2015.03.049

Papp, K., J. C. Szepietowski, L. Kircik and D. e. a. Toth (2021). “Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.” J Am Acad Dermatol 85(4): 863-872.

https://doi.org/10.1016/j.jaad.2021.04.085 DOI: https://doi.org/10.1016/j.jaad.2021.04.085

Papp, K., J. C. Szepietowski, L. Kircik and D. e. a. Toth (2023). “Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.” J Am Acad Dermatol 88(5): 1008-1016.

https://doi.org/10.1016/j.jaad.2022.09.060 DOI: https://doi.org/10.1016/j.jaad.2022.09.060

Papp, K. A., A. Papp, B. Dahmer and C. S. Clark (2011). “Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults.” J Am Acad Dermatol.

https://doi.org/10.1016/j.jaad.2011.02.032 DOI: https://doi.org/10.1016/j.jaad.2011.02.032

Passamonti, F., M. Griesshammer, F. Palandri, M. Egyed, G. Benevolo, T. Devos and J. e. a. Callum (2017). “Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.” Lancet Oncol 18(1): 88-99.

https://doi.org/10.1016/S1470-2045(16)30558-7 DOI: https://doi.org/10.1016/S1470-2045(16)30558-7

Patel, T. and G. Yosipovitch (2010). “The management of chronic pruritus in the elderly.” Skin Therapy Lett 15(8): 5-9.

Paul, C., J. Cather, M. Gooderham, Y. Poulin, U. Mrowietz, C. Ferrandiz, J. Crowley, C. Hu, R. M. Stevens, K. Shah, R. M. Day, G. Girolomoni and A. B. Gottlieb (2015). “Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).” Br J Dermatol 173(6): 1387-1399.

https://doi.org/10.1111/bjd.14164 DOI: https://doi.org/10.1111/bjd.14164

Paul, E. and R. H. Bodeker (1986). “Treatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 45 patients.” Eur J Clin Pharmacol 31(3): 277-280.

https://doi.org/10.1007/BF00981123 DOI: https://doi.org/10.1007/BF00981123

Pauli-Magnus, C., S. Klumpp, D. M. Alscher, U. Kuhlmann and T. Mettang (2000). “Short-term efficacy of tacrolimus ointment in severe uremic pruritus.” Perit Dial Int 20(6): 802-803.

https://doi.org/10.1177/089686080002000641 DOI: https://doi.org/10.1177/089686080002000641

Pauli-Magnus, C., G. Mikus, D. M. Alscher, T. Kirschner, W. Nagel, N. Gugeler, T. Risler, E. D. Berger, U. Kuhlmann and T. Mettang (2000). “Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study.” J Am Soc Nephrol 11(3): 514-519.

https://doi.org/10.1681/ASN.V113514 DOI: https://doi.org/10.1681/ASN.V113514

Paus, R., M. Schmelz, T. Biro and M. Steinhoff (2006). “Frontiers in pruritus research: scratching the brain for more effective itch therapy.” J Clin Invest 116(5): 1174-1186.

https://doi.org/10.1172/JCI28553 DOI: https://doi.org/10.1172/JCI28553

Pavlovsky, M., S. Baum, D. Shpiro, L. Pavlovsky and F. Pavlotsky (2011). “Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis?” J Eur Acad Dermatol Venereol 25(6): 727-729.

https://doi.org/10.1111/j.1468-3083.2010.03832.x DOI: https://doi.org/10.1111/j.1468-3083.2010.03832.x

Pazyar, N., R. Yaghoobi, A. Kazerouni and A. Feily (2012). “Oatmeal in dermatology: a brief review.” Indian J Dermatol Venereol Leprol 78: 142-145.

https://doi.org/10.4103/0378-6323.93629 DOI: https://doi.org/10.4103/0378-6323.93629

Pedersen, C. B., C. A. McHorney, L. S. Larsen, K. W. Lophaven, A. H. Moeller and M. Reaney (2016). “Reliability and validity of the Psoriasis Itch Visual Analog Scale in psoriasis vulgaris.” Journal of Dermatological Treatment 28(3): 213-220.

https://doi.org/10.1080/09546634.2016.1215405 DOI: https://doi.org/10.1080/09546634.2016.1215405

Peer, G., S. Kivity, O. Agami, E. Fireman, D. Silverberg, M. Blum and A. laina (1996). “Randomised crossover trial of naltrexone in uraemic pruritus.” Lancet 348(9041): 1552-1554.

https://doi.org/10.1016/S0140-6736(96)04176-1 DOI: https://doi.org/10.1016/S0140-6736(96)04176-1

Peng, C., C. Li, Y. Zhou and Q. e. a. Wang (2022). “Tofacitinib for Prurigo Nodularis: A Case Report.” Clin Cosmet Investig Dermatol 15: 503-506.

https://doi.org/10.2147/CCID.S354025 DOI: https://doi.org/10.2147/CCID.S354025

Pereira, M., A. Farcas, C. Zeidler and S. Ständer (2021). “Chronic Pruritus of Unknown Origin: Clinical Profile and Disease Related Burden.” Acta Derm Venereol 101: adv00550.

https://doi.org/10.2340/00015555-3892 DOI: https://doi.org/10.2340/00015555-3892

Pereira, M. P., L. Derichs, G. Meyer Zu Hörste, K. Agelopoulos and S. Ständer (2020). “Generalized chronic itch induced by small-fibre neuropathy: clinical profile and proposed diagnostic criteria.” JEADV 34: 1795-1802.

https://doi.org/10.1111/jdv.16151 DOI: https://doi.org/10.1111/jdv.16151

Pereira, M. P., A. E. Kremer, T. Mettang and S. Ständer (2016). “Chronic Pruritus in the Absence of Skin Disease: Pathophysiology, Diagnosis and Treatment.” Am J Clin Dermatol 17(4): 337-348.

https://doi.org/10.1007/s40257-016-0198-0 DOI: https://doi.org/10.1007/s40257-016-0198-0

Pereira, M. P. and S. Ständer (2017). “Assessment of severity and burden of pruritus.” Allergol Int 66(1): 3-7.

https://doi.org/10.1016/j.alit.2016.08.009 DOI: https://doi.org/10.1016/j.alit.2016.08.009

Pereira, M. P. and S. Ständer (2019). “Measurement tools for chronic pruritus: assessment of the symptom and the associated burden: a review.” Itch 4(4): e29.

https://doi.org/10.1097/itx.0000000000000029 DOI: https://doi.org/10.1097/itx.0000000000000029

Pereira, M. P., S. Steinke, C. Zeidler, C. Forner, C. Riepe, M. Augustin, S. Bobko, F. Dalgard, J. Elberling, S. Garcovich, U. Gieler, M. Gonçalo, J. A. Halvorsen, T. Leslie, M. Metz, A. Reich, E. Şavk, G. Schneider, E. Serra-Baldrich, H. Ständer, M. Streit, J. Wallengren, K. Weller, A. Wollenberg, P. Bruland, I. Soto-Rey, M. Storck, M. Dugas, E. Weisshaar, J. C. Szepietowski, F. J. Legat, S. Ständer and E. T. F. P. g. members (2018). “European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo.” J Eur Acad Dermatol Venereol 32(7): 1059-1065.

https://doi.org/10.1111/jdv.14570 DOI: https://doi.org/10.1111/jdv.14570

Pereira, M. P., C. Zeidler and S. Ständer (2022). “Improvement of chronic nodular prurigo with baricitinib.” J Eur Acad Dermatol Venereol 36(6): e486-e488.

https://doi.org/10.1111/jdv.17991 DOI: https://doi.org/10.1111/jdv.17991

Pereira, P. J. S. and E. A. Lerner (2014). “Interneurons Scratch an Itch.” Neuron 82(3): 503-505.

https://doi.org/10.1016/j.neuron.2014.04.026 DOI: https://doi.org/10.1016/j.neuron.2014.04.026

Pezzolo, E., A. Gambardella, M. Guanti and T. e. a. Bianchelli (2023). “Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study.” J Am Acad Dermatol 89(2): 430-432.

https://doi.org/10.1016/j.jaad.2023.04.056 DOI: https://doi.org/10.1016/j.jaad.2023.04.056

Pfab, F., J. Huss-Marp, A. Gatti, J. Fuqin, G. I. Athanasiadis, D. Irnich, U. Raap, W. Schober, H. Behrendt, J. Ring and U. Darsow (2010). “Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema - a blinded, randomized, placebo-controlled, crossover trial.” Allergy 65(7): 903-910.

https://doi.org/10.1111/j.1398-9995.2009.02284.x DOI: https://doi.org/10.1111/j.1398-9995.2009.02284.x

Pfab, F., P. C. Schalock, V. Napadow, G. I. Athanasiadis, J. Huss-Marp and J. Ring (2014). “Acupuncture for allergic disease therapy--the current state of evidence.” Expert Rev Clin Immunol 10: 831-841.

https://doi.org/10.1586/1744666X.2014.924855 DOI: https://doi.org/10.1586/1744666X.2014.924855

Pfab, F., M. Valet, T. Sprenger, J. Huss-Marp, G. I. Athanasiadis, H. J. Baurecht, A. Konstantinow, C. Zimmer, H. Behrendt, J. Ring, T. R. Tolle and U. Darsow (2010). “Temperature modulated histamine-itch in lesional and nonlesional skin in atopic eczema - a combined psychophysical and neuroimaging study.” Allergy 65(1): 84-94.

https://doi.org/10.1111/j.1398-9995.2009.02163.x DOI: https://doi.org/10.1111/j.1398-9995.2009.02163.x

Phan, N. Q., J. D. Bernhard, T. A. Luger and S. Stander (2012). “Systemic kappa opioid receptor (KOR) agonists in the treatment of chronic pruritus: a review.” Acta Derm Venereol 2012 Sep;92(5):555-60.

https://doi.org/10.2340/00015555-1353

Phan, N. Q., J. D. Bernhard, T. A. Luger and S. Ständer (2010). “Antipruritic treatment with systemic μ-opioid receptor antagonists: a review.” J Am Acad Dermatol 63(4): 680-688.

https://doi.org/10.1016/j.jaad.2009.08.052 DOI: https://doi.org/10.1016/j.jaad.2009.08.052

Phan, N. Q., C. Blome, F. Fritz, J. Gerss, A. Reich, T. Ebata, M. Augustin, J. C. Szepietowski and S. Stander (2012). “Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus.” Acta Derm Venereol 92(5): 502-507.

https://doi.org/10.2340/00015555-1246 DOI: https://doi.org/10.2340/00015555-1246

Phan, N. Q., T. Lotts, A. Antal, J. D. Bernhard and S. Stander (2012). “Systemic Kappa Opioid Receptor Agonists in the Treatment of Chronic Pruritus: A Literature Review.” Acta Derm Venereol.

https://doi.org/10.2340/00015555-1353 DOI: https://doi.org/10.2340/00015555-1353

Phan, N. Q., D. Siepmann, I. Gralow and S. Stander (2010). “Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia.” J Dtsch Dermatol Ges 8(2): 88-91.

https://doi.org/10.1111/j.1610-0387.2009.07213.x DOI: https://doi.org/10.1111/j.1610-0387.2009.07213.x

Phinyo, P., P. Koompawichit, S. Nochaiwong, N. Tovanabutra, S. Chiewchanvit and M. Chuamanochan (2021). “Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis.”.J Allergy Clin Immunol Pract 9(2): 956-970.e957.

https://doi.org/10.1016/j.jaip.2020.08.055 DOI: https://doi.org/10.1016/j.jaip.2020.08.055

Polat, G., B. Erni, A. Navarini, A. Kind and S. M. Mueller (2021). “Three patients with chronic vulvar pruritus successfully treated with cold atmospheric pressure plasma.” J Dtsch Dermatol Ges 19(9): 1346-1349.

https://doi.org/10.1111/ddg.14541 DOI: https://doi.org/10.1111/ddg.14541

Polat, M., P. Oztas, M. N. Ilhan, B. Yalçin and N. Alli (2008). “Generalized pruritus: a prospective study concerning etiology.” Am J Clin Dermatol 9(1): 39-44.

https://doi.org/10.2165/00128071-200809010-00004 DOI: https://doi.org/10.2165/00128071-200809010-00004

Ponticelli, C. and P. L. Bencini (1995). “Pruritus in dialysis patients: a neglected problem.” Nephrol Dial Transplant 10(12): 2174-2176.

https://doi.org/10.1093/ndt/10.12.2174 DOI: https://doi.org/10.1093/ndt/10.12.2174

Porzio, G., F. Aielli, L. Verna, C. Porto, M. Tudini, K. Cannita and C. Ficorella (2006). “Efficacy of pregabalin in the management of cetuximab-related itch.” J Pain Symptom Manage 32(5): 397-398.

https://doi.org/10.1016/j.jpainsymman.2006.07.006 DOI: https://doi.org/10.1016/j.jpainsymman.2006.07.006

Potter, P., E. Mitha, L. Barkai, G. Mezei, E. Santamaria, I. Izquierdo and M. Maurer (2016). “Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years.” Pediatr Allergy Immunol 27: 55-61.

https://doi.org/10.1111/pai.12460 DOI: https://doi.org/10.1111/pai.12460

Pour-Reza-Gholi, F., A. Nasrollahi, A. Firouzan, E. N. Esfahani and F. Farrokhi (2007). “Low-dose doxepin for treatment of pruritus in patients on hemodialysis.” Iran J Kidney Dis 1(1): 34-37.

Powell, R. J., S. C. Leech, S. Till, P. A. J. Huber, S. M. Nasser and A. T. Clark (2015). “BSACI guideline for the management of chronic urticaria and angioedema.” Clin Exp Allergy 45: 547-565.

https://doi.org/10.1111/cea.12494 DOI: https://doi.org/10.1111/cea.12494

Pratyusha, K., L. Dawman, K. VInay, K. Tiewsoh and L. K. Sharawat (2021). “Dermatological manifestations in children with chronic kidney disease: astudy from a North Indian tertiary care institute “ Clin Exp Dermatol 46: 1270-1276.

https://doi.org/10.1111/ced.14708 DOI: https://doi.org/10.1111/ced.14708

Purnamawati, S., N. Indrastuti, R. Danarti and T. Saefudin (2017). “The Role of Moisturizers in Addressing Various Kinds of Dermatitis: A Review.” Clin Med Res 15(3-4): 75-87.

https://doi.org/10.3121/cmr.2017.1363 DOI: https://doi.org/10.3121/cmr.2017.1363

Raiford, D. S. (1995). “Pruritus of chronic cholestasis.” QJM 88(9): 603-607.

Rayner, H., J. Baharani, S. Smith, V. Suresh and I. Dasgupta (2012). “Uraemic pruritus: relief of itching by gabapentin and pregabalin.” Nephron Clin Pract 122(3-4): 75-79.

https://doi.org/10.1159/000349943 DOI: https://doi.org/10.1159/000349943

Rayner, H. C., M. Larkina, M. Wang, M. Graham-Brown, S. N. van der Veer and T. Ecder, et al. (2017). “International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.” Clin J Am Soc Nephrol 12(12): 2000-2007.

https://doi.org/10.2215/CJN.03280317 DOI: https://doi.org/10.2215/CJN.03280317

Razeghi, E., D. Eskandari, M. R. Ganji, A. P. Meysamie, M. Togha and P. Khashayar (2009). “Gabapentin and uremic pruritus in hemodialysis patients.” Ren Fail 31(2): 85-90.

https://doi.org/10.1080/08860220802595476 DOI: https://doi.org/10.1080/08860220802595476

Rea, J. N., M. L. Newhouse and T. Halil (1976). “Skin disease in Lambeth. A community study of prevalence and use of medical care.” Br J Prev Soc Med 30(2): 107-114.

https://doi.org/10.1136/jech.30.2.107 DOI: https://doi.org/10.1136/jech.30.2.107

Reich, A., E. Chatzigeorkidis, C. Zeidler, N. Osada, M. Furue, K. Takamori, T. Ebata, M. Augustin, J. C. Szepietowski and S. Ständer (2017). “Tailoring the Cut-off Values of the Visual Analogue Scale and Numeric Rating Scale in Itch Assessment.” Acta Derm Venereol 97(6): 759-760.

https://doi.org/10.2340/00015555-2642 DOI: https://doi.org/10.2340/00015555-2642

Reich, A., C. Riepe, Z. Anastasiadou, K. Mędrek, M. Augustin, J. C. Szepietowski and S. Ständer (2016). “Itch Assessment with Visual Analogue Scale and Numerical Rating Scale: Determination of Minimal Clinically Important Difference in Chronic Itch.” Acta Derm Venereol 96(7): 978-980.

https://doi.org/10.2340/00015555-2433 DOI: https://doi.org/10.2340/00015555-2433

Reich, A., S. Stander and J. C. Szepietowski (2009). “Drug-induced pruritus: a review.” Acta Derm Venereol 89(3): 236-244.

https://doi.org/10.2340/00015555-0650 DOI: https://doi.org/10.2340/00015555-0650

Reich, A., K. Trybucka, A. Tracinska, D. Samotij, B. Jasiuk, M. Srama and J. C. Szepietowski (2008). “Acne itch: do acne patients suffer from itching?” Acta Derm Venereol 88(1): 38-42.

https://doi.org/10.2340/00015555-0355 DOI: https://doi.org/10.2340/00015555-0355

Reich, K., K. Kabashima, K. Peris and J. I. e. a. Silverberg (2020). “Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.” JAMA Dermatol 156(12): 1333-1343.

https://doi.org/10.1001/jamadermatol.2020.3260 DOI: https://doi.org/10.1001/jamadermatol.2020.3260

Reich, K., K. A. Papp, A. Blauvelt and R. G. e. a. Langley (2021). “Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.” Lancet 397(10273): 487-498.

https://doi.org/10.1016/S0140-6736(21)00125-2 DOI: https://doi.org/10.1016/S0140-6736(21)00125-2

Reich, K., J. P. Thyssen, A. Blauvelt, K. Eyerich and W. Soong, et al. (2022). “Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.” Lancet 400(10348): 273-282.

https://doi.org/10.1016/S0140-6736(22)01199-0 DOI: https://doi.org/10.1016/S0140-6736(22)01199-0

Reimann, S., T. Luger and D. Metze (2000). “[Topical administration of capsaicin in dermatology for treatment of itching and pain].” Hautarzt 51(3): 164-172.

https://doi.org/10.1007/s001050051014 DOI: https://doi.org/10.1007/s001050051014

Reszke, R., R. Białynicki-birula, K. Lindner, M. Sobieszczańska and J. C. Szepietowski (2019). “Itch in Elderly People: A Cross-sectional Study.” Acta Derm Venereol 99(11): 1016-1021.

https://doi.org/10.2340/00015555-3271 DOI: https://doi.org/10.2340/00015555-3271

Reszke, R., K. Kilis-Pstrusinska and J. C. Szepietowski (2021). “Chronic kidney disease-associated itch (CKD-aI) in children- a narrative review.” Toxins 13: 450.

https://doi.org/10.3390/toxins13070450 DOI: https://doi.org/10.3390/toxins13070450

Reszke, R. and J. C. Szepietowski (2019). “Can we use psychoactive drugs to treat pruritus?” Exp Dermatol 12: 1422-1431.

https://doi.org/10.1111/exd.13959 DOI: https://doi.org/10.1111/exd.13959

Revicki, D., M. K. Willian, J.-H. Saurat, K. A. Papp, J.-P. Ortonne, C. Sexton and A. Camez (2008). “Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.” Br J Dermatol 158(3): 549-557.

https://doi.org/10.1111/j.1365-2133.2007.08236.x DOI: https://doi.org/10.1111/j.1365-2133.2007.08236.x

Revicki, D. A., M. K. Willian, A. Menter and K. B. e. a. Gordon (2007). “Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.” J Dermatolog Treat 18(6): 341-350.

https://doi.org/10.1080/09546630701646172 DOI: https://doi.org/10.1080/09546630701646172

Rivard, J. and H. W. Lim (2005). “Ultraviolet phototherapy for pruritus.” Dermatol Ther 18(4): 344-354.

https://doi.org/10.1111/j.1529-8019.2005.00032.x DOI: https://doi.org/10.1111/j.1529-8019.2005.00032.x

Rodriguez, D., S. G. Kwatra, C. Dias-Barbosa, F. Zeng, Z. K. J. Lopez, C. Piketty and J. Puelles (2023). “Patient Perspectives on Living With Severe Prurigo Nodularis.” JAMA Dermatol 159(11): 1205-1212.

https://doi.org/10.1001/jamadermatol.2023.3251 DOI: https://doi.org/10.1001/jamadermatol.2023.3251

Roger, D., L. Vaillant, A. Fignon, F. Pierre, Y. Dacq, J. F. Bréchot, M. C. Grangeponte and G. Lorette (1994). “Specific pruritic diseases of pregnancy. A prospective study of 3192 pregnant women.” Arch Dermatol 130: 7234-7239.

https://doi.org/10.1001/archderm.1994.01690060064006 DOI: https://doi.org/10.1001/archderm.1994.01690060064006

Rombold, S., K. Lobisch, K. Katzer, T. C. Grazziotin, J. Ring and B. Eberlein (2008). “Efficacy of UVA1 phototherapy in 230 patients with various skin diseases.” Photodermatol Photoimmunol Photomed 24(1): 19-23.

https://doi.org/10.1111/j.1600-0781.2008.00328.x DOI: https://doi.org/10.1111/j.1600-0781.2008.00328.x

Rosenbaum, M. S. and T. Ayllon (1981). “The behavioral treatment of neurodermatitis through habit-reversal.” Behav Res Ther 19(4): 313-318.

https://doi.org/10.1016/0005-7967(81)90052-8 DOI: https://doi.org/10.1016/0005-7967(81)90052-8

Rosner, M. H. (2006). “Cromolyn sodium: a potential therapy for uremic pruritus?” Hemodial Int 10(2): 189-192.

https://doi.org/10.1111/j.1542-4758.2006.00093.x DOI: https://doi.org/10.1111/j.1542-4758.2006.00093.x

Rotter, G., M. Teut, R. Schleicher, M. Dell’Oro, M. Ortiz, S. Binting, T. Tissen-Diabaté, S. Roll, A. Michalsen, D. Staab, B. Wolfarth and B. Brinkhaus (2023). “Hypnotherapy, Intermittent Fasting, and Exercise Group Programs in Atopic Dermatitis: A Randomized Controlled Explorative Clinical Trial During the COVID-19 Pandemic.” J Integr Complement Med 29(2): 99-110.

https://doi.org/10.1089/jicm.2022.0699 DOI: https://doi.org/10.1089/jicm.2022.0699

Rukwied, R., A. Watkinson, F. McGlone and M. Dvorak (2003). “Cannabinoid agonists attenuate capsaicin-induced responses in human skin.” Pain 102(3): 283-288.

https://doi.org/10.1016/S0304-3959(02)00401-3 DOI: https://doi.org/10.1016/S0304-3959(02)00401-3

Ryczek, A. and A. Reich (2020). “Prevalence of Prurigo Nodularis in Poland.” Acta Derm Venereol 100(10): adv00155.

https://doi.org/10.2340/00015555-3518 DOI: https://doi.org/10.2340/00015555-3518

Sadeghi, S. and N. A. Mohandesi (2023). “Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review.” Exp Dermatol 32(5): 599-610.

https://doi.org/10.1111/exd.14753 DOI: https://doi.org/10.1111/exd.14753

Saini, L., P. K. Gunasekaran, S. Tiwari, D. Krishna, V. Laxmi, P. Jindal and P. Kumar (2023). “Patients With Chiari Malformation Type I: A Rare Phenotype.” Pediatr Neurol 140: 65-67.

https://doi.org/10.1016/j.pediatrneurol.2022.12.013 DOI: https://doi.org/10.1016/j.pediatrneurol.2022.12.013

Saini, S., A. Giménez-Arnau, M. Hide and M. e. a. Lebwohl (2023). “Fast symptom improvement and favorable safety profile with remibrutinib in chronic spontaneous urticaria: REMIX-1/-2 studies.” Ann Allergy Asthma Immunol 131(5 [Suppl 2]): S230.

https://doi.org/10.1016/j.anai.2023.10.019 DOI: https://doi.org/10.1016/j.anai.2023.10.019

Saini, S., A. K. Jain, S. Agarwal and D. Yadav (2021). “Iron Deficiency and Pruritus: A Cross-Sectional Analysis to Assess Its Association and Relationship.” Indian J Dermatol 66(6): 705.

https://doi.org/10.4103/ijd.ijd_326_21 DOI: https://doi.org/10.4103/ijd.ijd_326_21

Saki, N., S. Vahedi, M. M. Parvizi, M. Shafie’ei, S. A. Hosseini and N. Ahramiyanpour (2022). “Topical gabapentin 10% in the treatment of epidermolysis bullosa pruritus: A pilot, double-blind, split-site, randomized controlled trial.” Dermatol Ther 35(10): e15767.

https://doi.org/10.1111/dth.15767 DOI: https://doi.org/10.1111/dth.15767

Salavastru, C. M., O. Chosidow, M. J. Boffa, M. Janier and G. S. Tiplica (2017). “European guideline for the management of scabies.” J Eur Acad Dermatol Venereol 31(8): 1248-1253.

https://doi.org/10.1111/jdv.14351 DOI: https://doi.org/10.1111/jdv.14351

Saltzer, E. J. and G. Grove (1975). “Relief from uremic pruritus: a therapeutic approach.” Cutis 16: 298-299.

Sameni, F., B. Hajikhani, S. Yaslianifard, M. Goudarzi, P. Owlia, M. J. Nasiri, S. Shokouhi, M. Bakhtiyari and M. Dadashi (2020). “COVID-19 and Skin Manifestations: An Overview of Case Reports/Case Series and Meta-Analysis of Prevalence Studies.” Front Med 7: 573188.

https://doi.org/10.3389/fmed.2020.573188 DOI: https://doi.org/10.3389/fmed.2020.573188

Samotij, D., J. Szczęch, E. Antiga and D. e. a. Bonciani (2021). “Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional study.” Lupus 30(9): 1385-1393.

https://doi.org/10.1177/09612033211016098 DOI: https://doi.org/10.1177/09612033211016098

Santer, M., I. Muller, T. Becque, B. Stuart, J. Hooper, M. Steele, S. Wilczynska, T. H. Sach, M. J. Ridd, A. Roberts, A. Ahmed, L. Yardley, P. Little, K. Greenwell, K. Sivyer, J. Nuttall, G. Griffiths, S. Lawton, S. M. Langan, L. M. Howells, P. Leighton, H. C. Williams and K. S. Thomas (2022). “Eczema Care Online behavioural interventions to support self-care for children and young people: two independent, pragmatic, randomised controlled trials.” BMJ 379: e072007.

https://doi.org/10.1136/bmj-2022-072007 DOI: https://doi.org/10.1136/bmj-2022-072007

Saraceno, R., A. Chiricozzi, S. P. Nisticò, S. Tiberti and S. Chimenti (2010). “An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis.” J Dermatolog Treat 21(6): 363-366.

https://doi.org/10.3109/09546630903386606 DOI: https://doi.org/10.3109/09546630903386606

Sardana, K., A. Gupta and S. Sinha (2020). “An observational analysis of low-dose thalidomide in recalcitrant prurigo nodularis.” Clin Exp Dermatol 45(92-96).

https://doi.org/10.1111/ced.14015 DOI: https://doi.org/10.1111/ced.14015

Sardana, K., S. R. Mathachan and D. Agrawal (2023). “Treatment of recalcitrant paediatric prurigo nodularis with tofacitinib, an exquisite example of bench-to-bedside translation of JAK-STAT expression.” Indian J Dermatol Venereol Leprol 23: 1-3.

https://doi.org/10.25259/IJDVL_362_2023 DOI: https://doi.org/10.25259/IJDVL_362_2023

Saverall, C., F. L. Sand and S. F. Thomsen (2015). “Dermatological diseases associated with pregnancy: pemphigoid gestationis, polymorphic eruption of pregnancy, intrahepatic cholestasis of pregnancy and atopic eruption of pregnancy.” Dermatol Res Pract 2015: 979635.

https://doi.org/10.1155/2015/979635 DOI: https://doi.org/10.1155/2015/979635

Savin, J. A. (1998). “How should we define itching?” J Am Acad Dermatol 39 (2 Pt 1) 268-269.

https://doi.org/10.1016/S0190-9622(98)70087-8 DOI: https://doi.org/10.1016/S0190-9622(98)70087-8

Savk, E. (2016). “Neurologic itch management.” Curr Probl Dermatol 50: 116-123.

https://doi.org/10.1159/000446053 DOI: https://doi.org/10.1159/000446053

Savk, E., O. Savk, O. Bolukbasi, N. Culhaci, E. Dikicioglu, G. Karaman and N. Sendur (2000). “Notalgia paresthetica: a study on pathogenesis.” Int J Dermatol 39(10): 754-759.

https://doi.org/10.1046/j.1365-4362.2000.00080.x DOI: https://doi.org/10.1046/j.1365-4362.2000.00080.x

Savk, O. and E. Savk (2005). “Investigation of spinal pathology in notalgia paresthetica.” J Am Acad Dermatol 52(6): 1085-1087.

https://doi.org/10.1016/j.jaad.2005.01.138 DOI: https://doi.org/10.1016/j.jaad.2005.01.138

Sbidian, E., A. Chaimani, I. Garcia-Doval and L. e. a. Doney (2022). “Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.” Cochrane Database Syst Rev 5(5): CD011535.

https://doi.org/10.1002/14651858.CD011535.pub5 DOI: https://doi.org/10.1002/14651858.CD011535.pub5

Schaper-Gerhardt, K., K. Rossbach, E. Nikolouli, T. Werfel, R. Gutzmer and S. Mommert (2020). “The role of the histamine H(4) receptor in atopic dermatitis and psoriasis.” Br J Pharmacol 177(3): 490-502.

https://doi.org/10.1111/bph.14550 DOI: https://doi.org/10.1111/bph.14550

Schmid, Y., A. Navarini, Z. M. Thomas, B. Pfleiderer, S. Krähenbühl and S. M. Mueller (2019). “Sex differences in the pharmacology of itch therapies-a narrative review.” Curr Opin Pharmacol 46(122-142).

https://doi.org/10.1016/j.coph.2019.05.008 DOI: https://doi.org/10.1016/j.coph.2019.05.008

Schneider, G., G. Driesch, G. Heuft, S. Evers, T. A. Luger and S. Stander (2006). “Psychosomatic cofactors and psychiatric comorbidity in patients with chronic itch.” Clin Exp Dermatol 31(6): 762-767.

https://doi.org/10.1111/j.1365-2230.2006.02211.x DOI: https://doi.org/10.1111/j.1365-2230.2006.02211.x

Schneider, G., A. Grebe, P. Bruland, G. Heuft and S. Ständer (2020). “Criteria suggestive of psychological components of itch and somatoform itch: study of a large sample of patients with chronic pruritus.” Acta Derm Venereol 100: adv00075.

https://doi.org/10.2340/00015555-3424 DOI: https://doi.org/10.2340/00015555-3424

Schulz, S., M. Metz, D. Siepmann, T. A. Luger, M. Maurer and S. Stander (2009). “[Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series].” Hautarzt 60(7): 564-568.

https://doi.org/10.1007/s00105-009-1730-4 DOI: https://doi.org/10.1007/s00105-009-1730-4

Schut, C., S. Grossmann, U. Gieler, J. Kupfer and G. Yosipovitch (2015). “Contagious itch: what we know and what we would like to know.” Front Hum Neurosci 11(9): 57.

https://doi.org/10.3389/fnhum.2015.00057 DOI: https://doi.org/10.3389/fnhum.2015.00057

Schworer, H. and G. Ramadori (1993). “Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists.” Clin Investig 71(8): 659-662.

https://doi.org/10.1007/BF00184497 DOI: https://doi.org/10.1007/BF00184497

Seckin, D., Z. Demircay and O. Akin (2007). “Generalized pruritus treated with narrowband UVB.” Int J Dermatol 46(4): 367-370.

https://doi.org/10.1111/j.1365-4632.2007.03048.x DOI: https://doi.org/10.1111/j.1365-4632.2007.03048.x

Sène, D. (2018). “Small fiber neuropathy: Diagnosis, causes, and treatment.” Joint Bone Spine 85(5): 553-559.

https://doi.org/10.1016/j.jbspin.2017.11.002 DOI: https://doi.org/10.1016/j.jbspin.2017.11.002

Serling, S. L. C., K. Leslie and T. Maurer (2011). “Approach to pruritus in the adult HIV-positive patient.” Semin Cutan Med Surg 30(2): 101-106.

https://doi.org/10.1016/j.sder.2011.04.004 DOI: https://doi.org/10.1016/j.sder.2011.04.004

Sesi, J. and S. R. Feldman (2024). “Comparative efficacy of systemic treatments for atopic dermatitis in adults.” Expert Rev Clin Immunol 20(3): 313-320.

https://doi.org/10.1080/1744666X.2023.2291038 DOI: https://doi.org/10.1080/1744666X.2023.2291038

Shafie’ei, M., M. Jamali, Z. Akbari, N. Sarvipour, M. Ahmadzade and N. Ahramiyanpour (2022). “Cutaneous adverse reactions following COVID-19 vaccinations: A systematic review and meta-analysis.” J Cosmet Dermatol.

https://doi.org/10.1111/jocd.15261 DOI: https://doi.org/10.1111/jocd.15261

Shahda, S., P. J. Loehrer, R. S. Clark, A. J. Spittler, S. K. Althouse and E. G. Chiorean (2016). “Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.” Oncologist 21(6): 664-665.

https://doi.org/10.1634/theoncologist.2016-0071 DOI: https://doi.org/10.1634/theoncologist.2016-0071

Shakiba, M., H. Sanadgol, H. R. Azmoude, M. A. Mashhadi and H. Sharifi (2012). “Effect of sertraline on uremic pruritus improvement in ESRD patients.” Int J Nephrol 2012: 363901.

https://doi.org/10.1155/2012/363901 DOI: https://doi.org/10.1155/2012/363901

Sharma, M., C. Bennett, S. N. Cohen and B. Carter (2014). “H1-antihistamines for chronic spontaneous urticaria.” Cochrane Database Syst Rev(11): CD006137.

https://doi.org/10.1002/14651858.CD006137.pub2 DOI: https://doi.org/10.1002/14651858.CD006137.pub2

Shelley, W. B. and E. D. Shelley (1998). “Aquadynia: noradrenergic pain induced by bathing and responsive to clonidine.” J Am Acad Dermatol 38(2 Pt 2): 357-358.

https://doi.org/10.1016/S0190-9622(98)70583-3 DOI: https://doi.org/10.1016/S0190-9622(98)70583-3

Shelley, W. B., E. D. Shelley and N. Y. Talanin (1996). “Self-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream.” J Am Acad Dermatol 34(1): 143-144.

https://doi.org/10.1016/S0190-9622(96)90864-6 DOI: https://doi.org/10.1016/S0190-9622(96)90864-6

Shi, V. Y., T. Bhutani, L. Fonacier and M. e. a. Deleuran (2022). “Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND).” J Am Acad Dermatol 87(2): 351-358.

https://doi.org/10.1016/j.jaad.2022.04.009 DOI: https://doi.org/10.1016/j.jaad.2022.04.009

Shohrati, M., S. M. Davoudi, S. Keshavarz, B. Sadr and A. Tajik (2007). “Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial.” Cutan Ocul Toxicol 26(3): 249-255.

https://doi.org/10.1080/15569520701212340 DOI: https://doi.org/10.1080/15569520701212340

Shohrati, M., A. Tajik, A. A. Harandi, S. M. Davoodi and M. Akmasi (2007). “Comparison of hydroxyzine and doxepin in treatment of pruritus due to sulfur mustard.” Skinmed 6(2): 70-72.

https://doi.org/10.1111/j.1540-9740.2007.05880.x DOI: https://doi.org/10.1111/j.1540-9740.2007.05880.x

Sidbury, R., A. Alikhan and L. e. a. Bercovitch (2023). “Guidelines of Care for the Management of Atopic Dermatitis in Adults With Topical Therapies.” J Am Acad Dermatol 89(1): e1-e20.

https://doi.org/10.1016/j.jaad.2022.12.029 DOI: https://doi.org/10.1016/j.jaad.2022.12.029

Siegel, F. P., J. Tauschert and P. E. Petrides (2013). “Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients.” Am J Hematol 88: 665-669.

https://doi.org/10.1002/ajh.23474 DOI: https://doi.org/10.1002/ajh.23474

Siegfried, E. C., J. C. Jaworski and A. A. Hebert (2013). “Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.” Am J Clin Dermatol 14(3): 163-178.

https://doi.org/10.1007/s40257-013-0020-1 DOI: https://doi.org/10.1007/s40257-013-0020-1

Siemens, W., C. Xander, J. J. Meerpohl, S. Buroh, G. Antes, G. Schwarzer and G. Becker (2016). “Pharmacological interventions for pruritus in adult palliative care patients.” Cochrane Database Syst Rev 16(11): CD008320.

https://doi.org/10.1002/14651858.CD008320.pub3 DOI: https://doi.org/10.1002/14651858.CD008320.pub3

Siepmann, D., T. Lotts, C. Blome, M. Braeutigam, N. Q. Phan, T. Butterfass-Bahloul, M. Augustin, T. A. Luger and S. Ständer (2013). “Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial.” Dermatology 227(4): 353-360.

https://doi.org/10.1159/000355671 DOI: https://doi.org/10.1159/000355671

Siepmann, D., T. A. Luger and S. Stander (2008). “Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series.” J Dtsch Dermatol Ges 6(11): 941-946.

https://doi.org/10.1111/j.1610-0387.2008.06745.x DOI: https://doi.org/10.1111/j.1610-0387.2008.06745.x

Silva, S. R., P. C. Viana, N. V. Lugon, M. Hoette, F. Ruzany and J. R. Lugon (1994). “Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial.” Nephron 67(3): 270-273.

https://doi.org/10.1159/000187978 DOI: https://doi.org/10.1159/000187978

Silverberg, J. I., E. Guttman-Yassky, D. Thaçi, A. D. Irvine and e. a. Stein Gold. L. (2023). “Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.” N Engl J Med 388(12): 1080-1091.

https://doi.org/10.1056/NEJMoa2206714 DOI: https://doi.org/10.1056/NEJMoa2206714

Silverberg, J. I., A. Pinter and G. e. a. Pulka (2020). “Phase 2B Randomized Study of Nemolizumab in Adults With Moderate-to-Severe Atopic Dermatitis and Severe Pruritus.” J Allergy Clin Immunol 145(1): 173-182.

https://doi.org/10.1016/j.jaci.2019.08.013 DOI: https://doi.org/10.1016/j.jaci.2019.08.013

Silverberg, J. I., E. L. Simpson, J. P. Thyssen and M. e. a. Gooderham (2020). “Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.” JAMA Dermatol 156(8): 863-873.

https://doi.org/10.1001/jamadermatol.2020.1406 DOI: https://doi.org/10.1001/jamadermatol.2020.1406

Silverberg, J. I., D. Toth, T. Bieber and A. F. e. a. Alexis (2021). “Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.” Br J Dermatol 184(3): 450-463.

https://doi.org/10.1111/bjd.19573 DOI: https://doi.org/10.1111/bjd.19573

Silverberg, J. I., A. Wollenberg, A. Reich and D. e. a. Thaçi (2024). “Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.” Lancet 404(10451): 445-460.

https://doi.org/10.1016/S0140-6736(24)01203-0 DOI: https://doi.org/10.1016/S0140-6736(24)01203-0

Silverberg, J. I., G. Yosipovitch, E. L. Simpson, B. S. Kim, J. J. Wu, L. Eckert, I. Guillemin, Z. Chen, M. Ardeleanu, A. Bansal, M. Kaur, A. B. Rossi, N. M. H. Graham, N. Patel and A. Gadkari (2020). “Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.” J Am Acad Dermatol 82(6): 1328-1336.

https://doi.org/10.1016/j.jaad.2020.02.060 DOI: https://doi.org/10.1016/j.jaad.2020.02.060

Simon, D. (2011). “Systemic therapy of atopic dermatitis in children and adults.” Curr Probl Dermatol 41: 156-164.

https://doi.org/10.1159/000323309 DOI: https://doi.org/10.1159/000323309

Simon, D. and T. Bieber (2014). “Systemic therapy for atopic dermatitis.” Allergy 69(1): 46-55.

https://doi.org/10.1111/all.12339 DOI: https://doi.org/10.1111/all.12339

Simpson, D. and S. Noble (2005). “Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions.” Drugs 65(6): 827-858.

https://doi.org/10.2165/00003495-200565060-00011 DOI: https://doi.org/10.2165/00003495-200565060-00011

Simpson, E. L., T. Bieber, E. Guttman-Yassky, L. A. Beck and A. Blauvelt, et al. (2016). “Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.” N Engl J Med 375(24): 2335-2348.

https://doi.org/10.1056/NEJMoa1610020 DOI: https://doi.org/10.1056/NEJMoa1610020

Simpson, E. L., L. F. Eichenfield, J. Alonso-Llamazares and Z. D. e. a. Draelos (2024). “Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.” JAMA Dermatol 160(11): 1161-1170.

https://doi.org/10.1001/jamadermatol.2024.3121 DOI: https://doi.org/10.1001/jamadermatol.2024.3121

Simpson, E. L., M. Gooderham, A. Wollenberg and S. e. a. Weidinger (2023). “Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).” JAMA Dermatol 159(2): 182-191.

https://doi.org/10.1001/jamadermatol.2022.5534 DOI: https://doi.org/10.1001/jamadermatol.2022.5534

Simpson, E. L., J.-P. Lacour, L. Spelman, R. Galimberti and L. F. Eichenfield, et al. (2020). “Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.” Br J Dermatol 183(2): 242-255.

https://doi.org/10.1111/bjd.18898 DOI: https://doi.org/10.1111/bjd.18898

Simpson, E. L., A. S. Paller, E. C. Siegfried and M. e. a. Boguniewicz (2020). “Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.” JAMA Dermatol 156(1): 44-56.

https://doi.org/10.1001/jamadermatol.2019.3336 DOI: https://doi.org/10.1001/jamadermatol.2019.3336

Singer, E. M., D. B. Shin, L. A. Nattkemper, B. M. Benoit, R. S. Klein, C. A. Didigu, A. Q. Loren, T. Dentchev, M. Wysocka, G. Yosipovitch and A. H. Rook (2013). “IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus.” J Invest Dermatol 133(12): 2783-2785.

https://doi.org/10.1038/jid.2013.227 DOI: https://doi.org/10.1038/jid.2013.227

Singh, F. and D. Rudikoff (2003). “HIV-associated pruritus: etiology and management.” Am J Clin Dermatol 4(3): 177-188.

https://doi.org/10.2165/00128071-200304030-00004 DOI: https://doi.org/10.2165/00128071-200304030-00004

Singleton, H., A. Hodder, O. Almilaji and S. J. e. a. Ersser (2024). “Educational and psychological interventions for managing atopic dermatitis (eczema).” Cochrane Database Syst Rev 2024(8): CD014932.

https://doi.org/10.1002/14651858.CD014932.pub2 DOI: https://doi.org/10.1002/14651858.CD014932.pub2

Sinikumpu, S.-P., J. Jokelainen, K. Tasanen, M. Timonen and L. Huilaja (2023). “Association between Pruritus and Psychosocial Well-being: A Population-based Study among 6,809 Subjects.” Acta Derm Venereol 103: adv00837.

https://doi.org/10.2340/actadv.v103.2922 DOI: https://doi.org/10.2340/actadv.v103.2922

Smith, C. H., Z. Z. N. Yiu, T. Bale and A. D. e. a. Burden (2024). “British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023: a pragmatic update.” Br J Dermatol 190(2): 270-272.

https://doi.org/10.1093/bjd/ljad347 DOI: https://doi.org/10.1093/bjd/ljad347

Sobell, J. M., P. Foley, D. Toth, U. Mrowietz, G. Girolomoni, J. Goncalves, R. M. Day, R. Chen and G. Yosipovitch (2016). “Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis.” Acta Derm Venereol 96(4): 514-520.

https://doi.org/10.2340/00015555-2360 DOI: https://doi.org/10.2340/00015555-2360

Sommer, F., P. Hensen, B. Bockenholt, D. Metze, T. A. Luger and S. Stander (2007). “Underlying diseases and co-factors in patients with severe chronic pruritus: a 3-year retrospective study.” Acta Derm Venereol 87(6): 510-516.

https://doi.org/10.2340/00015555-0320 DOI: https://doi.org/10.2340/00015555-0320

Spring, P., I. Gschwind and M. Gilliet (2014). “Prurigo nodularis: retrospective study of 13 cases managed with methotrexate.” Clin Exp Dermatol 39(4): 468-473.

https://doi.org/10.1111/ced.12365 DOI: https://doi.org/10.1111/ced.12365

Staab, D., T. L. Diepgen, M. Fartasch, J. Kupfer, T. Lob-Corzilius, J. Ring, S. Scheewe, R. Scheidt, G. Schmid-Ott, C. Schnopp, R. Szczepanski, T. Werfel, M. Wittenmeier, U. Wahn and U. Gieler (2006). “Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial.” BMJ 332(7547): 933-938.

https://doi.org/10.1136/bmj.332.7547.933 DOI: https://doi.org/10.1136/bmj.332.7547.933

Staab, D., U. von Rueden, R. Kehrt, M. Erhart, K. Wenninger, P. Kamtsiuris and U. Wahn (2002). “Evaluation of a parental training program for the management of childhood atopic dermatitis.” Pediatr Allergy Immunol 13(2): 84-90.

https://doi.org/10.1034/j.1399-3038.2002.01005.x DOI: https://doi.org/10.1034/j.1399-3038.2002.01005.x

Stahle-Backdahl, M., O. Hagermark, L. E. Lins, O. Torring, M. Hilliges and O. Johansson (1989). “Experimental and immunohistochemical studies on the possible role of parathyroid hormone in uraemic pruritus.” J Intern Med 225(6): 411-415.

https://doi.org/10.1111/j.1365-2796.1989.tb00104.x DOI: https://doi.org/10.1111/j.1365-2796.1989.tb00104.x

Ständer, S., M. Augustin, A. Reich, C. Blome, T. Ebata, N. Quan Phan and J. C. Szepietowski (2013). “Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials.” Acta Derm Venereol 93(5): 509-514.

https://doi.org/10.2340/00015555-1620 DOI: https://doi.org/10.2340/00015555-1620

Ständer, S., M. Augustin, D. Roggenkamp, C. Blome, T. Heitkemper, A. C. Worthmann and G. Neufang (2017). “Novel TRPM8 agonist cooling compound against chronic itch: results from a randomized, double-blind, controlled, pilot study in dry skin.” J Eur Acad Dermatol Venereol 31(6): 1064-1068.

https://doi.org/10.1111/jdv.14041 DOI: https://doi.org/10.1111/jdv.14041

Ständer, S., B. Bockenholt, F. Schurmeyer-Horst, C. Weishaupt, G. Heuft, T. A. Luger and G. Schneider (2009). “Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study.” Acta Derm Venereol 89(1): 45-51.

https://doi.org/10.2340/00015555-0553 DOI: https://doi.org/10.2340/00015555-0553

Ständer, S., M. Ketz, D. Akumo, N. Kossack, M. Pignot, R. Chavda and S. Gabriel (2024). “Comorbidities, healthcare resource utilization & treatment pattern among patients with prurigo nodularis, compared to a benchmark in Germany: A real-world evidence claims data study.” J Eur Acad Dermatol Venereol 38(5): 883-894.

https://doi.org/10.1111/jdv.19700 DOI: https://doi.org/10.1111/jdv.19700

Ständer, S., P. Kwon, J. Hirman, A. J. Perlman, E. Weisshaar, M. Metz, T. A. Luger and T.-S. Group (2019). “Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.” J Am Acad Dermatol 80(5): 1395-1402.

https://doi.org/10.1016/j.jaad.2019.01.052 DOI: https://doi.org/10.1016/j.jaad.2019.01.052

Ständer, S., T. Luger and D. Metze (2001). “Treatment of prurigo nodularis with topical capsaicin.” J Am Acad Dermatol 44(3): 471-478.

https://doi.org/10.1067/mjd.2001.110059 DOI: https://doi.org/10.1067/mjd.2001.110059

Ständer, S. and T. A. Luger (2003). “[Antipruritic effects of pimecrolimus and tacrolimus].” Hautarzt 54(5): 413-417.

https://doi.org/10.1007/s00105-003-0521-6 DOI: https://doi.org/10.1007/s00105-003-0521-6

Ständer, S. and T. A. Luger (2015). “NK-1 antagonists and itch.” Handb Exp Pharmacol 226: 237–255.

https://doi.org/10.1007/978-3-662-44605-8_14 DOI: https://doi.org/10.1007/978-3-662-44605-8_14

Ständer, S., M. P. Pereira, T. Berger, C. Zeidler, M. Augustin, S. Bobko, E. Brenaut, S. C. Chen, S. Chisolm, F. J. Dalgard, J. Elberling, S. B. Elmariah, A. W. M. Evers, S. Garcovich, M. Goncalo, J. A. Halvorsen, B. S. Kim, J. Kupfer, S. Kwatra, J. Lambert, F. J. Legat, E. A. Lerner, T. A. Leslie, L. Lönndahl, A. Lvov, M. Metz, L. Misery, E. Papadavid, N. N. Potekaev, A. Reich, E. Savk, G. Schneider, C. Schut, E. Serra-Baldrich, H. F. Ständer, M. Streit, J. C. Szepietowski, M. D. Tharp, J. Wallengren, A. Nast, E. Weisshaar and G. Yosipovitch (2020). “IFSI-Guideline on Chronic Prurigo including Prurigo nodularis.” ITCH 5: e42.

https://doi.org/10.1097/itx.0000000000000042 DOI: https://doi.org/10.1097/itx.0000000000000042

Ständer, S., M. P. Pereira and C. e. a. Zeidler (2024). “EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions.” J Eur Acad Dermatol Venereol 38: 1687–1693.

https://doi.org/10.1111/jdv.20102 DOI: https://doi.org/10.1111/jdv.20102

Ständer, S., E. Pogatzki-Zahn, A. Stumpf, F. Fritz, B. Pfleiderer and A. Ritzkat, et al. (2015). “Facing the challenges of chronic pruritus: a report from a multi-disciplinary medical itch centre in Germany.” Acta Derm Venereol 95(3): 266–271.

https://doi.org/10.2340/00015555-1949 DOI: https://doi.org/10.2340/00015555-1949

Ständer, S., H. W. Reinhardt and T. A. Luger (2006). “[Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus].” Hautarzt 57(9): 801–807.

https://doi.org/10.1007/s00105-006-1180-1 DOI: https://doi.org/10.1007/s00105-006-1180-1

Ständer, S., M. Schmelz, E. Lerner, et al. (2025). A multidisciplinary Delphi consensus on the modern definition of pruritus: Sensation and disease. J Eur Acad Dermatol Venereol. Published online July 17, 2025.

https://doi.org/10.1111/jdv.20851 DOI: https://doi.org/10.1111/jdv.20851

Ständer, S., I. Schäfer, N. Q. Phan, C. Blome, K. Herberger, H. Heigel and M. Augustin (2010). “Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730.” Dermatology 221(3): 229–235.

https://doi.org/10.1159/000319862 DOI: https://doi.org/10.1159/000319862

Ständer, S., F. Schürmeyer-Horst, T. A. Luger and E. Weisshaar (2006). “Treatment of pruritic diseases with topical calcineurin inhibitors.” Ther Clin Risk Manag 2(2): 213–218.

https://doi.org/10.2147/tcrm.2006.2.2.213 DOI: https://doi.org/10.2147/tcrm.2006.2.2.213

Ständer, S., D. Siepmann, I. Herrgott, C. Sunderkötter and T. A. Luger (2010). “Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.” PLoS One 5(6): e10968.

https://doi.org/10.1371/journal.pone.0010968 DOI: https://doi.org/10.1371/journal.pone.0010968

Ständer, S., A. Stumpf, N. Osada, S. Wilp, E. Chatzigeorgakidis and B. Pfleiderer (2013). “Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden.” Br J Dermatol 168(6): 1273–1280.

https://doi.org/10.1111/bjd.12267 DOI: https://doi.org/10.1111/bjd.12267

Ständer, S., E. Weisshaar, T. Mettang, M. Streit, U. Darsow, G. Schneider, D. Metze and M. Schmelz (2006). “[Clinical classification of chronic pruritus. Interdisciplinary consensus proposal for a diagnostic algorithm].” Hautarzt 57(5): 390–394.

https://doi.org/10.1007/s00105-006-1122-y DOI: https://doi.org/10.1007/s00105-006-1122-y

Ständer, S., E. Weisshaar, T. Mettang, J. C. Szepietowski, E. Carstens, A. Ikoma, N. V. Bergasa, U. Gieler, L. Misery, J. Wallengren, U. Darsow, M. Streit, D. Metze, T. A. Luger, M. W. Greaves, M. Schmelz, G. Yosipovitch and J. D. Bernhard (2007). “Clinical classification of itch: a position paper of the International Forum for the Study of Itch.” Acta Derm Venereol 87(4): 291–294.

https://doi.org/10.2340/00015555-0305 DOI: https://doi.org/10.2340/00015555-0305

Ständer, S., G. Yosipovitch, F. J. Legat, J.-P. Lacour and C. Paul, et al. (2020). “Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.” N Engl J Med 382(8): 706–716.

https://doi.org/10.1056/NEJMoa1908316 DOI: https://doi.org/10.1056/NEJMoa1908316

Stangier, U., A. Ehlers and U. Gieler (2004). “Predicting long-term outcome in group treatment of atopic dermatitis.” Psychother Psychosom 73(5): 293–301.

https://doi.org/10.1159/000078846 DOI: https://doi.org/10.1159/000078846

Staubach, P., A. Peveling-Oberhag, B. M. Lang, S. Zimmer, A. Sohn and C. Mann (2020). “Severe chronic spontaneous urticaria in children - treatment options according to the guidelines and beyond - a 10 years review.” J Dermatolog Treat 26: 1–4.

https://doi.org/10.1080/09546634.2020.1782326 DOI: https://doi.org/10.1080/09546634.2020.1782326

Stäubli, M. (1981). “Pruritus-a little known iron-deficiency symptom.” Schweiz Med Wochenschr 111(38): 1394–1398.

Stefaniak, A. A., R. Białynicki-birula, P. K. Krajewski, Ł. Matusiak, M. Goldust and J. C. Szepietowski (2020). “Itch in the era of COVID-19 pandemic: An unfolding scenario.” Dermatol Ther 33(5): e13477.

https://doi.org/10.1111/dth.13477 DOI: https://doi.org/10.1111/dth.13477

Stefaniak, A. A., M. P. Pereira, C. Zeidler and S. Ständer (2022). “Pruritus in Pregnancy.” Am J Clin Dermatol 23(2): 231–246.

https://doi.org/10.1007/s40257-021-00668-7 DOI: https://doi.org/10.1007/s40257-021-00668-7

Stefaniak, A. A., A. Zubkiewicz-Kucharska, L. Matusiak, A. Noczynska and J. C. Szepietowski (2020). “Itch in children with type 1 diabetes: A cross sectional study.” Dermatol Ther (Heidelb) 10(4): 745–756.

https://doi.org/10.1007/s13555-020-00403-w DOI: https://doi.org/10.1007/s13555-020-00403-w

Steffens, E., M. Kaplan and E. Weisshaar (2023). “[An unexpected discovery in a patient suffering from chronic prurigo].” Dermatolgie (Heidelb) 74(4): 286–288.

https://doi.org/10.1007/s00105-023-05131-8 DOI: https://doi.org/10.1007/s00105-023-05131-8

Stein Gold, L., K. Papp, D. Pariser and L. e. a. Green (2022). “Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.” J Am Acad Dermatol 86(1): 77–85.

https://doi.org/10.1016/j.jaad.2021.07.040 DOI: https://doi.org/10.1016/j.jaad.2021.07.040

Steinhoff, M., F. Cevikbas, A. Ikoma and T. G. Berger (2011). “Pruritus: management algorithms and experimental therapies.” Semin Cutan Med Surg 30(2): 127–137.

https://doi.org/10.1016/j.sder.2011.05.001 DOI: https://doi.org/10.1016/j.sder.2011.05.001

Steinhoff, M., A. L. Oaklander, I. L. Szabó, S. Ständer and M. Schmelz (2019). “Neuropathic itch.” Pain 160(Suppl 1): S11-S16.

https://doi.org/10.1097/j.pain.0000000000001551 DOI: https://doi.org/10.1097/j.pain.0000000000001551

Steinhoff, M., M. Schmelz, I. L. Szabó and A. L. Oaklander (2018). “Clinical presentation, management, and pathophysiology of neuropathic itch.” Lancet Neurol 17(8): 709–720.

https://doi.org/10.1016/S1474-4422(18)30217-5 DOI: https://doi.org/10.1016/S1474-4422(18)30217-5

Steinke, S., C. Zeidler, C. Riepe, P. Bruland, I. Soto-Rey, M. Storck, M. Augustin, S. Bobko, S. Garcovich, F. J. Legat, A. Lvov, L. Misery, N. Osada, A. Reich, E. Şavk, E. Serra-Baldrich, M. Streit, J. C. Szepietowski, W. Weger, M. Dugas and S. Ständer (2018). “Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial.” J Am Acad Dermatol 79(3): 457–463.e455.

https://doi.org/10.1016/j.jaad.2018.04.044 DOI: https://doi.org/10.1016/j.jaad.2018.04.044

Steinman, H. K. and M. W. Greaves (1985). “Aquagenic pruritus.” J Am Acad Dermatol 13(1): 91–96.

https://doi.org/10.1016/S0190-9622(85)70149-1 DOI: https://doi.org/10.1016/S0190-9622(85)70149-1

Stellon, A. (2002). “Neurogenic pruritus: an unrecognised problem? A retrospective case series of treatment by acupuncture.” Acupunct Med 20(4): 186–190.

https://doi.org/10.1136/aim.20.4.186 DOI: https://doi.org/10.1136/aim.20.4.186

Stern, R. S. and P. F. u. Study (2001). “The risk of melanoma in association with long-term exposure to PUVA.” J Am Acad Dermatol 44(5): 755–761.

https://doi.org/10.1067/mjd.2001.114576 DOI: https://doi.org/10.1067/mjd.2001.114576

Stevens, M. T. and A. M. Edwards (2015). “The effect of 4% sodium cromoglicate cutaneous emulsion compared to vehicle in atopic dermatitis in children - A meta-analysis of total SCORAD scores.” J Dermatolog Treat 26(3): 284–290.

https://doi.org/10.3109/09546634.2014.933766 DOI: https://doi.org/10.3109/09546634.2014.933766

Stewart, K. M. A. (2010). “Clinical care of vulvar pruritus, with emphasis on one common cause, lichen simplex chronicus.” Dermatol Clin 28(4): 669–680.

https://doi.org/10.1016/j.det.2010.08.004 DOI: https://doi.org/10.1016/j.det.2010.08.004

Stockenhuber, F., G. Sunder-Plassmann and P. Balcke (1987). “Increased plasma histamine levels in chronic renal failure.” N Engl J Med 317(6): 386.

https://doi.org/10.1056/NEJM198708063170614 DOI: https://doi.org/10.1056/NEJM198708063170614

Storck, M., S. Sandmann, P. Bruland, M. P. Pereira, S. Steinke, C. Riepe, I. Soto-Rey, S. Garcovich, M. Augustin, C. Blome, S. Bobko and F. J. Legat, et al. (2021). “Pruritus Intensity Scales across Europe: a prospective validation study.” J Eur Acad Dermatol Venereol 35(5): 1176–1185.

https://doi.org/10.1111/jdv.17111 DOI: https://doi.org/10.1111/jdv.17111

Streit, M., V. Von Felbert and L. R. Braathen (2002). “[Pruritus sine marteria. Pathophysiology, diagnostic assessment and therapy].” Hautarzt 53(12): 830–849.

https://doi.org/10.1007/s00105-002-0455-4 DOI: https://doi.org/10.1007/s00105-002-0455-4

Strober, B., B. Sigurgeirsson, G. Popp, R. Sinclair, J. Krell, S. Stonkus, M. Septe, B. E. Elewski, A. B. Gottlieb, Y. Zhao, M. H. Tran, A. Karpov, L. D. McLeod, M. Mordin, C. Papavassilis and J. Nyirady, Lebwohl, M. (2016). “Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials.” Int J Dermatol 55(4): 401–407.

https://doi.org/10.1111/ijd.13236 DOI: https://doi.org/10.1111/ijd.13236

Stumpf, A., M. Burgmer, G. Schneider, G. Heuft and M. e. e. Schmelz (2013). “Sex differences in itch perception and modulation by distraction--an FMRI pilot study in healthy volunteers.” PLoS One 8(11): e79123.

https://doi.org/10.1371/journal.pone.0079123 DOI: https://doi.org/10.1371/journal.pone.0079123

Stumpf, A. and S. Ständer (2013). “Neuropathic itch: diagnosis and management.” Dermatol Ther 26(2): 104–109.

https://doi.org/10.1111/dth.12028 DOI: https://doi.org/10.1111/dth.12028

Su, L. N., X. Xu, L. Tang, N. Yu and Y. F. Ding (2016). “UVA1 phototherapy in the treatment of palmoplantar pustulosis: a pilot prospective study.” Lasers Med Sci 31(8): 1641–1643.

https://doi.org/10.1007/s10103-016-2031-7 DOI: https://doi.org/10.1007/s10103-016-2031-7

Sun, T., X. Zhang, C. Hou, S. Yu, Y. Zhang, Z. Yu, L. Kong, C. Liu, L. Feng, D. Wang and G. Ni (2022). “Cold Plasma Irradiation Attenuates Atopic Dermatitis via Enhancing HIF-1α-Induced MANF Transcription Expression.” Front Immunol 14(13): 941219.

https://doi.org/10.3389/fimmu.2022.941219 DOI: https://doi.org/10.3389/fimmu.2022.941219

Suys, E. (2012). “Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani.” J Am Acad Dermatol 66(2): 327–328.

https://doi.org/10.1016/j.jaad.2011.05.024 DOI: https://doi.org/10.1016/j.jaad.2011.05.024

Swanbeck, G. and G. Rajka (1970). “Antipruritic effect of urea solutions. An experimental and clinical study.” Acta Derm Venereol 50(3): 225–227.

Swerlick, R. A. (1985). “Photochemotherapy treatment of pruritus associated with polycythemia vera.” J Am Acad Dermatol 13(4): 675–677.

https://doi.org/10.1016/S0190-9622(85)80459-X DOI: https://doi.org/10.1016/S0190-9622(85)80459-X

Symvoulakis, E. K., K. Krasagakis, I. D. Komninos, I. Kastrinakis, I. Lyronis, A. Philalithis and A. D. Tosca (2006). “Primary care and pattern of skin diseases in a Mediterranean island.” BMC Fam Pract 7: 6.

https://doi.org/10.1186/1471-2296-7–6 DOI: https://doi.org/10.1186/1471-2296-7-6

Szeimies, R. M., W. Stolz, U. Wlotzke, H. C. Korting and M. Landthaler (1994). “Successful treatment of hydroxyethyl starch-induced pruritus with topical capsaicin.” Br J Dermatol 131(3): 380–382.

https://doi.org/10.1111/j.1365-2133.1994.tb08529.x DOI: https://doi.org/10.1111/j.1365-2133.1994.tb08529.x

Szepietowski, J. C., Ł. Matusiak, M. Szepietowska, P. K. Krajewski and R. Białynicki-Birula (2020). “Face Mask-induced Itch: A Self-questionnaire Study of 2,315 Responders During the COVID-19 Pandemic.” Acta Derm Venereol 100(10): adv00152.

https://doi.org/10.2340/00015555-3536 DOI: https://doi.org/10.2340/00015555-3536

Szepietowski, J. C., A. Morita and T. Tsuji (2002). “Ultraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritus.” Med Hypotheses 58(2): 167–170.

https://doi.org/10.1054/mehy.2001.1505 DOI: https://doi.org/10.1054/mehy.2001.1505

Szepietowski, J. C. and R. Reszke (2016). “Psychogenic Itch Management.” Curr Probl Dermatol 50: 124–132.

https://doi.org/10.1159/000446055 DOI: https://doi.org/10.1159/000446055

Szepietowski, J. C., T. Szepietowski and A. Reich (2005). “Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study.” Acta Dermatovenerol Croat 13(2): 97–103.

Szolcsanyi, J. (2004). “Forty years in capsaicin research for sensory pharmacology and physiology.” Neuropeptides 38(6): 377–384.

https://doi.org/10.1016/j.npep.2004.07.005 DOI: https://doi.org/10.1016/j.npep.2004.07.005

Szzech, J., A. Wiatrowski, L. Hirnle and A. Reich (2017). “Prevalence and Relevance of Pruritus in Pregnancy.” Biomed Res Int 2017.

https://doi.org/10.1155/2017/4238139 DOI: https://doi.org/10.1155/2017/4238139

Tada, Y., R. Watanabe, H. Noma, Y. Kanai, T. Nomura and K. Kaneko (2020). “Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.” J Dermatol Sci 99(1): 53–61.

https://doi.org/10.1016/j.jdermsci.2020.06.003 DOI: https://doi.org/10.1016/j.jdermsci.2020.06.003

Taghaddos, D., I. Savinova and M. Abu-Hilal (2024). “Clinical Characteristics and Treatment Outcomes of Prurigo Nodularis: A Retrospective Study.” J Clin Med Surg 28(2): 141–145.

https://doi.org/10.1177/12034754241227808 DOI: https://doi.org/10.1177/12034754241227808

Tang, E. C., E. Vittinghoff, P. L. Anderson and S. E. e. a. Cohen (2018). “Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.” J Acquir Immune Defic Syndr 77(2): 193–198.

https://doi.org/10.1097/QAI.0000000000001566 DOI: https://doi.org/10.1097/QAI.0000000000001566

Tarng, D. C., Y. L. Cho, H. N. Liu and T. P. Huang (1996). “Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream.” Nephron 72(4): 617–622.

https://doi.org/10.1159/000188949 DOI: https://doi.org/10.1159/000188949

Taylor, P. C., G. Dolan, J. P. Ng, B. Paul, R. Collin and J. T. Reilly (1996). “Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data.” Br J Haematol 92(1): 55–59.

https://doi.org/10.1046/j.1365-2141.1996.00303.x DOI: https://doi.org/10.1046/j.1365-2141.1996.00303.x

Tefferi, A. and R. Fonseca (2002). “Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus.” Blood 99(7): 2627.

https://doi.org/10.1182/blood.V99.7.2627 DOI: https://doi.org/10.1182/blood.V99.7.2627

Tefferi, A., A. M. Vannucchi and T. Barbui (2018). “Polycythemia vera treatment algorithm 2018.” Blood Cancer Journal 8(1): 3.

https://doi.org/10.1038/s41408-017-0042-7 DOI: https://doi.org/10.1038/s41408-017-0042-7

Teofoli, P., O. De Pita, A. Frezzolini and T. Lotti (1998). “Antipruritic effect of oral cyclosporin A in essential senile pruritus.” Acta Derm Venereol 78(3): 232.

https://doi.org/10.1080/000155598441675 DOI: https://doi.org/10.1080/000155598441675

Terg, R., E. Coronel, J. Sorda, A. E. Munoz and J. Findor (2002). “Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study.” J Hepatol 37(6): 717–722.

https://doi.org/10.1016/S0168-8278(02)00318-5 DOI: https://doi.org/10.1016/S0168-8278(02)00318-5

Tey, H. L. and G. Yosipovitch (2011). “Targeted treatment of pruritus - a look into the future.” Br J Dermatol 165(1): 5–17.

https://doi.org/10.1111/j.1365-2133.2011.10217.x DOI: https://doi.org/10.1111/j.1365-2133.2011.10217.x

Thaçi, D., A. M. Soliman, K. Eyerich and A. e. a. Pinter (2021). “Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial.” J Eur Acad Dermatol Venereol 35(8): 1686–1691.

https://doi.org/10.1111/jdv.17109 DOI: https://doi.org/10.1111/jdv.17109

Thaipisuttikul, Y. (1998). “Pruritic skin diseases in the elderly.” J Dermatol 25(3): 153–157.

https://doi.org/10.1111/j.1346–8138.1998.tb02371.x DOI: https://doi.org/10.1111/j.1346-8138.1998.tb02371.x

Thangam, E. B., E. A. Jemina, H. Singh, M. S. Baig, M. Khan, C. B. Mathias, M. K. Chuch and R. Saluja (2018). “The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets.” Front Immunol 9(1873).

https://doi.org/10.3389/fimmu.2018.01873 DOI: https://doi.org/10.3389/fimmu.2018.01873

Thébaut, A., D. Habes, F. Gottrand, C. Rivet, J. Cohen, D. Debray, E. Jacquemin and E. Gonzales (2016). “Sertraline as an additional treatment for cholestatic pruritus in children.” J Pediatr Gastroenterol Nutr.

https://doi.org/10.1097/MPG.0000000000001385 DOI: https://doi.org/10.1097/MPG.0000000000001385

Théréné, C., E. Brenaut, T. Barnetche and L. Misery (2018). “Efficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis.” J Invest Dermatol 138(1): 38–45.

https://doi.org/10.1016/j.jid.2017.05.039 DOI: https://doi.org/10.1016/j.jid.2017.05.039

Theodosiou, G., T. Nissen, E. Weisshaar, et al. (2022). Prevalence of Itch in German Schoolchildren: A Population-based Study. Acta Derm Venereol. 102:adv00718.

https://doi.org/10.2340/actadv.v102.1063 DOI: https://doi.org/10.2340/actadv.v102.1063

Thompson, R. J., H. Arnell, R. Artan, U. Baumann and P. L. e. a. Calvo (2022). “Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.” Lancet Gastroenterol Hepatol 7(9): 830–842.

https://doi.org/10.1016/S2468-1253(22)00093-0 DOI: https://doi.org/10.1016/S2468-1253(22)00093-0

Thurmond, R. L. (2015). “The histamine H4 receptor: from orphan to the clinic.” Front Pharmacol 6: 65.

https://doi.org/10.3389/fphar.2015.00065 DOI: https://doi.org/10.3389/fphar.2015.00065

Thurmond, R. L., K. Kazerouni, S. R. Chaplan and A. J. Greenspan (2015). “Antihistamines and Itch.” Handb Exp Pharmacol 226: 257–290.

https://doi.org/10.1007/978-3-662-44605-8_15 DOI: https://doi.org/10.1007/978-3-662-44605-8_15

Tinegate, H. and J. McLelland (2002). “Transcutaneous electrical nerve stimulation may improve pruritus associated with haematological disorders.” Clin Lab Haematol 24(6): 389–390.

https://doi.org/10.1046/j.1365-2257.2002.00472.x DOI: https://doi.org/10.1046/j.1365-2257.2002.00472.x

Todberg, T., C. Zachariae and L. Skov (2020). “Treatment and burden of disease in a cohort of patients with prurigo nodularis: a survey-based study.” Acta Derm Venereol 100(8): adv00119.

https://doi.org/10.2340/00015555-3471 DOI: https://doi.org/10.2340/00015555-3471

Tomas-Aragones, L., S. M. Consoli, S. G. Consoli, F. Poot, K. M. Taube, M. D. Linder, G. B. Jemec, J. C. Szepietowski, J. Korte, A. N. Lvov and U. Gieler (2016). “Self-Inflicted Lesions in Dermatology: A Management and Therapeutic Approach - A Position Paper From the European Society for Dermatology and Psychiatry.” Acta Derm Venereol.

https://doi.org/10.2340/00015555-2522 DOI: https://doi.org/10.2340/00015555-2522

Tominaga, M., S. Tengara, A. Kamo, H. Ogawa and K. Takamori (2009). “Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis.” J Dermatol Sci 55(1): 40–46.

https://doi.org/10.1016/j.jdermsci.2009.03.007 DOI: https://doi.org/10.1016/j.jdermsci.2009.03.007

Topp, J., C. Apfelbacher, S. Ständer, M. Augustin and C. Blome (2022). “Measurement Properties of Patient-Reported Outcome Measures for Pruritus: An Updated Systematic Review.” J Invest Dermatol 142(2): 343–354.

https://doi.org/10.1016/j.jid.2021.06.032 DOI: https://doi.org/10.1016/j.jid.2021.06.032

Torres, T., I. Fernandes, M. Selores, R. Alves and M. Lima (2012). “Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues.” J Am Acad Dermatol 66(1): e14–15.

https://doi.org/10.1016/j.jaad.2011.01.016 DOI: https://doi.org/10.1016/j.jaad.2011.01.016

Treudler, R. (2010). “Allergische Erkrankungen bei Schwangeren.” Hautarzt 61: 1027–1033.

https://doi.org/10.1007/s00105-010-2008-6 DOI: https://doi.org/10.1007/s00105-010-2008-6

Tsabouri, S., S. Arasi, B. Beken, M. K. Church, M. Alvaro-Lozano, C. Caffarelli, C. Flohr, S. R. Janmohamed, G. N. Konstantinou, S. Lau, S. Lefevre, C. G. Mortz, G. Pajno, H. Pite, K. Rutkowski, P. Staubach, L.-A. Van der Poe, T. Zuberbier and T. A. Leslie (2022). “A European survey of management approaches in chronic urticaria in children : EAACI pediatric urticaria taskforce “ Pediatr Allergy Immunol 33: e13674.

https://doi.org/10.1111/pai.13674 DOI: https://doi.org/10.1111/pai.13674

Tsai, S. Y., W. Phipatanakul and E. B. e. a. Hawryluk (2024). “Comparative Safety of Oral Janus Kinase Inhibitors Versus Dupilumab in Patients With Atopic Dermatitis: A population-Based Cohort Study.” J Allergy Clin Immunol 154(5): 1195–1203.

https://doi.org/10.1016/j.jaci.2024.07.019 DOI: https://doi.org/10.1016/j.jaci.2024.07.019

Tsianakas, A., C. Zeidler, C. Riepe, M. Borowski, C. Forner, J. Gerss, M. Metz, P. Staubach, U. Raap, M. Kaatz, M. Urban, T. A. Luger and S. Ständer (2019 [Epub ahead of print]). “Aprepitant in histamine-refractory chronic nodular prurigo: a multicentre, randomized, double-blind, placebo-controlled, cross-over, phase- II trial (APREPRU).” Acta Derm Venereol.

https://doi.org/10.2340/00015555-3120 DOI: https://doi.org/10.2340/00015555-3120

Tupker, R. A., P. J. Coenraads and J. B. van der Meer (1992). “Treatment of prurigo nodularis, chronic prurigo and neurodermatitis circumscripta with topical capsaicin.” Acta Derm Venereol 72(6): 463.

https://doi.org/10.2340/0001555572463 DOI: https://doi.org/10.2340/0001555572463

Twycross, R., M. W. Greaves, H. Handwerker, E. A. Jones, S. E. Libretto, J. C. Szepietowski and Z. Zylicz (2003). “Itch: scratching more than the surface.” QJM 96(1): 7–26.

https://doi.org/10.1093/qjmed/hcg002 DOI: https://doi.org/10.1093/qjmed/hcg002

Umeuchi, H., Y. Togashi, T. Honda, K. Nakao, K. Okano, T. Tanaka and H. Nagase (2003). “Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system.” Eur J Pharmacol 477: 29–35.

https://doi.org/10.1016/j.ejphar.2003.08.007 DOI: https://doi.org/10.1016/j.ejphar.2003.08.007

Umezawa, Y., A. Asahina, S. Imafuku and Y. e. a. Tada (2021). “Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results.” Dermatol Ther (Heidelb) 11(3): 943–960.

https://doi.org/10.1007/s13555-021-00520-0 DOI: https://doi.org/10.1007/s13555-021-00520-0

Uter, W., A. Bauer and A. Belloni Fortina, et al. (2021). “Patch test results with the European baseline series and additions thereof in the ESSCA network, 2015-2018.” Contact Dermatitis 84(2): 109–120.

https://doi.org/10.1111/cod.13704 DOI: https://doi.org/10.1111/cod.13704

Valdes-Rodriguez, R., C. Stull and G. Yosipovitch (2015). “Chronic pruritus in the elderly: pathophysiology, diagnosis and management.” Drugs Aging 32: 201–215.

https://doi.org/10.1007/s40266-015-0246-0 DOI: https://doi.org/10.1007/s40266-015-0246-0

van den Broek, H. (1980). “Treatment of prurigo nodularis with thalidomide.” Arch Dermatol 116(5): 571–572.

https://doi.org/10.1001/archderm.1980.01640290081018 DOI: https://doi.org/10.1001/archderm.1980.01640290081018

van Joost, T., E. Stolz and F. Heule (1987). “Efficacy of low-dose cyclosporine in severe atopic skin disease.” Arch Dermatol 123(2): 166–167.

https://doi.org/10.1001/archderm.1987.01660260034008 DOI: https://doi.org/10.1001/archderm.1987.01660260034008

van Os-Medendorp, H., W. J. Ros, P. C. Eland-de Kok, C. Kennedy, B. H. Thio, A. van der Schuur-van der Zande, M. H. Grypdonck and C. A. Bruijnzeel-Koomen (2007). “Effectiveness of the nursing programme ‘Coping with itch’: a randomized controlled study in adults with chronic pruritic skin disease.” Br J Dermatol 156(1235–1244).

https://doi.org/10.1111/j.1365-2133.2007.07919.x DOI: https://doi.org/10.1111/j.1365-2133.2007.07919.x

Van Voorhees, A. S., L. Stein Gold, M. Lebwohl and B. e. a. Strober (2020). “Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.” J Am Acad Dermatol 83(1): 96–103.

https://doi.org/10.1016/j.jaad.2020.01.072 DOI: https://doi.org/10.1016/j.jaad.2020.01.072

Vannucchi, A. M., J. J. Kiladjian, M. Griesshammer, T. Masszi, S. Durrant, F. Passamonti and C. N. e. a. Harrison (2015). “Ruxolitinib versus standard therapy for the treatment of polycythemia vera.” N Engl J Med 372(5): 426–435.

https://doi.org/10.1056/NEJMoa1409002 DOI: https://doi.org/10.1056/NEJMoa1409002

Veien, N. K. and G. Laurberg (2011). “Brachioradial pruritus: a follow-up of 76 patients.” Acta Derm Venereol 91(2): 183–185.

https://doi.org/10.2340/00015555-1006 DOI: https://doi.org/10.2340/00015555-1006

Verdu, E., I. Blanc-Brisset, G. Meyer, G. Le Roux, C. Bruneau and M. Deguigne (2020). “Second-generation antihistamines: a study of poisoning in children.” Clin Toxicol (Phila) 58(4): 275–283.

https://doi.org/10.1080/15563650.2019.1634812 DOI: https://doi.org/10.1080/15563650.2019.1634812

Verweyen, E., S. Ständer, K. Kreitz and I. e. a. Höben (2019). “Validation of a Comprehensive Set of Pruritus Assessment Instruments: The Chronic Pruritus Tools Questionnaire PRURITOOLS.” Acta Derm Venereol 99(7): 657–663.

https://doi.org/10.2340/00015555-3158 DOI: https://doi.org/10.2340/00015555-3158

Vessal, G., M. M. Sagheb, S. Shilian, P. Jafari and S. M. Samani (2010). “Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study.” Nephrol Dial Transplant 25(5): 1541–1547.

https://doi.org/10.1093/ndt/gfp628 DOI: https://doi.org/10.1093/ndt/gfp628

Vestergaard, C., A. Wollenberg and S. e. a. Barbarot (2019). “European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period.” J Eur Acad Dermatol Venereol 2019: 1644–1659.

https://doi.org/10.1111/jdv.15709 DOI: https://doi.org/10.1111/jdv.15709

Viegas, L. P., M. B. Ferreira and A. P. Kaplan (2014). “The maddening itch: an approach to chronic urticaria.” J Investig Allergol Clin Immunol 24(1): 1–5.

Vila, T., J. Gommer and A. C. Scates (2008). “Role of gabapentin in the treatment of uremic pruritus.” Ann Pharmacother 42(7): 1080–1084.

https://doi.org/10.1345/aph.1L038 DOI: https://doi.org/10.1345/aph.1L038

Vincenzi, B., M. E. Fratto, D. Santini and G. Tonini (2010). “Aprepitant against pruritus in patients with solid tumours.” Support Care Cancer 18(9): 1229–1230.

https://doi.org/10.1007/s00520-010-0895-9 DOI: https://doi.org/10.1007/s00520-010-0895-9

Vincenzi, B., G. Tonini and D. Santini (2010). “Aprepitant for erlotinib-induced pruritus.” N Engl J Med 363(4): 397–398.

https://doi.org/10.1056/NEJMc1003937 DOI: https://doi.org/10.1056/NEJMc1003937

Vincze, A., E. Herczeg-Lisztes, K. Szabó and T. G. Béldi, et al. (2023). “Pruritogenic molecules in the skin of patients with dermatomyositis.” Front Med (Lausanne) 10: 1168359.

https://doi.org/10.3389/fmed.2023.1168359 DOI: https://doi.org/10.3389/fmed.2023.1168359

Visse, K., C. Blome, N. Q. Phan, M. Augustin and S. Ständer (2017). “Efficacy of Body Lotion Containing N-palmitoylethanolamine in Subjects with Chronic Pruritus due to Dry Skin: A Dermatocosmetic Study.” Acta Derm Venereol 97(5): 639–641.

https://doi.org/10.2340/00015555-2593 DOI: https://doi.org/10.2340/00015555-2593

Wachholz, P. A., P. Y. Masuda, A. C. V. D. Pinto and A. C. C. Martelli (2017). “Impact of drug therapy on brachioradial pruritus.” An Bras Dermatol 92(2): 281–282.

https://doi.org/10.1590/abd1806-4841.20175321 DOI: https://doi.org/10.1590/abd1806-4841.20175321

Wagner, T., A. Roth-Daniek, A. Sell, J. England and K. U. Kern (2012). “Capsaicin 8% patch for peripheral neuropathic pain: review of treatment best practice from ‘real-world’ clinical experience.” Pain Manag 2(3): 239–250.

https://doi.org/10.2217/pmt.12.13 DOI: https://doi.org/10.2217/pmt.12.13

Wahid, Z. and A. Kanjee (1998). “Cutaneous manifestations of diabetes mellitus.” J Pak Med Assoc 48(10): 304–305.

Wahlgren, C. F. (2005). “Children’s rating of itch: an experimental study.” Pediatr Dermatol 22(2): 97–101.

https://doi.org/10.1111/j.1525-1470.2005.22201.x DOI: https://doi.org/10.1111/j.1525-1470.2005.22201.x

Wahlgren, C. F., A. Scheynius and O. Hagermark (1990). “Antipruritic effect of oral cyclosporin A in atopic dermatitis.” Acta Derm Venereol 70(4): 323–329.

https://doi.org/10.2340/0001555570323329 DOI: https://doi.org/10.2340/0001555570323329

Wallengren, J. (1998). “Brachioradial pruritus: a recurrent solar dermopathy.” J Am Acad Dermatol 39(5 Pt 1): 803–806.

https://doi.org/10.1016/S0190-9622(98)70058-1 DOI: https://doi.org/10.1016/S0190-9622(98)70058-1

Wallengren, J. (2004). “Prurigo: diagnosis and management.” Am J Clin Dermatol 5(2): 85–95.

https://doi.org/10.2165/00128071-200405020-00003 DOI: https://doi.org/10.2165/00128071-200405020-00003

Wallengren, J. (2011). “Tea tree oil attenuates experimental contact dermatitis.” Arch Dermatol Res 303(5): 333–338.

https://doi.org/10.1007/s00403-010-1083-y DOI: https://doi.org/10.1007/s00403-010-1083-y

Wallengren, J. and R. Hakanson (1992). “Effects of capsaicin, bradykinin and prostaglandin E2 in the human skin.” Br J Dermatol 126(2): 111–117.

https://doi.org/10.1111/j.1365-2133.1992.tb07806.x DOI: https://doi.org/10.1111/j.1365-2133.1992.tb07806.x

Wallengren, J. and M. Klinker (1995). “Successful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study.” J Am Acad Dermatol 32(2 Pt 1): 287–289.

https://doi.org/10.1016/0190-9622(95)90152-3 DOI: https://doi.org/10.1016/0190-9622(95)90152-3

Wallengren, J. and F. Sundler (2001). “Cutaneous field stimulation in the treatment of severe itch.” Arch Dermatol 137(10): 1323–1325.

https://doi.org/10.1001/archderm.137.10.1323 DOI: https://doi.org/10.1001/archderm.137.10.1323

Wallengren, J. and F. Sundler (2004). “Phototherapy reduces the number of epidermal and CGRP-positive dermal nerve fibres.” Acta Derm Venereol 84(2): 111–115.

https://doi.org/10.1080/00015550310022899 DOI: https://doi.org/10.1080/00015550310022899

Walt, R. P., T. K. Daneshmend, I. W. Fellows and P. J. Toghill (1988). “Effect of stanozolol on itching in primary biliary cirrhosis.” Br Med J (Clin Res Ed) 296(6622): 607.

https://doi.org/10.1136/bmj.296.6622.607 DOI: https://doi.org/10.1136/bmj.296.6622.607

Wang, C. P., Y. C. Lu, I. T. Tsai, W. H. Tang, C. C. Hsu, W. C. Hung, T. H. Yu, S. C. Chen, F. M. Chung, Y. J. Lee and J. Y. Houng (2016). “Increased Levels of Total p-Cresylsulfate Are Associated with Pruritus in Patients with Chronic Kidney Disease.” Dermatology 232(3): 363–370.

https://doi.org/10.1159/000445429 DOI: https://doi.org/10.1159/000445429

Wang, G. S., K. M. Reynolds, W. Banner, G. R. Bond, R. E. Kauffman, R. B. Palmer, I. M. Paul, M. Rapp-Olsson, J. L. Green and R. C. Dart (2020). “Adverse Events Related to Accidental Unintentional Ingestions From Cough and Cold Medications in Children.” Pediatr Emerg Care 38(1): e100-e104.

https://doi.org/10.1097/PEC.0000000000002166 DOI: https://doi.org/10.1097/PEC.0000000000002166

Wang, H. and G. Yosipovitch (2010). “New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma.” Int J Dermatol 49(1): 1–11.

https://doi.org/10.1111/j.1365-4632.2009.04249.x DOI: https://doi.org/10.1111/j.1365-4632.2009.04249.x

Wang, P.-F., Y. Chen, S.-Y. Song and T.-J. e. a. Wang (2017). “Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.” Front Pharmacol 8: 730.

https://doi.org/10.3389/fphar.2017.00730 DOI: https://doi.org/10.3389/fphar.2017.00730

Wang, X. D., G. Yang, Y. Bai, Y. P. Feng and H. LI (2018). “The behavioral study on the interactive aggravation between pruritus and depression.” Brain Behav 8(6): e00964.

https://doi.org/10.1002/brb3.964 DOI: https://doi.org/10.1002/brb3.964

Wang, X. Y., M. Lim-Jurado, N. Prepageran, P. Tantilipikorn and W. d. Y. (2016). “Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine.” Ther Clin Risk Manag 12: 585–597.

https://doi.org/10.2147/TCRM.S105189 DOI: https://doi.org/10.2147/TCRM.S105189

Wang, Y., D. Kong, C. Wang and J. Chen, et al. (2020). “A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials.” Technol Cancer Res Treat 19: 1533033820967454.

https://doi.org/10.1177/1533033820967454 DOI: https://doi.org/10.1177/1533033820967454

Weick, J. K., P. B. Donovan, Y. Najean, C. Dresch, A. V. Pisciotta, A. A. Cooperberg and J. D. Goldberg (1982). “The use of cimetidine for the treatment of pruritus in polycythemia vera.” Arch Intern Med 142(2): 241–242. DOI: https://doi.org/10.1001/archinte.1982.00340150041009

https://doi.org/10.1001/archinte.1982.003401500410010 DOI: https://doi.org/10.1001/archinte.1982.003401500410010

Weiss, M., T. Mettang, U. Tschulena and E. Weisshaar (2016). “Health-related quality of life in haemodialysis patients suffering from chronic itch: results from GEHIS (German Epidemiology Haemodialysis Itch Study).” Qual Life Res 25(12): 3097–3106.

https://doi.org/10.1007/s11136-016-1340-4 DOI: https://doi.org/10.1007/s11136-016-1340-4

Weisshaar, E. (2008). “Intractable chronic pruritus in a 67-year-old man.” Acta Derm Venereol 88(5): 488–490.

https://doi.org/10.2340/00015555-0520 DOI: https://doi.org/10.2340/00015555-0520

Weisshaar, E. (2015). “[Genitoanal pruritus].” Hautarzt 66(1): 53–59.

https://doi.org/10.1007/s00105-014-3547-z DOI: https://doi.org/10.1007/s00105-014-3547-z

Weisshaar, E. (2020). “[Antihistamines for treating pruritus : The end of an era?].” Hautarzt 71(7): 525–527.

https://doi.org/10.1007/s00105-020-04617-z DOI: https://doi.org/10.1007/s00105-020-04617-z

Weisshaar, E., C. Apfelbacher, G. Jager, E. Zimmermann, T. Bruckner, T. L. Diepgen and H. Gollnick (2006). “Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients.” Br J Dermatol 155(5): 957–964.

https://doi.org/10.1111/j.1365-2133.2006.07430.x DOI: https://doi.org/10.1111/j.1365-2133.2006.07430.x

Weisshaar, E. and F. Dalgard (2009). “Epidemiology of itch: adding to the burden of skin morbidity.” Acta Derm Venereol 89(4): 339–350.

https://doi.org/10.2340/00015555-0662 DOI: https://doi.org/10.2340/00015555-0662

Weisshaar, E., T. L. Diepgen, T. Bruckner, M. Fartasch, J. Kupfer, T. Lob-Corzilius, J. Ring, S. Scheewe, R. Scheidt, G. Schmid-Ott, C. Schnopp, D. Staab, R. Szcepanski, T. Werfel, M. Wittenmeier, U. Wahn and U. Gieler (2008). “Itch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life, coping behaviour and SCORAD severity in 823 children.” Acta Derm Venereol 88(3): 234–239.

https://doi.org/10.2340/00015555-0432 DOI: https://doi.org/10.2340/00015555-0432

Weisshaar, E., T. L. Diepgen, T. A. Luger, S. Seeliger, R. Witteler and S. Stander (2005). “Pruritus in pregnancy and childhood--do we really consider all relevant differential diagnoses?” Eur J Dermatol 15(5): 320–331.

Weisshaar, E., C. Forster, M. Dotzer and G. Heyer (1997). “Experimentally induced pruritus and cutaneous reactions with topical antihistamine and local analgesics in atopic eczema.” Skin Pharmacol 10(4): 183–190.

https://doi.org/10.1159/000211503 DOI: https://doi.org/10.1159/000211503

Weisshaar, E., G. Heyer, C. Forster, O. P. Hornstein and H. O. Handwerker (1996). “[Antipruritic effect of antihistaminic and local anesthetic topical agents after iontophoretic histamine stimulation].” Hautarzt 47(5): 355–360.

https://doi.org/10.1007/s001050050430 DOI: https://doi.org/10.1007/s001050050430

Weisshaar, E., J. P. Kupfer and P. e. a. Bentz (2024). “Validation of the German Pruritus Questionnaire for the systematic assessment of chronic pruritus.” JDDG: Journal der Deutschen Dermatologischen Gesellschaft 22: 956–963.

https://doi.org/10.1111/ddg.15430 DOI: https://doi.org/10.1111/ddg.15430

Weisshaar, E., M. Weiss, T. Mettang, G. Yosipovitch and Z. Zylicz (2015). “Paraneoplastic itch: An expert position statement from the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI).” Acta Derm Ven 95: 261–165.

https://doi.org/10.2340/00015555-1959 DOI: https://doi.org/10.2340/00015555-1959

Welsh, A. L. (1955). Dermatologist’s handbook. Springfield, Illinois, Charls C Thomas. Publisher.

Werfel, T., L. G., M. Yeadon, L. Whitlock, I. Osterloh, P. Jimenez, W. Liu, V. Lynch, A. Asher, A. Tsianakas and L. Purkins (2018). “Efficacy and safety of the histamine H 4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis.” J Allergy. Clin Immunol 143(5): 1830–1837.e1834.

https://doi.org/10.1016/j.jaci.2018.07.047 DOI: https://doi.org/10.1016/j.jaci.2018.07.047

Wieczorek, A., P. Krajewski, M. Kozioł-Gałczyńska and J. C. Szepietowski (2020). “Opioid receptors expression in the skin of haemodialysis patients suffering from uraemic pruritus.” J Eur Acad Dermatol Venereol 34: 2368–2372.

https://doi.org/10.1111/jdv.16360 DOI: https://doi.org/10.1111/jdv.16360

Wikstrom, B., R. Gellert, S. D. Ladefoged, Y. Danda, M. Akai, K. Ide, M. Ogasawara, Y. Kawashima, K. Ueno, A. Mori and Y. Ueno (2005). “Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies.” J Am Soc Nephrol 16(12): 3742–3747.

https://doi.org/10.1681/ASN.2005020152 DOI: https://doi.org/10.1681/ASN.2005020152

Winkelmann, R. K., S. M. Connolly, J. A. Doyle and A. Padilha-Goncalves (1984). “Thalidomide treatment of prurigo nodularis.” Acta Derm Venereol 64(5): 412–417.

https://doi.org/10.2340/0001555564412417 DOI: https://doi.org/10.2340/0001555564412417

Wiznia, L. E., S. W. Callahan, D. E. Cohen and S. J. Orlow (2018). “Rapid improvement of prurigo nodularis with cyclosporine treatment.” J Am Acad Dermatol 78: 1209–1211.

https://doi.org/10.1016/j.jaad.2018.02.024 DOI: https://doi.org/10.1016/j.jaad.2018.02.024

Woelber, L., K. Prieske, W. Mendling, B. Schmalfeldt, H. J. Tietz and A. Jaeger (2019). “Vulvar pruritus-Causes, Diagnosis and Therapeutic Approach.” Dtsch Arztebl Int 116(8): 126–133.

https://doi.org/10.3238/arztebl.2020.0126 DOI: https://doi.org/10.3238/arztebl.2020.0126

Wojtowicz-Prus, E., K. Kilis-Pstrusinska, A. Reich, K. Zachwieja, M. Miklaszewska and M. Szczepanska (2016). “Chronic Kidney Disease-associated pruritus in children.” Acta derm Venereol.

https://doi.org/10.2340/00015555-2454 DOI: https://doi.org/10.2340/00015555-2454

Wolf, R. and A. Krakowski (1988). “Variations in aquagenic pruritus and treatment alternatives.” J Am Acad Dermatol 18(5 Pt 1): 1081–1083.

https://doi.org/10.1016/S0190-9622(88)70110-3 DOI: https://doi.org/10.1016/S0190-9622(88)70110-3

Wolfhagen, F. H., E. Sternieri, W. C. Hop, G. Vitale, M. Bertolotti and H. R. Van Buuren (1997). “Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.” Gastroenterology 113(4): 1264–1269.

https://doi.org/10.1053/gast.1997.v113.pm9322521 DOI: https://doi.org/10.1053/gast.1997.v113.pm9322521

Wolking, S., H. Lerche and M. Dihné (2013). “Episodic itch in a case of spinal glioma.” BMC Neurol(13): 124.

https://doi.org/10.1186/1471-2377-13-124 DOI: https://doi.org/10.1186/1471-2377-13-124

Wollenberg, A., S. Barbarot, T. Bieber, S. Christen-Zaech, M. Deleuran, A. Fink-Wagner, U. Gieler, G. Girolomoni, S. Lau, A. Muraro, M. Czarnecka-Operacz, T. Schäfer, P. Schmid-Grendelmeier, D. Simon, Z. Szalai, J. C. Szepietowski, A. Taïeb, A. Torrelo, T. Werfel, J. Ring, t. E. D. F. (EDF), t. E. A. o. D. a. V. (EADV), t. E. A. o. A. a. C. I. (EAACI), t. E. T. F. o. A. D. (ETFAD), E. F. o. A. a. A. D. P. A. (EFA), t. E. S. f. D. a. P. (ESDaP), t. E. S. o. P. D. (ESPD), G. A. a. A. E. N. (GA2LEN) and t. E. U. o. M. S. (UEMS) (2018). “Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.” J Eur Acad Dermatol Venereol 32(5): 657–682.

https://doi.org/10.1111/jdv.14891 DOI: https://doi.org/10.1111/jdv.14891

Wollenberg, A., S. Barbarot, T. Bieber, S. Christen-Zaech, M. Deleuran, A. Fink-Wagner, U. Gieler, G. Girolomoni, S. Lau, A. Muraro, M. Czarnecka-Operacz, T. Schäfer, P. Schmid-Grendelmeier, D. Simon, Z. Szalai, J. C. Szepietowski, A. Taïeb, A. Torrelo, T. Werfel, J. Ring, E. D. F. (EDF)., t. E. A. o. D. a. V. (EADV)., t. E. A. o. A. a. C. I. (EAACI)., t. E. T. F. o. A. D. (ETFAD)., E. F. o. A. a. A. D. P. A. (EFA)., t. E. S. f. D. a. P. (ESDaP)., t. E. S. o. P. D. (ESPD)., G. A. a. A. E. N. (GA2LEN). and t. E. U. o. M. S. (UEMS). (2018). “Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.” J Eur Acad Dermatol Venereol 32(6): 850–878.

https://doi.org/10.1111/jdv.14888 DOI: https://doi.org/10.1111/jdv.14888

Wollenberg, A., A. Blauvelt, E. Guttman-Yassky, M. Worm, C. Lynde, J. P. Lacour, L. Spelman, N. Katoh, H. Saeki, Y. Poulin, A. Lesiak, L. Kircik, S. H. Cho, P. Herranz, M. J. Cork, K. Peris, L. A. Steffensen, B. Bang, A. Kuznetsova, T. N. Jensen, M. L. Østerdal and E. L. Simpson (2021). “Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).” Br J Dermatol 184(3): 437–449.

https://doi.org/10.1111/bjd.19574 DOI: https://doi.org/10.1111/bjd.19574

Wollenberg, A., S. Christen-Zäch, A. Taieb, P. C., J. P. Thyssen, M. de Bruin-Weller, C. Vestergaard, J. Seneschal, T. Werfel, M. J. Cork, B. Kunz, R. Fölster-Holst, M. Trzeciak, U. Darsow, Z. Szalai, M. Deleuran, L. von Kobyletzki, S. Barbarot, A. Heratizadeh, U. Gieler, D. J. Hijnen, S. Weidinger, L. De Raeve, Å. Svensson, D. Simon, J. F. Stalder, R. J; and E. T. F. o. A. D. E. E. T. Force (2020). “ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.” J Eur Acad Dermatol Venereol 34(12): 2717–2744.

https://doi.org/10.1111/jdv.16892 DOI: https://doi.org/10.1111/jdv.16892

Wollenberg, A. and A. Giménez-Arnau (2022). “Sensitive skin: A relevant syndrome, be aware.” J Eur Acad Dermatol Venereol 36(Suppl 5): 3–5.

https://doi.org/10.1111/jdv.17903 DOI: https://doi.org/10.1111/jdv.17903

Wollenberg, A., A. Oranje, M. Deleuran, D. Simon, Z. Szalai, B. Kunz, A. Svensson, S. Barbarot, L. von Kobyletzki, A. Taieb, M. de Bruin-Weller, T. Werfel, M. Trzeciak, C. Vestergard, J. Ring and U. Darsow (2016). “European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.” J Eur Acad Dermatol Venereol 30(5): 729–747.

https://doi.org/10.1111/jdv.13599

Wollenberg, A., A. Oranje, M. Deleuran, D. Simon, Z. Szalai, B. Kunz, A. Svensson, S. Barbarot, L. von Kobyletzki, A. Taieb, M. de Bruin-Weller, T. Werfel, M. Trzeciak, C. Vestergard, J. Ring, U. Darsow and E. E. T. F. European Task Force on Atopic Dermatitis (2016). “ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.” J Eur Acad Dermatol Venereol 30(5): 729–747.

https://doi.org/10.1111/jdv.13599

Wollenberg, A., A. Oranje, M. Deleuran, D. Simon, Z. Szalai, B. Kunz, A. Svensson, S. Barbarot, L. von Kobyletzki, A. Taieb, M. de Bruin-Weller, T. Werfel, M. Trzeciak, C. Vestergard, J. Ring, U. Darsow and E. T. F. o. A. D. E. E. T. Force (2016). “ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.” J Eur Acad Dermatol Venereol 30(5): 729–747.

https://doi.org/10.1111/jdv.13599 DOI: https://doi.org/10.1111/jdv.13599

Wollina, U., G. Hansel, A. Koch and M. B. Abdel-Naser (2006). “Topical pimecrolimus for skin disease other than atopic dermatitis.” Expert Opin Pharmacother 7(14): 1967–1975.

https://doi.org/10.1517/14656566.7.14.1967 DOI: https://doi.org/10.1517/14656566.7.14.1967

Xifra, A., J. M. Carrascosa and C. Ferrandiz (2005). “Narrow-band ultraviolet B in aquagenic pruritus.” Br J Dermatol 153(6): 1233–1234.

https://doi.org/10.1111/j.1365-2133.2005.06962.x DOI: https://doi.org/10.1111/j.1365-2133.2005.06962.x

Xu, L., H. Yu, S. Xu, Y. Wang and Y. Cao (2024). “Comparative efficacy and safety of the treatment by Omalizumab for chronic idiopathic urticaria in the general population: A systematic review and network meta-analysis.” Skin Res Technol 30(5): e13749.

https://doi.org/10.1111/srt.13749 DOI: https://doi.org/10.1111/srt.13749

Xu, S., X. Gao, J. Deng, J. Yang and F. Pan (2021). “Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis.” J Dtsch Dermatol Ges 19(1): 47–56.

https://doi.org/10.1111/ddg.14308 DOI: https://doi.org/10.1111/ddg.14308

Yagi, M., A. Tanaka, T. Namisaki, A. Takahashi, M. Abe, A. Honda, Y. Matsuzaki, H. Ohira, H. Yoshiji, H. Takikawa and J. P. S. G. (JPBCSG) (2018). “Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.” J Gastroenterol. DOI: https://doi.org/10.1016/S0168-8278(18)30672-X

https://doi.org/10.1007/s00535-018-1465-z DOI: https://doi.org/10.1007/s00535-018-1465-z

Yalcin, B., E. Tamer, G. G. Toy, P. Oztas, M. Hayran and N. Alli (2006). “The prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients.” Int J Dermatol 45(6): 672–676.

https://doi.org/10.1111/j.1365-4632.2005.02607.x DOI: https://doi.org/10.1111/j.1365-4632.2005.02607.x

Yang, V., T. W. Kragstrup, C. McMaster and P. e. a. Reid (2023). “Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors.” Drug Saf 46(11): 1049–1071.

https://doi.org/10.1007/s40264-023-01333-0 DOI: https://doi.org/10.1007/s40264-023-01333-0

Yang, Y., Y. Sun, C. Zhu, X. Shen, J. Sun, T. Jing, S. Jun, C. Wang, G. Yu, X. Dong, M. Sheng and Z. Tang (2023). “Allantoin induces pruritus by activating MrgprD in chronic kidney disease.” J Cell Physiol 238(4): 813–828.

https://doi.org/10.1002/jcp.30977 DOI: https://doi.org/10.1002/jcp.30977

Yeam, C. T., T. E. Yo, Y. L. C. Tan, A. Liew and J. J. B. Seng (2021). “Complementary and alternative medicine therapies for uremic pruritus - A systematic review of randomized controlled trials.” Complement Ther Med 56: 102609.

https://doi.org/10.1016/j.ctim.2020.102609 DOI: https://doi.org/10.1016/j.ctim.2020.102609

Yin, M., R. Wu, J. Chen and X. Dou (2022). “Successful treatment of refractory prurigo nodularis with baricitinib.” Dermatol Ther 35(8): e15642.

https://doi.org/10.1111/dth.15642 DOI: https://doi.org/10.1111/dth.15642

Yin, Q., J. Li, Y. Xia, R. Zhang, J. Wang, W. Lu, Y. Zhou, Y. Zheng, H. Abudumijiti, R. Chen, K. Chen, S. Li, T. Liu, F. Wang, J. Lu, Y. Zhou and C. Guo (2015). “Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.” Drug Des Devel Ther 9: 5407–5419.

https://doi.org/10.2147/DDDT.S92041 DOI: https://doi.org/10.2147/DDDT.S92041

Yokozeki, H., H. Murota, T. Matsumura, H. Komazaki and f. t. N.-J. S. Group (2024). “Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.” Br J Dermatol 191(2): 200–208. DOI: https://doi.org/10.1093/bjd/ljae338

https://doi.org/10.1093/bjd/ljae131 DOI: https://doi.org/10.1093/bjd/ljae131

Yoon, S., K. Kim, K. Shin and H.-S. e. a. Kim (2024). “The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.” J Eur Acad Dermatol Venereol 38(1): 52–61.

https://doi.org/10.1111/jdv.19426 DOI: https://doi.org/10.1111/jdv.19426

Yosipovitch, G. (2010). “Chronic Pruritus: a Paraneoplastic Sign.” dermatol Ther 23(6): 590–596.

https://doi.org/10.1111/j.1529-8019.2010.01366.x DOI: https://doi.org/10.1111/j.1529-8019.2010.01366.x

Yosipovitch, G., A. Awad, R. H. Spencer, C. Munera and F. Menzaghi (2023). “A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus.” J Am Acad Dermatol 89(2): 261–268.

https://doi.org/10.1016/j.jaad.2023.03.051 DOI: https://doi.org/10.1016/j.jaad.2023.03.051

Yosipovitch, G., M. I. Duque, K. Fast, A. G. Dawn and R. C. Coghill (2007). “Scratching and noxious heat stimuli inhibit itch in humans: a psychophysical study.” Br J Dermatol 156(4): 629–634.

https://doi.org/10.1111/j.1365-2133.2006.07711.x DOI: https://doi.org/10.1111/j.1365-2133.2006.07711.x

Yosipovitch, G., A. Goon, J. Wee, Y. H. Chan and C. L. Goh (2000). “The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis.” Br J Dermatol 143: 969–973.

https://doi.org/10.1046/j.1365-2133.2000.03829.x DOI: https://doi.org/10.1046/j.1365-2133.2000.03829.x

Yosipovitch, G., N. Mollanazar, S. Ständer and S. G. e. a. Kwatra (2023). “Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.” Nature Medicine 29: 1180–1190.

https://doi.org/10.1038/s41591-023-02320-9 DOI: https://doi.org/10.1038/s41591-023-02320-9

Yosipovitch, G., C. Szolar, X. Y. Hui and H. Maibach (1996). “Effect of topically applied menthol on thermal, pain and itch sensations and biophysical properties of the skin.” Arch Dermatol Res 288(5–6): 245–248.

https://doi.org/10.1007/BF02530092 DOI: https://doi.org/10.1007/BF02530092

Young, T. A., T. S. Patel, F. Camacho, A. Clark, B. I. Freedman, M. Kaur, J. Fountain, L. L. Williams, G. Yosipovitch and A. B. J. Fleischer (2009). “A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients.” J Dermatolog Treat 20(2): 76–81.

https://doi.org/10.1080/09546630802441218 DOI: https://doi.org/10.1080/09546630802441218

Yuan, C., X. M. Wang, A. Guichard, Y. M. Tan, C. Y. Qian, L. J. Yang and P. Humbert (2014). “N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients.” Clin Interv Aging 17(9): 1163–1169.

https://doi.org/10.2147/CIA.S65448 DOI: https://doi.org/10.2147/CIA.S65448

Yue, J., S. Jiao, Y. Xiao, W. Ren, T. Zhao and J. Meng (2015). “Comparison of pregabalin with ondansetron in treatment of uremic pruritus in dialysis patients: a prospective, randomized, double-blind study.” Int Urol Nephrol 47(1): 161–167.

https://doi.org/10.1007/s11255-014-0795-x DOI: https://doi.org/10.1007/s11255-014-0795-x

Zanardelli, M., M. Kovacevic, J. McCoy, X. Wang, A. Goren and T. Lotti (2016). “Management of chronic pruritus with a UV filtering topical cream.” Dermatol Ther 29(2): 101–103.

https://doi.org/10.1111/dth.12309 DOI: https://doi.org/10.1111/dth.12309

Zeidler, C., J. Kupfer and F. J. e. a. Dalgard (2024). “Dermatological patients with itch report more stress, stigmatization experience, anxiety and depression compared to patients without itch: Results from a European multi-centre study.” J Eur Acad Dermatol Venereol 38: 1649–1661.

https://doi.org/10.1111/jdv.19913 DOI: https://doi.org/10.1111/jdv.19913

Zeidler, C., H. Lüling, A. Dieckhöfer, N. Osada, F. Schedel, S. Steinke, M. Augustin and S. Ständer (2015). “Capsaicin 8% cutaneous patch: a promising treatment for brachioradial pruritus?” Br J Dermatol 172(6): 1669–1671.

https://doi.org/10.1111/bjd.13501 DOI: https://doi.org/10.1111/bjd.13501

Zeidler, C. and S. Ständer (2014). “Secondary generalized brachioradial pruritus. An uncommon but easy-to-use differential diagnostic approach to generalized pruritus.” Hautarzt 65(1): 56–58.

https://doi.org/10.1007/s00105-013-2679-x DOI: https://doi.org/10.1007/s00105-013-2679-x

Zeidler, C., S. Steinke, C. Riepe, P. Bruland, I. Soto-Rey, M. Storck, S. Garcovich, C. Blome, S. Bobko, F. J. Legat, N. Potekaev, A. Lvov, L. Misery, W. Weger, A. Reich, E. Şavk, M. Streit, E. Serra-Baldrich, J. C. Szepietowski, G. Yosipovitch, S. C. Chen, M. Dugas and S. Ständer (2019). “Cross-European validation of the ItchyQOL in pruritic dermatoses.” J Eur Acad Dermatol Venereol 33: 391–397.

https://doi.org/10.1111/jdv.15225 DOI: https://doi.org/10.1111/jdv.15225

Zhai, W., R. Tang, Y. Gao, H. Su, H. Mao, W. Liu, S. Ao, J. Han and F. Wang (2023). “Efficacy and associated neurotransmitters of digital cognitive behavior therapy for atopic dermatitis: A comparative effectiveness research.” Asian Pac J Allergy Immunol Epub ahead of print.

Zhao, Z. Q., F. Q. Huo, J. Jeffry, L. Hampton, S. Demehri, S. Kim, X. Y. Liu, D. M. Barry, L. Wan, Z. C. Liu, H. Li, A. Turkoz, K. Ma, L. A. Cornelius, R. Kopan, J. F. J. Battey, J. Zhong and Z. F. Chen (2013). “Chronic itch development in sensory neurons requires BRAF signaling pathways.” J Clin Invest 123(11): 4769–4780.

https://doi.org/10.1172/JCI70528 DOI: https://doi.org/10.1172/JCI70528

Zhou, T., Y. Zhang, Y. Ma, W. Ma and X. e. a. Wu (2022). “Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial.” Cancer 128(22): 3969–3976.

https://doi.org/10.1002/cncr.34474 DOI: https://doi.org/10.1002/cncr.34474

Zhu, J., X. Zhao, A. A. Navarini and S. M. Mueller (2024). “Device-based physical therapies in chronic pruritus: A narrative review.” J Am Acad Dermatol 91(4): 699–705.

https://doi.org/10.1016/j.jaad.2024.06.045 DOI: https://doi.org/10.1016/j.jaad.2024.06.045

Zirwas MJ, B. S. (2017). “Anti-pruritic efficacy of itch relief lotion and cream in patients with atopic history: comparison with hydrocortisone cream.” J Drugs Dermatol 16(3): 243–247.

Zuberbier, T., A. H. Abdul Latiff, M. Abuzakouk, S. Aquilina, R. Asero, D. Baker, B. Ballmer-Weber, C. Bangert, M. Ben-Shoshan, J. A. Bernstein, C. Bindslev-Jensen, K. Brockow, Z. Brzoza, C. N. H. J., M. K. Church, P. R. Criado, I. V. Danilycheva, C. Dressler, L. F. Ensina and L. e. a. Fonacier (2021). “The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.” Allergy.

https://doi.org/10.26416/Aler.6.4.2021.5815 DOI: https://doi.org/10.26416/Aler.6.4.2021.5815

Zuberbier, T., W. Aberer, R. Asero, A. H. Abdul Latiff, D. Baker, B. Ballmer-Weber, J. A. Bernstein, C. Bindslev-Jensen, Z. Brzoza, R. Buense Bedrikow, G. W. Canonica, M. K. Church, T. Craig, I. V. Danilycheva, C. Dressler, L. F. Ensina, A. Giménez-Arnau, K. Godse, M. Gonçalo, C. Grattan, J. Hebert, M. Hide, A. Kaplan, A. Kapp, C. H. Katelaris, E. Kocatürk, K. Kulthanan, D. Larenas-Linnemann, T. A. Leslie, M. Magerl, P. Mathelier-Fusade, R. Y. Meshkova, M. Metz, A. Nast, E. Nettis, H. Oude-Elberink, S. Rosumeck, S. S. Saini, M. Sánchez-Borges, P. Schmid-Grendelmeier, P. Staubach, G. Sussman, E. Toubi, G. A. Vena, C. Vestergaard, B. Wedi, R. N. Werner, Z. Zhao and M. Maurer (2018). “The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.” Allergy 3(7): 1393–1414.

https://doi.org/10.1111/all.13397 DOI: https://doi.org/10.1111/all.13397

Zuberbier, T., W. Aberer, R. Asero, A. H. Abdul Latiff, D. Baker, B. Ballmer-Weber, J. A. Bernstein, C. Bindslev-Jensen, Z. Brzoza, R. Buense Bedrikow, G. W. Canonica, M. K. Church, T. Craig, I. V. Danilycheva, C. Dressler, L. F. Ensina, A. Giménez-Arnau, K. Godse, M. Gonçalo, C. Grattan, J. Hebert, M. Hide, A. Kaplan, A. Kapp, C. H. Katelaris, E. Kocatürk, K. Kulthanan, D. Larenas-Linnemann, T. A. Leslie, M. Magerl, P. Mathelier-Fusade, R. Y. Meshkova, M. Metz, A. Nast, E. Nettis, H. Oude-Elberink, S. Rosumeck, S. S. Saini, M. Sánchez-Borges, P. Schmid-Grendelmeier, P. Staubach, G. Sussman, E. Toubi, G. A. Vena, C. Vestergaard, B. Wedi, R. N. Werner, Z. Zhao and M. Maurer (2018). “The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update.” Allergy.

Zuberbier, T., W. Aberer, R. Asero, C. Bindslev-Jensen, Z. Brzoza, G. W. Canonica, M. K. Church, L. F. Ensina, A. Gimenez-Arnau, K. Godse, M. Gonçalo, C. Grattan, J. Hebert, M. Hide, A. Kaplan, A. Kapp, A. H. Abdul Latiff, P. Mathelier-Fusade, M. Metz, Nast, A., Saini, S. S., M. Sanchez-Borges, P. Schmid-Grendelmeier, F. E. R. Simons, P. Staubach, G. Sussman, E. Toubi, G. A. Vena, B. Wedi, X. J. Zhu and M. Maurer (2014). “The EAACI/GA (2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update.” Allergy 69: 868–887.

https://doi.org/10.1111/all.12313 DOI: https://doi.org/10.1111/all.12313

Zuberbier, T., C. Bindslev-Jensen, W. Canonica, C. E. Grattan, M. W. Greaves, B. M. Henz, A. Kapp, M. M. Kozel, M. Maurer, H. F. Merk, T. Schafer, D. Simon, G. A. Vena, B. Wedi and Eaaci/Ga2Len/Edf (2006). “EAACI/GA2LEN/EDF guideline: management of urticaria.” Allergy 61(3): 321–331.

https://doi.org/10.1111/j.1398-9995.2005.00962.x DOI: https://doi.org/10.1111/j.1398-9995.2005.00962.x

Zylicz, Z., M. Krajnik, A. A. Sorge and M. Costantini (2003). “Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial.” J Pain Symptom Manage 26(6): 1105–1112.

https://doi.org/10.1016/j.jpainsymman.2003.05.004 DOI: https://doi.org/10.1016/j.jpainsymman.2003.05.004

Zylicz, Z., C. Smits and M. Krajnik (1998). “Paroxetine for pruritus in advanced cancer.” J Pain Symptom Manage 16(2): 121–124.

Zylicz, Z., R. Twycross and E. A. Jones (2004). Pruritus in advanced disease. Oxford, Oxford University Press.

https://doi.org/10.1093/acprof:oso/9780198525103.001.0001 DOI: https://doi.org/10.1093/acprof:oso/9780198525103.001.0001

Downloads

Published

2025-08-22

How to Cite

Weisshaar, E., Müller, S., Szepietowski, J. C., Dalgard, F., Garcovich, S., Kupfer, J., … Ständer, S. (2025). European S2k Guideline on Chronic Pruritus: In cooperation with the European Dermatology Forum (EDF) . Acta Dermato-Venereologica, 105, adv44220. https://doi.org/10.2340/actadv.v105.44220

Issue

Vol. 105 (2025)

Section

Supplements

Categories

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC